var title_f38_18_39200="Approach to anisocoria";
var content_f38_18_39200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Flowchart explaining the approach to a patient with anisocoria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 664px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39200=[""].join("\n");
var outline_f38_18_39200=null;
var title_f38_18_39201="Triamterene nephrotoxicity";
var content_f38_18_39201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Triamterene nephrotoxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39201/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39201/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39201/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/18/39201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     Triamterene",
"    </a>",
"    is a potassium-sparing diuretic that is commonly used in the treatment of hypertension in combination with a thiazide (Dyazide&trade;, Maxzide&trade;). It is not widely appreciated, however, that triamterene is a potential nephrotoxin, frequently inducing crystalluria and cast formation, and rarely causing stone formation or reversible acute kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRYSTALLURIA AND CAST FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excretion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    crystals and granular casts occurs in as many as one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/3\">",
"     3",
"    </a>",
"    ]. The mechanism responsible for the cast formation is unclear; this finding is not seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    , another potassium-sparing diuretic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRIAMTERENE STONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although stone formation is a rare complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ], some studies suggest that triamterene may contribute to 1 in every 200 to 250 stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/5\">",
"     5",
"    </a>",
"    ]. Most of these stones contain both triamterene and calcium oxalate, but pure triamterene stones can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who form",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    -containing stones are more likely to have a prior history of stone disease, suggesting that metabolic predisposition is an important risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .) Triamterene stones are faintly opaque on x-ray examination and their formation is pH-independent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACUTE KIDNEY INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible acute kidney injury is another rare problem with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    (but not other potassium-sparing diuretics). Two different mechanisms have been described: intratubular obstruction by crystals; and concurrent therapy with a nonsteroidal antiinflammatory drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39201/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Why triamterene seems to make the patient more sensitive to a NSAID than other diuretics is not clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20367461\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     Triamterene",
"    </a>",
"    , a commonly used potassium-sparing diuretic, may produce crystalluria and granular casts in as many as one-half of patients, sometimes leading to nephrolithiasis or acute kidney injury.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/1\">",
"      Sica DA, Gehr TW. Triamterene and the kidney. Nephron 1989; 51:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/2\">",
"      Perazella MA. Crystal-induced acute renal failure. Am J Med 1999; 106:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/3\">",
"      Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin Nephrol 1986; 26:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/4\">",
"      Woolfson RG, Mansell MA. Does triamterene cause renal calculi? BMJ 1991; 303:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/5\">",
"      Carr MC, Prien EL Jr, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. J Urol 1990; 144:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/6\">",
"      Sabot JF, Bornet CE, Favre S, Sabot-Gueriaux S. The analysis of peculiar urinary (and other) calculi: an endless source of challenge. Clin Chim Acta 1999; 283:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/7\">",
"      S&ouml;rgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol 1985; 134:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/8\">",
"      Farge D, Turner MW, Roy DR, Jothy S. Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition. Am J Kidney Dis 1986; 8:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/9\">",
"      Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med 1982; 96:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39201/abstract/10\">",
"      Weinberg MS, Quigg RJ, Salant DJ, Bernard DB. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40:216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7365 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39201=[""].join("\n");
var outline_f38_18_39201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20367461\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRYSTALLURIA AND CAST FORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRIAMTERENE STONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20367461\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_18_39202="Beractant: Pediatric drug information";
var content_f38_18_39202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beractant: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17763?source=see_link\">",
"    see \"Beractant: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Survanta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Survanta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Lung Surfactant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endotracheal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prophylactic treatment: 4 mL/kg (100 mg phospholipids/kg) as soon as possible; as many as 4 doses may be administered during the first 48 hours of life, no more frequently than 6 hours apart. The need for additional doses is determined by evidence of continuing respiratory distress or if the infant is still intubated and requiring at least 30% inspired oxygen to maintain a PaO",
"     <sub>",
"      2",
"     </sub>",
"     &le;80 torr.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rescue treatment: 4 mL/kg (100 mg phospholipids/kg) as soon as the diagnosis of RDS is made; may repeat if needed, no more frequently than every 6 hours to a maximum of 4 doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intratracheal [bovine derived, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Survanta&reg;: Phospholipids 25 mg/mL (4 mL, 8 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endotracheal: For endotracheal administration only. Do not shake; if settling occurs during storage, gently swirl. Suction infant prior to administration; inspect solution to verify complete mixing of the suspension. Administer endotracheally by instillation through a 5-French end-hole catheter inserted into the infant's endotracheal tube. Administer the dose in four 1 mL/kg aliquots. Each quarter-dose is instilled over 2-3 seconds; each quarter-dose is administered with the infant in a different position; slightly downward inclination with head turned to the right, then repeat with head turned to the left; then slightly upward inclination with head turned to the right, then repeat with head turned to the left.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate; protect from light; prior to administration warm by standing at room temperature for 20 minutes or hold in hand for 8 minutes; artificial warming methods should",
"     <b>",
"      not",
"     </b>",
"     be used; unused, unopened vials warmed to room temperature may be returned to the refrigerator within 8 hours of warming only once",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of respiratory distress syndrome (RDS) in premature infants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Prophylactic therapy: Infants with body weight &lt;1250 g who are at risk for developing or with evidence of surfactant deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rescue therapy: Treatment of infants with RDS confirmed by x-ray and requiring mechanical ventilation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Survanta&reg; may be confused with Sufenta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F140450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     During the dosing procedure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Transient bradycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Oxygen desaturation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Apnea, endotracheal tube blockage, hypercarbia, hyper-/hypotension, post-treatment nosocomial sepsis probability increased, pulmonary air leaks, pulmonary interstitial emphysema, vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of beractant in infants &lt;600 g birth weight or &gt;1750 g birth weight has not been evaluated",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rapidly affects oxygenation and lung compliance and should be restricted to a highly supervised use in a clinical setting with immediate availability of clinicians experienced with intubation and ventilatory management of premature infants. If transient episodes of bradycardia and decreased oxygen saturation occur, discontinue the dosing procedure and initiate measures to alleviate the condition; produces rapid improvements in lung oxygenation and compliance that may require immediate reductions in ventilator settings and FiO",
"     <sub>",
"      2",
"     </sub>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F17916770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Beractant is only indicated for use in premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous heart rate and transcutaneous O",
"     <sub>",
"      2",
"     </sub>",
"     saturation should be monitored during administration; frequent ABG sampling is necessary to prevent postdosing hyperoxia and hypocarbia.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces deficient or ineffective endogenous lung surfactant in neonates with respiratory distress syndrome (RDS) or in neonates at risk of developing RDS. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13040 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-E259C7487F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39202=[""].join("\n");
var outline_f38_18_39202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140419\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140420\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056812\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442084\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140410\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140398\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056815\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056810\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056814\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140451\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140450\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056807\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056806\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298853\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140406\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916770\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056811\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056805\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17763?source=related_link\">",
"      Beractant: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_18_39203="Resisted thumb extension";
var content_f38_18_39203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resisted thumb extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39203=[""].join("\n");
var outline_f38_18_39203=null;
var title_f38_18_39204="Steroid acne 1";
var content_f38_18_39204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Steroid acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Monomorphous inflammatory papular eruption involving the trunk of a patient treated with systemic corticosteroids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39204=[""].join("\n");
var outline_f38_18_39204=null;
var title_f38_18_39205="Reported cases of tularemia in US in 2010";
var content_f38_18_39205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Map of reported cases of tularemia in the United States and territories, 2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 376px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF4Ai0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P8T6+NBXTlXTr7UrnULr7JBb2ZiDs4iklJJldFACxP8AxelZ/wDwlGr/APQieJP+/wDp3/yVR4y/5GPwJ/2GpP8A03XldVQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQBxWreOL3SNKvdS1DwT4khsrOF7ieTzbBtkaKWY4F0ScAHgAmu1rlfix/ySzxl/wBgW9/9EPXVUAcr4y/5GPwJ/wBhqT/03XldVXK+Mv8AkY/An/Yak/8ATdeV1VABRRRQAUUUUAZWjeINM1m4vINPu0lntJXhmj6MrKxU8HqMgjI44rVrxjStNDWjwJdXMF/pl5PCl9C22QssjAtzkNuzyGBByeK3G8Za14eSOXWYBrGn7hG8tlDsuUJOAxTdtYZwCRtx1welVyu1wNbxL4n1jSvFi6fZ6fZ3Vm1kLgebM8UjNvZWAbaynHycf7X0y+Dx9ZpgatpuqaccHLtB58f/AH1EWwOO4HbvxXLS6lban41e7WZp0vNNivNPkLcLbuQsiKM4zvRS2P7y1rU4wuhNnZ6Tr2k6wG/srU7O8KjLLBMrsvbkA5HTvWlXleoaRp2pENfWVvO46O8YLDtweo/CkhtL+y/5BGvapaDGNkkouk79ptxHXsRQ4MLnqtFeexeJ/Elnjz7PTdTTu0UjWr9P7p3qfzFaMXxA0uNWOrWuo6UFGWa4t98Y9fnjLKMe5FS00M7Gis7Sdc0rV1J0rUrO8woYiCZXIB6EgHitGkAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9dVQByvjL/kY/An/Yak/9N15XVVyvjL/kY/An/Yak/wDTdeV1VABRRRQAUUVX1K8i0/T7q8uCRDbRNNIQMnaoJP6CgDyjw3eRXEutos8Tzx6tfCSNWG5P9Jk2hgDxxivJvjT4hmvtbm0Ce5NhpttH5hcL5ouJtm5VbaflHIHPTIbHSu9+Foe80q71u4tLWGXUrmSdGSJVlaNmJ/eMOW+YtjPbFa+oeEND1HWf7Tv7CO4usDiQlkJAxkpnaTjAyR2Fa2bikhXszmvgjpUNv4PtdTJle5ug6KZWyYolkfbGvouct7lvpXoTHmlRVRFRAFUDAA4AFVtRtIb+zmtbpS8EyFHUMVJB68g5H4GqSsrCerLCn3p3415joem2+h/FSG3j0+z0iKfTpRawaacxXIWQZeb5Vw4BXA2nqfnOMV6dTQB+Nc58RJHXwfqEEOTNeKtlGB1LSsIx/wChV0f41h6qn27xf4O0wNgSagbx/dbdGk/9C2fjilJ6AtzY+Lmk6ZYfDm4W30+0a9RIbGyleFWkjZ2WJSrYyCAxOR6VQt9Kks0jXT9Y1m0KD5dt68ijjH3JCy/hjFanxl4tvC7TDFkutQmZv7rbHEefbeV5+lJWcEmNsig1HxRaDEWtW14PS+slLHj+9EyAevQ1ch8X6/BgXuh2dyoxmSzvdrNxydjqAOe28/WoKKvkQrmpF8QNPXjUNN1mx6DL2hmGT7wlwMep4rRsfGfhu9YJBren+aSB5UkyxyZPQFGwwz9K5qori3huY9lzDHMh/hkUMPyNT7Mdz0lWDKGUgg9CKWvI4vDul2777G3awcdGsZXtj1z/AMs2GeatRw6tbgLZ+JtYiQHO2Qwzg89CZEZv1pcjC56lRXmial4rgQiHWrC4Oc5vNO3H6fu5EH6VZTxP4ohDb7LRb3n5ds8ttx/3zJ/n9Vysdz0KiuEh8b6ogJvfDEpwBgWV7FKSe/8ArPL/AM/rZi8f2f8Ay+aTrdoAMktaib8P3TOc0rMDsqK5WH4geGpCBJqD2xxn/S7aW3A+pkUAVNF488IylQnijQyzYAH2+LJz7bqQHSUVlWviPRLuXyrXWdNmkxnZHdIxx64BrRjnikXMcqOD3VgaAJKKKKACiiigAooooAKKxvDviKz1575LRJ4pLOUxSJMACeSA4wT8pKsAf9k1s0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZviDWINEsVubiKedpJUgiggUNJK7HAVQSMnqevQE9qxP+E2tdQhVPC9u2tagVDPbRSKgt/UTOciNhgjafmyOnerN2f7S8c2dt1t9KtzdyDIx50mY48j2UTH8RXQQwxQ7/ACYkj3sXfYoG5j1J9T70AZ+h63bauJ0iWa3u7dts9rcJsliPbI7g9mGQexNalc1rH+geM9DvhxHepLpsp5+9jzYye3HlyDnu/wCfS0AFFFFAHK/Fj/klnjL/ALAt7/6Ieuqrlfix/wAks8Zf9gW9/wDRD11VAHK+Mv8AkY/An/Yak/8ATdeV1Vcr4y/5GPwJ/wBhqT/03XldVQAUUUUAFc18SJ3h8DayI8iWeA2qEAHDSkRg8+hfNdLXCfEK5N9qml6LGQY0cahddfuof3S/jIN3/bOhK+gHnOp+Hh4PtLvWfCbi1jtonmurCV2eC4RVycc5RwBwR9CMGu0065+26fa3QXZ58Sy7c5xuAOM/jTNWsk1PSr2wmdkjuoXgZlPIDKVJHvzXMWNp40sbdLGC40CW2t0EcVxMkokcAADcinAPrg1vsLc7Kq2p2NtqdjNZ30Yltpl2uhJGR9Qcj8K5uPxVfacRB4k0S9hmx/x8WEbXUEnuCvzL9GH51P8A8JzoJJAuLssOqiwuCw+o2ZFF0Kxb0fwxpek3z3lpFM940fkme5upbiQJnOwNIzELnnA4rbrlm8cabz5VrrEy9mj02fDfTKipbTxx4enm8iTUUs7jGTDeq1uw/wC+8fpRdBZnSVS8Iwm/+K1zOVDRaVpQTJ/hlnkz/wCgxH86tRSxzRrJDIskbDKsrZBHsaf8IIxcTeK9WIObrUzbIT3jgRUGPbd5lTUeg0bHxU0W+8QeBdS07SlR7uTy5FjZ9nmBJFcqrfwsduAex9Oo5fQdWh1rTUu4EliO5o5IZV2yRSKcMjDsQQRXqteO+KlHgvxpqd9cQ3CeHtXCXTXEcLPHb3QwjhyoO0OAjZPGc1EHZjZu/jR+NMhlSaJJYXV43UMrKchgeQRT/wAa2JD8aM+9H40UAIWpc570w9aytL8SaPqer3emadqMF1e2qh544W3iPkjBYcZyCMZyO4oA2KKPxo/GgAz70fjR+NH40AUdfnFroWozswAitpHJJxjCk9ao+DbWKPwhocbRqStjCPmXnOwZ/XNRfEOXyfAuvNnrZyp/30pH9a2rCAWtjb24IxFGsYwfQYpdQ6EUul6fKuJbG1cdcNEpqnN4X8PzsWm0PS5HIwWa0jJ/PFbH40U7AYa+EtARdsekWca5ziNAgJ/CrCaHZJHshe+gQcAQX08e36bXGPwqO58S6Pb+ILXQ5NRg/te53eXaq25/lQudwGdvygkbsZ7ZrXByOaVkBljRUV1aPVNeTBzgazdEfiDIc0r2N9DFK9nr2trPsYJvvGkGcccPkVqZ96Pxo5V2C5P8P4LvxD4J0TVpvEGsefdWqPLteMDfjDYzH03A10H/AAj8/wD0MGtf9/Iv/jdYHwVlH/CGzWIGDp2o3doR9JmYfo4rvawKONXSLvwzqdrdaNZ3WpWbWzW91GJoxMW83eknzlQ3+smzyDyMA9ri+NtFhfydYnOi3RGVt9TKwO4zj5OSH/4CT1Ga6amNFG0qyNGhkQEKxXkZ64NAGDY+MNGvb+CzjmuY5rg7YPtFnNCkx2lsIzoFY4BOAa6GszxDolnrunta3kY3DLQzhQZLeTBAkjJ+6wz1rFXQ9c0fbPo2ry6nM4xcQatMfLlbOfMVlU+WRn7qrtIAGB1oA62iuW/s7xXGRcrrljLdNkPbyWZW2ReMbQG37hjqWIOeg6VmW3inxBc36WemafpWrsjhLm4trmSOCI8Zy5QjPOdiljQB3lFIM4GRg0tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO6JEIfGHiUA584Ws59iUKY/8h5/GuirmvCEp1O81fW0INrdzCC1xyHihyu//gTmQj/Z2nvXS0AYHjm2mn8M3UtnE0t5ZlL23jUZZ5ImEgUD1bbt/Grmia7p+trIdOnMjRY8xHjaN0znGVYA4ODg9DitOub8S2GoW89xrmhzxLfRWbRvbywGVbgLl0X5WBBBLAHn7x4oA6SiqGharba1pUF/YuXt5gcEqV5BIIwQDwQR+FX6AOV+LH/JLPGX/YFvf/RD11Vcr8WP+SWeMv8AsC3v/oh66qgDlfGX/Ix+BP8AsNSf+m68rqq5Xxl/yMfgT/sNSf8ApuvK6qgAooooAZNKkMLyzOqRIpZmY4CgckmvK9Imk1GS81q4UrLqUvmopIykA+WJeP8AZwx/2mauj+JGoCW1h8P20o+1ahgzhWIaO1B+djjpuxsH+8fSs0AAADAAGAB2rSmuomL+NFFIzBQSTx1JzWghfxozWTp/iPRdRu2tdP1jTru6XO6GC6SRxjrlQc1rA0AFQ3drb3kRivIIZ4j1SVA4P4Gpvxo/GgDmJfA2hCVprCCbTJyMeZp8725/JTt/Sui+DF1/Z9nqPhO6ObvS5mmilY5a5gmdnWQ+rbiyt9B61R8RaxDommPdTK8shYRwwRjLzyscKijuSa6b4b+FptDsrjUNZKy+IdSIlvJAciIfwwp/soOPc5PPFZzsNHZVwPxmvX/4Rm30S2ci51y5Sx+U4ZYfvTN9NisD/vCu+rzL4j6F4nvvGWkajoFna3tvDaSWyfaJxGtpK7rumYdWUqAMLk8H1rMZNEiRRJHGAqIAqqOgA6CnfjWJ4ZvL+VtVsNYaF7/TLx7SSWFSiyjarK+0njIYcZ7Vt/jXQndEh+NFH40UANYc5rzjTNd0iX40aikWqWDvJpUNsircIS0qzSloxzyw7r1Fek0fjQwD8aPxo/Gj8aAD8aPxo/GigDlficWbwbdQxnDzzQQj/gUyA/oTXVVy3j518jQ4W58/WLVcdc4fef0Q11P40uoB+NFH40UwPN/Huu6TZfEXwWt5qlhA1rNdNcCW4RTCGtmCl8n5QSRjPXNejr0pTz1o+lCAPxoo/GigBPhPKYdZ8ZadjiO/ju1PqJYUz+sbV6NXl/gmRrb4qarAPuX2kwz/AFaKVlP6Sj869QrB7lBRRRSAKhu7mGztZbm6lSGCJS7yOcBQO5qavK7DWNd8YXy6kmgNc+H1mZdPiN1HHG0kcjI0txk7uq/Kqqw9exoA6hLObxbibVYpINDzmGzLMr3Q7NMBj5O4Q9cjd6V1FtBDawJBbRRwwoNqRxqFVR6ADpXF3beJNP17Sb3U7ue4sT5vn2emWZeJDswgJ5kbkk7uBx93vTrDxHd+Lru9s/D7nTILKUQ3dxcx/wCkq3UqsLfdyOjv6nCnFAG/rfiCy0h4oZTJPfTf6mzt08yaT3CjoOOWOFHc1xmm3niLxd4kDQaimm6VplwBcxWmHLSrjMLSHhyM/NtAUHj5iDjuNG0Sx0hXNrGzXEoHnXMrb5piBgF3PJrlLD4WeHrS81O7Y38t1fzSTPIbt1CFnLgBVIX5WYkZBweaAO9orlYNQ1/SIPst5ot3rJiO1LuylgUyqOjOkkiYbscZ56daIbXVfEUnn6ob3RdPXiOximCXDnP3pZI2OBxwqt35PagDpLi5gtghuZ4og7BFMjhdzE4AGepJIAFTVx+o+BNFmspYtOt7WDUwUeO+uEN1NGysrAlnbe2Soz8wz61Bf63qPh3UNPbX9c0qeylnMFz5VoYDBuQ7G5lcgbgoJPHzdqAO3oqGzure9t1ns54riB87ZInDqcHBwRx1BFTUAFFFFABRRRQAUUUUAFFFU9W1Oz0mzNzqE6wxZCgkElmPRVA5YnsBzQBcormf7f1e6B/svwzeEfwyahNHaofwBeQfin+FYV9qvik+MdK0O+u9O0yHUbaaeOSyiM8geIpuj3SYU8MTnZ+HegD0OvMPib471LSjfW/hlrCV7G1F5cyu3mkDfhkCjgEKC3J7jgda6oeDtPnKtq9xf6u45P225ZoyeOfKXbH2/u/zNef67baa3xPmsdJtoBZQaN9kvYoIwkcTGTciHGBkqz8emKaV3YD0jwPpFloXhPTLDTJfPtY4Qyzn/lsW+Yyf8CJLfjW7XDfBq9km8Ew6fcuXutHmk0yUnuIzhD+MZQ1208qQQySynbHGpZj6ADJpAYGt+M9B0S9urPUr9Yru2tlu5IQjM3lFtoKgD5uR0GT0rJ0jVr/xs9z9l/tLQdNtisU0c9t5N48pXcVy2dihWjOQCTu4IrN8MaJo3jbVbvxbqejzeZ9rjbTJLpJIZFhWGIg4yMgvvI6g59zXpVICtptlb6bYQWVlGIraBAkaA5wB7nqfc1Zoopgcr8WP+SWeMv8AsC3v/oh66quV+LH/ACSzxl/2Bb3/ANEPXVUAcr4y/wCRj8Cf9hqT/wBN15XVVyvjL/kY/An/AGGpP/TdeV1VABVHXdSj0fR73UZ1Z47aJpSq9WwOg+tXq5z4jf8AIi65/wBer0Acfp0FwZrm/wBSZJNTvGDzsowFA+7Gv+yoOB68nvV78aPxo/GuhKxIVFcGNYpGmKCIKS5cjaB3zntUv40jgOrK4DKwwQeQRQB5rriRW/jnwU6vZXGmNLKmnW1jGImgzCcyFgSJI8A8KEAyv3sV6SprN07w9oul3L3GmaRp1ncOMNLb2yRs31IGTWoOKEAfjRR+NFAGT4ItodY+Jepy6u/+kaNGh06zb7uyQfNc/wC02cp/s/U5r1uvMfhzD/aHxA8SaqVby7GCHS4nzwWP72X8t0Yr06sHuUFFFFIDyHWJho3xS1mK/wB0MWsrbzWUjKQksiR+W6Bum4BFOOvNbNbnxK0G58Q+E57bThH/AGnBLHd2Zc4AljcMOe2QCv8AwKuPh8M/EN8LNeeGoSib96xzOJWP8BXI2gc/MCc8cda0jOysxNGoSACScD61Bb3ltcjNtcwzA/8APOQN/I1xPxIsfH2l6BfajcHSoLK1gMMkdpK0n2kzERgjcoKlCwIHf3rTh8A+HDp9rBdaRZSSxRKjSpHsZyBgsSuCSfXrVKV9gsdVRXLP4H0tVxZXGrWB9bbUZl/QsR6/nQ/hnUol/wBA8WaxE3/TwIZx+qfXvT1EdT+NH41yzWHi63X9xrumXbelzYMn6pJ/Sg3XjK3QGXTNFvT3EF5JET/30hH60XCx1P40Vy3/AAkWtQRh77wlqA45+y3MM/5DcCe/ag+NrOKPffabrlkvcz6fIQPxXcPXvRdBYr+Phdzar4XttOFu12b150FwWEfyQucnbz3498VbM/jFFybLQZcdlu5VLfTMZx+dZEet6d4k8f6CdKuTOlla3U0g8tlKlvLQZDAY6mu9pLUZyrar4ujxnw1YzZ/556pjH1zHTk1vxJj974Skz38vUYWH4ZIz+OK6ijNO3mI5lvEWrR487wnqgz08ue3k/PEnFRHxhMrYl8L+I1wcMVtkcD34kOfwzXV5ozRZgcyPGEP8ejeIUz0zpsjZ/wC+c0x/HWjx5+0R6pBt+95mnTjb9flrqaKNQOR8M+KtN1P4t+GxpFzJI01rd20yvBLEdu1ZF+8oyMxn9K9zrxyxnbw98SrXVr2IXdjqqxaXHLzvsZGb5QBnBR2IyeoOOcdfY6xlvqUFFFFIDG8U+I7Hw1YR3N+J5XmkENvb20RklnkIJCIo6ng+g96y/hZpd7o/gqztNStzbXHm3E3kM4do1kmeRVYjgkBhnFZnxIjm07xH4U8RRSRTC2vF0/7HKuQ32lljMiEdHA9Qcgnp39AoAK5vxD4J8P8AiC8F5qWng3yqFW6gkeGYAdPnQgnHvXSUUAcQfBeq2RdtB8Z63bEjAjvtl9GP+/g3f+PVWvtW8Z+F4ftut2+ma3o8IzcS6dE8N1GneTy2ZlYDuAQcV6BVHXdPGraJqGnGaSAXdvJbmWP7yb1K7h7jOaAOc8b+Mf7F8MWWo6Javqt5qDxrY20SMzThhvJCjniMMfyzXOaLd+MfG2talZ6vHceGNHsZAp+xuPPuCyqwjMhBxtBO5kxywAPGa4Sx8WXvh2COfVAmoatowl0LRLfC4uJjKVaXCYG1YxBHkHOdwJyc19Fxsy26tcFA4UFyOFBxz17UhnCa34E8LaRol7qMWlXZurWF5zcWdxKL2QhcnEobcxOOhJFYfg/w/froEGqX+kaL4m/tAC7LSuHulV+VUSyDZJhNo/gGQfUmsTWPF1342+KOgeG0DxeEL0yyKUlaN9QSNJMsSpB8ospAH8W3PQ17dp1jbabYwWdhBHb2sChI4o1wqgdgKAMTQdb0kSxaTBaS6RcDd5dlPamAH+I7CBsfqT8hPf3ro65b4lWM994TuDaFlmtZYrsNGP3gEbh28s9n2hgDzzx3ro7K5ivLOC6tpPMgmjWSNx/EpGQfyNMRNRRRQAUUUUAFFFFADZZEhieWV1SNFLMzHAUDqSa5fw9bf25qI8SX0IKYK6XG45ihPWXB6PJ1z1C7R61D8T2uV0SyEUAubOS/ghvLfzAnmxu4QKWIPy72QsO6gjOM12AGAABgCgArgviQRY+JfAmsHrDqxsT6BbiJkyfxC13tc18RvD8vifwdqGmWkiRXrhZLaV+AkqMHQ55xyuM+hNAHS14n8OcTeHDfFAs1/d3N05HVy0z4J7n5cdea9I8BeIpfEuhNc3lslpqFvczWd3bo+9Y5Y3KkA4HUYP415v8ADNseCNLjBw8CvA3+8jsp/VaunuJnReBobrTPiDq6C2m/s3VrWO5E4UmNbiI7GXPQEoVPvtNaMfh+28W6zc6nrqTT2llfNHY2sjHyGSNNjM0ZJVsybyCRn5Vxx14vxdomkJpN/qMWnaNaX0SNObs2UasxHPzsoDHPrnPP59l4e8GWc2g6bcx3+uWdzNbRySfZtYuDHuKgnCNIyYz6D86UlZjR3MUaRRpHEipGgCqqjAUDoAPSsnxR4m0Xwrprah4i1O20+0GQHmfBcgZ2qvVmwD8qgn2qlY+HNTsryGRPFutXFujAvbXUds6uB23CEOM/71ZPxx1Ow074V+J01C9tbV7rTriC3WeVUM0hibCJk/Mx9BzUgdta3Ed3aw3Fu2+GZBIjYIypGQcH2qWsHwJqVjqnhDSZ9Mvba8gW2jjMlvKsihlQBlypIyDwR2reoA5X4sf8ks8Zf9gW9/8ARD11Vcr8WP8AklnjL/sC3v8A6IeuqoA5Xxl/yMfgT/sNSf8ApuvK6quV8Zf8jH4E/wCw1J/6bryuqoAK4/4qYn8LLpp3H+0rqG1baSPk3b5OQQR8iOM+9dhXnXiq/j1jxba21q3mW+jiQzuD8ouHUKqD1KoXz6bgO/DSuwOUHhnU7Af8SPxLfRqMnyb9Rdxn0GThwP8AgVH9q+KNOH/Ez0ODUI1GTNpdx83/AH7kwc+wY11dH41tYm5zNr440OScW95cSabdHH7nUImt25924P4E10cUqTRiSJ1dG6MrZB/Gm3VvBdwtDdQxTxN1SRQyn8DXOSeB9HSVptL+1aROzbi+nTtCD/wDJTH/AAGjUNDqKPxrz/Rrnxc2oatb2GoWGp2lhcC3D38ZieQ7AzANHxkFgMlTmtVfE+p2mBrPhjUYc8eZZMt2n1+Uhh/3zRzBY6v8aZPKkEEk0rYjjUsx9ABk1g6d4z8PX8gih1SCOfOPJuCYZM+m18GmePZHn8MvY2bKbjVZYtOhOeCZnCHn/dLH8KL6XCx2Xwas3g8CWl7OhS51WWTUpcnr5rFl/wDHNg/Cu3qGytorKzgtbddkEEaxxr6KowB+QqasCgooooAKKKKAOA+M0jPoejaejAfb9XtYnGeqITKf/RVQ1B8SpBc+O/CNkHP+jx3d86A/7KxqT/38b8qn/GtaewmFFH41Fc3ENrA89zKkMKDc8kjBVUepJPFWIlo/Gs3SNd0nWfM/sjU7G+2ff+y3Cy7frtJxWl+NABRR+NFAHLxKsvxNuZAQTBpEaHnOC8znHt9wfpXUfjXLaCGk8d+KpmOVRLSBeemI2c/+hj/JrqfxpIGFZXifVJtH0a5vrfT59QaFGcwwuiHAUnJLsABxzjJ54BrVrH8Xm5bw7fQWNjcX1xcQvCsULxqQWUgMTI6jA7859jTAi03Wpb/wlYa1b6dPPLd2sNytnBIm/wDeKp2hnKKcbupI6dM8UngnXv8AhJvDNhrH2Y2v2kMfJL79uGK9cDPSqHg9tR0rwHplvd6JfC+0+1gtWtVkty8pREUsjeZs25z95lPynjpmH4TWWo6V4NstL1fTbixubQMpMkkTrJudmypR26AjOcfjQB2dFFH40AYfir7+gf8AYc0//wBKEr2GvHvFP3/D/wD2G9P/APShK9hrKe40FFFFQM4r4pQ3B07RL2CyuL2307VoL26itl3SeUgf5lXPzEMUOBz37V0ug6zp2v6ZFqGj3cV3aSj5XjPQ9wR1BHcHkVoVxWu+DZodSl1zwbdJpOtPzPGyk2t97TIP4v8AbHzDJ60AdrUdwJWt5Rbukc5UiN5ELqrY4JUEEjPbIz6isHwb4jfXoLyG+sJNO1awlEF5aOwfY5UMCrD7yEEEGt64ErW8ot3SOcqRG8iF1VscEqCCRntkZ9RQBxHwo1fWtUXxZD4ivob6507XZ7KKSG3ECLGsUTBVXJOAXb7zMeeSa6zXoby50PUINLn+z38lvIlvNjPlyFSFb8Dg1zXgHwprHhnUNbmv9Z0+/t9VvJNQkjg057dkndY1+VjM42bY/ukZyc7u1dpQB4h4Z8EnTdf8KaXqQjm1QA6nehDlLeGHiKFc9jNIHJ/iZWJ7V3/xVLP4TWyV2UahfWdi+0kFkkuEV1z2ypYfQ03wqPtnj3xjfyYY28ltpsR/uokIlI/77mb9Kd8QWLXvhCDgJLrcRYnoAkUrjn13KtIZ00On2cHkGG1gQ26COIrGAY1AwFX0GO1WqKKYjC8W30sNkNPsYRcajf5ghiLbVUEfNI57Koyfc4A5NR6VqekaRJY+Gf7Rja+tbeKEK2QThQFBPQMQM7c5xzjFQeItN1n+3INW0EWMlwLR7Nku5GQIGdW8wbVO7G37vGfUVI3hKxfwvd6PMqztdhnnuJUBaSdh/rjn+IHBHpgAdBQB0lFZHhLUX1Tw3p91Pn7S0eycEYxKp2yDH+8rVr0AFFFIwJUgEgkdR2oAiu7qCzt3nu54oIEGWklcKqj3J4qsdZ0saeb46jZiyGP9I89fL5OB82cdcVyvgvQtOvbJLjWYP7S1uxme2nmvnM7JKhI3IG4TcCGG0DhhXRHwzoJ1CO/Oi6Z9tj+5cfZU8xfo2M9z+dAGFq92fGdodJ0iOb+yrlSLrUyhQKnYQbh8zk4ww4A5BJxXZgYAHPHrS0UAFFFFAHjdj4luvCnjrxvo+m6Fean5t7DfxiN0ijQzQqXLOx6Fl4wD0b8cfSrLxfCt2lumjadb3F5PdASPJcvEJHL7ABtU4LYznn0rQ17U2074teJ4o9O1O/uJ7WyeOKytmlYqquCSeijLAZJArShtfG2pHFl4fs9MiIyJdUvAT/37i3H82FVGyVwZz8mhwXWsRWfinxE2q3ceJ4tLeJbeObgEFY8fvsegZsHg+lehfCvVbSXwqlu9wY7yDfPc206tG9qHdnCEOAcKDtzyODzXmmp2evXH/CXWniDWtJ8vQVt5mtZdPVrS6Ei713l9zKOGUEYIPOaseGW1XUBaal4St9SgWNvs5ivf9KiglPLIrMwlRAB13snK/IaTdwse5adfWupWcd3p9zDdWsoyk0Lh0YZxwRwas14x4Qk1H4cve22tRyWGlXE5nVpohNZxsx+crcwgeWp9JIkAwAD6+qX9zd3mhtceGZtPnuZlVraWdi9uwJHzZTkjbkjB5OOR1pAadFcB4F8WajrPizVtImvNH1qwsreOQ6rpMTRRJMzEG3YGSQFwBu4bgHBANd/QByvxY/5JZ4y/7At7/wCiHrqq5X4sf8ks8Zf9gW9/9EPXVUAcr4y/5GPwJ/2GpP8A03XldVXK+Mv+Rj8Cf9hqT/03XldVQBBfxzTWFzFazGC4eNljlAB2MQcNg+h5ryvwoyP4esmVSjlP3oJyfNBIkyTyTu3ZzXrdeV2GBqviEQkm1Gpy+TnORwvmf+RfNx7Yq4biZfo/Gj8aPxrUQVHcTJb28s0rYjjUux9ABk1JXL/EmaQeE7m0tz/pGovHYRjPUysFP/jpY0PRAL8N4JI/CdtdXCBLnUHkv5cHOWlYuP8Ax0qPwrp6jt4Y7a3jghUJFGoRFHYAYAqT8aFogK1/YWeoReXf2lvdR/3Z41cfka5uTwBoQkjlsUu9Olik86N7O6kj2PzhlXJUEZPQd662j8aGkwuZEH/CX6cY/wCzvFZu4k6Q6pZxzbvq6bG/WrsHjXxfZAjUvDen6iM/6zTb3yzj/clHX/gX51azR+NTyIdyRfivodukja5Za1oyoMl7uxdk/B4t4/Wuh0Pxn4a11ITpOuadcvKAViWdRJz6ocMD7EZrzD4lt5nhZ7FWZZNRuILJSDz88ig/+O7q1tR8PaNqQxf6XZXBAwDJCpI+h61HJqFz1mivFofCFjZg/wBj3ur6Tn/nx1CVF/75LFf0q5HH4tsgg0/xjPLGv8GoWUU+R7suxvxzS5GO5NrUovfi3qbgHGnaXb2uc/xSO8h/QJ+QrS/GuV8FXN5qOpeJ9R1SS3kvpdR8iR7ZSsZ8qJEG0EkjuMZPOa6r8a0hoiWFVNWNkLGT+1DbfYzgP9pK+WckAA7uOuPxq3UN7bQXls9vdwxTwOMPHKoZWHuDwaoDgtMWWD4vzpqD291dyaQfJktY/KW3hEw+SRCWJYkght38JAUc16HWbpOi6Xo6yJpGm2VgshBcWsCxBj6naBmtKhAH40UfjR+NAHB+GvEWkW2u+K21DVbG2mbUjGFnuERiqRInQnpkEfhXWw6zpk3+p1Kyk4z8s6nj865rwTp1nfRa3dXlnbTtLq90VaSNWO0PsHX/AHa3H8L+H3GH0PSmHXm0jP8ASkr2Gakc8UuPLlR8jI2sDkfnUlczN4D8LTA79DsRk5+RNn8jTY/AfhyMAQ2UsIHTyruZMfTDjFGojqKPxrl38E6dz9nvNZth2EWpz/L7jLGkj8HmPPleI/Eajrhr7fz/AMCU/l0o1A6n8aK5K403xDozi60jU59ZjHEtlqDIGcesciqoVvYgg+tOl17xJJHvs/CUm3BP+k38UbHHYBd3J98UXCweOLm+XUPDNnpeni9uptThmjVrhYU3QsJdpZum4K3r06E4B7sar48IH/FMaKP+4u3/AMZrzmw1+w8U+OvCOlgy2ssN495cW9wpjljkhjLIhHuWzkcEKee1e91lPVlI4xL7x9Nnbofh23x/z11OVt302w04z/EAjjTvCoPr9vuDj8PJrsaKkDjWb4hY+WLwoT7y3A/9lqFl+JLnKS+D4R/dMdzL+Ody/liu4ooA8q0w6/4d+KFpc+IzpUv/AAkkP2M/2YkiYlgDOjursSRtLLkcDjOOp9VrjPiDp+oLe6F4i0azN/eaNNI0lor7Xmt5E2yBM8FxhWA4ztx7GuvxZ8FeUjTa3HBKw+a3kicSo2cFWQDIYEYx/iKQHd0Vwx+KnhQqTBd3tyw4Cw6bctn2z5eP1qu3xU0xn222ieJrj0ZNMdVP4vtH50wNH4dkfaPFoYAXH9uT+aASf+Wcew/jHs6fr1q78QtKm1fwneRWQH9o2+28sye08TB4/wAyoH4muZ+HOvRaj468VItjfWAvUt7+OG9RUdsJ5LkBWPHyR9889Bxn0HUbyDTrC5vbyQRW1vG0srt0VVGSfyFAFbw7qsGuaDp+qWh/cXkCToO4DDOD7jpWjXJfCy0ntfBdm91GYXu5Jb1bf/ngk0jSLH+AYfjmutoAKgv7uCwsp7u8kWK3gQySOeiqBk1PXN+LP9Pv9H0RQSl1P9ouRjI8iHDEH2ZzGv0Y0AVvhxcrfWGrXlusyWVxqc8tsJY2jO07d3ysAR+88zggc5rraBUF/eW2n2sl1fXEVtbx43yyuFVcnAyT7kCgCeuf1zWnN7/Y2iPHLrEgy5yCtonGZHHrgjavckds1y/inxxft/ZkWi2N1aWOo3JtV1W6i287HYeXE2GOdhwzADuA1c2/hGNNS+3WOsaxY3LxeVcS21ziS4+Ytl3ILE5J5BFNRb2DY9a0yxs9C05kVwibjLNPM3zSOerux6k8c1i6l8RvCGnyCOfxBYSSnjy7Z/tD59Nse4/pXBDwToUkxmvraXUpycmTULiS5JPr87EfpW1Z2VnYRiOwtLe2jAxthjCDH0FUqbFcuS/FC3n3rovh3X9QbHyO1uttE3/ApWU4/CqUni7xrelTaaLouloev2y6e5f/AL5jCj/x6rIY+tOBzVezQXMyw8Ya94c1iFvGN9a3uiXjCI3UFt5IsZScLu+Y5jbONx6HHbr6upDAEEEHkEd68u1uS1h0a+l1CITWccDvNGV3BkCkkY78DpXI+BtF1vStCtr7RNbm026uSblrBgJ7IK53BPLJ4wuBuUg/WplDsFz0HXz/AGV8YPDWoZxFqtjcaZKWOFUx4mjP1Pzitk+KXviw8OaVc6qoYoLnesNtkHBxI3LAEHlFbp9M8LpsGq/ErWrOLxXpUUGj6M03mSWtwWgvrn5VwAcMoUFwevUjPFevRRpDEkcSKkaAKqqMBQOgAqBnnt34Bu9e1y+1HxBfRW8F9bx2tzp9gu5Jkjcsm+Rxknnnaq8YHrnvLCzt9Ps4rWyhSC2iXakaDAUVYooAKzdXi1CDRpY/Dcdgl8gXyI7oMsH3hkHZyMrnBAODg4PStKigDiPD3h3WX8f3nirXk02zlfT106KzsJ3nDKJN5kkkaOMs2eANvAJ55rt6KKAOV+LH/JLPGX/YFvf/AEQ9dVXK/Fj/AJJZ4y/7At7/AOiHrqqAOV8Zf8jH4E/7DUn/AKbryuqrlfGX/Ix+BP8AsNSf+m68rqqAAnAJ615F4RbzPD9tOxHm3Be4mA7SyOzuDz1DMwr12vMtStTovi+8s+lnqIa+tiSeJM4mTk+pVx/vnjirg7MTLH40fjRR+NaiCuU14/b/ABx4e0/AaO1SXUpQT0IHlxn/AL6cn8K6uuU8NkX3jHxNfnafIeLT4+fmVUXe34FpP0pMEdXR+NH40UwELYoBzUVxIsMUkrhyqKWIRS7EAdgMkn2GTWR4V8SWfiSK/lsYbuJbO7ezkF1CYWLqqsSFPzAYcfeAPtQBu/jR+NFFAHLeJ9114s8LWIKmNZpr2Qd8Rx7VP/fUg/yK6muVtAt58S9RmGSNP06K256B5XZz/wCOqn+TXVZ96SBhSMwVSWOAOTS/jQcEEHBBpgcl8L54rnwlFcoyma6nnupQGBYF5XIyM8HGPyrra5y68EeGbkkvotkjH+KFPKP5oQagPgu2iQLp2r67YKvKrDfuyj/gL7hSV0B1X40V5/ocHia/l1VbXxSRFY3rWkf2iyilLhUUksV2nOWI/DvWu8fjSFMQ3Xh+6I7ywzQk/kzD9KLhY6nij8a5Yal4tgj/AH/h+wuW9bbUdufwdB/PvSr4n1GJf9O8KaxGf+mDQzj9JM+nai4WOo/GiuVj8cacM/bbLWrH/r406Yf+gg0knjzw3JBcCLWbZJlRiElYxHODgfNjn/Pei6Cw/wCGcgm8GWc69J5J5gemQ8zsD+RrqPxrj/h5qmlW/g3RLUanY+ctrFvjE6BlZlBIIznOT+dddFKkqb4nV0PdWyP50LYGOoz70UHkUwG7qN1NryfQ9Hg8GXWh2+v+GNDnlu794IdXtisk6zO7yR7g0SsOONwY420bAeuUUDpRQByvj7R47jTxrNpbRNrelMl5aTbfmzGwfb7g4PHqa9k0fUINW0my1GzbdbXcKTxk/wB1gCP51wpwQQeQe1O+DNwbbTdW8OSH5tGvGSEYP/HtL+8i5PXGWX/gNZzXUaPQ6KKKzGFFFFABXlvxT0eHRL208VaVL9kvJru3s72ID93eI7hMsP76gkhhz2ORXceNNcPhrwtqWsi0e8NlCZfIV9pYA+uDgDqTg8CvNZItb8S6np2peKJ7FbayJmtdPsgxjEhGFkd2PzsATjgAZ492k29AN+ij8aK3JMHXr+Pw7rWieJZn2W1nMbW8bsLebCkn2VxG34H8bHxE8Z6Zr9pbaNoAn1y0lnik1NtNCyKtuDuMe8sF3OQAVzkKWz2znfExPM8CawevlxCUfVGDD+VdJAsSxjyAgRvmGzGDnvxUOF2O9kEnxE1YgfZPBGpOP+mt5bR/T+M1U1T4j+I9P0y6vpvB1usNtE00mdXBOFBJwBEc8D2q9+NUtbtxd6Lf2zAFZreSMg98qR/Wj2aC5rWs/j/WLe1uIH8M6XaXEYkDDzryQKwBGP8AVrnn3FGneHfFun+ILjVZta0zV5JYEgUXFmbfylBZiqFCcAkgkncTtHoK2PhrdC9+HvhqfcWLadbhif7wjAP6g10lZDOI0Txbr95p+bzwbqcGoszBY/MjWLAOAWdmBGRyflPtmtS30rUtSv4LvxE1mIbdjJBY24Z1V+Nru7Y3MOcYUAZ79a6OigDgvjXHs8GR6ju2nTL+1vM5xwJVVs+212qvWh8abgW3wr8SSG1N0DamPYGxt3ELv/4DndjvtxxXPeHLwah4f028Bz9oto5fzUH+taU+wmaJPBqtdQJdW0sEplVJFKsYpGjYA+jKQwPuCDVn8ar3dul1bSwSmRY5FKkxSNGwB9GUgg+4INaiOK+EEK2+garDGXKR6xeou9y7YEpAyxJJPuTmu6XrWL4e8NaZ4eM/9lJdRidi8iy3k0yliclsO7AMTySOT3rYkljgQvNIkaD+JmAFJaAQ6vaf2hpN7ZeZ5f2mB4d+M7dykZxnnrXO+GdblsxHoOt2zQatbQHyVi+ZL1EHWEk8sQPukg5NSaz480DTYpfLvUv7hFZvs9kRM52glidpwoABJJIAANR+F9MudRvI/EuvbTfTR/6JbA5SziYZwPVyD8zfgOOst66D9Tp/hRrKpK3h86jBcLbw+bHHPC1teqxZi4lichiec7goB564r0uvMNE0C08U+IdVfWYvtumWUMNtFDMMpHcZZ3kjPVXCtGNykH+m6PD3iDRDnw1rpu7UdLDWy04A9EuB+9Xty/mfSsnoxnZUVTu7MalpZtb/AM2EyoPNFpdSRMp4JCyoUcc9xgkfXFcJ+zzGsPwl0mJM7EuL5RkknAvJu55NID0eiiigAooooA5X4sf8ks8Zf9gW9/8ARD11Vcr8WP8AklnjL/sC3v8A6IeuqoA5Xxl/yMfgT/sNSf8ApuvK6quV8Zf8jH4E/wCw1J/6bryuqoAK4L4q2V5DYjxHazGRdGt5pWs2ACsCvzOD/eAHHbG7ua72uX+J5f8A4QTVwiF1eNUlAQviJnUSEgdghYn6UAeYfC3WtZ13w8LrW1gJB2RzIQHkKkq29BwpBHbrnoO/ZfjXNeC/DqeHP7RisbhZNJuphc2sQOfK3L8wBzyvAx/knpa3jexLCuP8UxP4f1ZfFFkrGDaIdViTP7yEdJcd2T/0EkV2FI6rIjI4DKwwQeQRTauA2GWOeJJYZFkikUMjq2QwPIIPcU/8a47w5I3hrWm8NXLN9hn3TaVIxz8vV4CfVc5Hqp9q7H8aFqBFcyLDDJK4cqiliEUuxA54UZJPsOa4T4Y3B/tHxTHJZ6lbm71aa9ga5sJ4FeEpEoIZ0AzkH5c7uCcYr0CigAoo/Gq+pXaWGnXV5LzHbxPKwz2UEn+VAHPeB83Fx4i1FiGN1qciIwPVIgIl/wDQTXU1zvw7tTZ+CNHjcESPbidweu6TLnP4sa6KktgYE4pA2TWXr1peXiQi01ebS44yWmeGKN3ZcdAZAyqO+cGsj4capfavoc9xfTrdxJeTRWl4EVDdQK2FlIXAyeRwADjIHNMDrKKPxqjrt2LDRNQu2OFgt5JSf91SaAMT4bbZPDTXin/j+u7m6J9d0zYPX0Arqaw/A1stl4N0SBRjbZxEj/aKgn9Sa3PxpLYGFH40fjQTTAKjmhinXbNGkg9GANPBzS0AZF14a0K6ObnRtNlPq9shP54qjJ4F8LuSf7Es0PrGuz+RFdLRRZBc5L4dwRWkOvWtsXFtBqksUSNIz7FCR8AsScZyfxrra858H6xqNrFq5tNAvr23n1W7mSaKWJQQZCMYZwcgg10C+J7wDEvhbXQ46hBAw/PzealNWG0dIyqwIIyCMGue07wXoWn3lrc29rK0lruNsJ7qWZIN3Xy0dyqf8BAqM+LJVyG8N+IQ3oLdD+okIqNvGiocSeHvEqt6DT2f9VJFO6EdXR+Ncqvjez/5a6Xr8LdhJpkuT78A09fHGkc+dHqkB7CTTbjn8kNF0Fjp6x/D+t6f4f8AiZqn9rX9pYWl9pcEglup1iVnjlkXblj1w/8AP3qifHWgA4e6uY/+uljOufzSuS8b+KvDss2m6xaXKS39hLzDLbOv2iBuJEG5QCQPmHuPeplZoaPdP+E78I/9DVoH/gxh/wDiqqH4leCwf+Rn0r/wIWuU0s6Lqtml1py2Nzbv0eJVYfQ46H2rQ+zwgYEUeP8AdFL2fmFzVn+KngeFwr+JdPJIz8jFx+YBqP8A4Wz4HOAniG3kY9Fjjkdj+AUmqKIqAhFCj2GKdR7PzC5U8cfELQdV8G6hp/h+6XVdS1S3ms4LSGNi4LDYzSKRlFXdnLYz2p2m25s9OtbZpDK0MSRlz1bAAz+Nc59kt4PilFcQxIk1xpM3muo5crLEAT74NdZThGwMr397a6faSXV/cw21tGMvNNIERRnHJJwOTVbQdasNf0qHUtJuBcWUxYRyhWUNtYqeDg9VIqxqF5a2FpJdX9zDbW0XLzTSBEUZxyxOB1rhfghqNld+BYLe1vLaeeCe5M0cUqs0Ye5lKlgDkbhyM9R0q+ojqvGcJufCGtwrjc9lMBk99hxVjw3O1z4d0udiS0trE5+pQH+tW7uPz7OaLn542Xg+oxWF8Obj7T4D0F85xZxx+n3Rt/pS6gdCWNKDkc02nL0qgLvwUwnw30y3BybWS4tiO42TyKAfwArua8++DW6PTPEVuxJEGuXIUegcJJj/AMiV6DXMUFFFVNX1CDSdKvdRvCwtrSF7iUqMkIiljgd+AaAOT+NVzJbfC7xAYQTJNCtsoGefNdY//Z68y8H+JLDRtIi0C6a5n1TT5prJre1tpZn/AHcrKOFB7Ada7nStJ1Xx9d2et+Kd9j4fjZbnT9FjfmXGCktyw6nowQcDjPQg+l002ndAeIx+KL+8u7+10zwzqrXFlEs8/wBvMdkqRtnDEyMDj5W5x2Ncbf8Aj/xNJa21xFp9jpdpdTrDFd3cc7wlSceb5u1U2D2yfbFex+LPAL+I/GEGoT6g8OjSWi21/ZRZVrsI7Oisw5CZc5x1Ax3yMT4jahZ6/rOieFtIa3lgsp49RvniIZIUiJEcOBxuZu3ZV6c0+aTDQ53wrpd5qevz6N408Vzw3ksUd1Yf2RcRR297A/eOTYHYgggjg9xkc122o+AvBHh/T5tX1TR5NQW1XdJJdGa+fGQCdjFs+pwOmTXLf8ID4a8y5YaXEBOANoYhY8HOYwD8hz/dx/jrfDq819fE2uaK2sG/0bTbVGWS8AaaKWTJRGk6sAqlsnJwRRKLW4XPINRil8YXniPxBADpWhaXHCYNMtlERe0kJR5QowP9U0hJx1OO2D2OkW3iPw7od5a2Vy2q3uivFBLpDW++SWFmCxy28iYJQqc/MG27WBPGaqfDzUJbvxRF4engtJ9Nfw4dK1FlcA2iwmRWdiWwwZ3JBAGVdCOjVuC/1qwtvBt3qPhG4N/ociWlzqMksMXnqUaBFjdm3MrM6NjHPP4wnbYbPVfAulSaR4ZtIboYvZt1zdZ6+dIS7DqehO0c9FFb9FFMRW1Kyi1GyltLhrhIpRhmt7iSCQc54eMqy9OxFZfhLwnpHhK0ktdCju4baQ7vJmvp7hFO5mJVZHYJksxO3GScnNbtFABRRRQAUUUUAcr8WP8AklnjL/sC3v8A6Ieuqrlfix/ySzxl/wBgW9/9EPXVUAcr4y/5GPwJ/wBhqT/03XldVXK+Mv8AkY/An/Yak/8ATdeV1VABSMAVIYAgjnNLSMMgg9DxQB5D4ZKyLfT2JI0Se4Mmmox+ZYSo/wDHS24qOykVssazNDt20kz6BOR5ul7YYz/z0gx+6fr/AHRtP+0rVpt0Pet47Evc5XV/Gltpt9qVvFp2pX/9mRrLfSWqRlbcMu4Z3upY7fmwobiuksbuG/sbe8tX8y3uI1ljfkblYZBwfY15F4x0g3WveK21Sw11J7qBIbCXSIpSlzF5ZBjlMYKk7yc+bjAAwQK9Q8LRXVv4a0qHUIoobyO1iSaOL7iOEAIHsDQtwI/FWipruktbiTybqNhNa3A6wzLyrj+vsTUfhHW21nTm+1xiDU7Vzb3kGf8AVyjqR/snqD6HvW5XIeKoZdC1SPxRYI7xKoh1OFOfMgHSQDuydfdcih6ah5HX/jR+NR288dzbxzwSLJDIodHU5DKRkEe2DUn40wD8a5j4kysvg6+t4n2TXpjs09zK4Q9/RjXT1yvi8i51/wAK6djIe9a7b2EMZI/8eZKT2BHTwxrDCkUfCIoUD2FPoopgc54x0G/1w6eLLU4rSG3lMk1vPbtNFdcYVXCyISoPOM4JxnpWjodtqFpbGLUrmxnK4WIWdo1uiKBjG0yP+hH0rSz70fjQAfjXMfEuYxeB9VVT806LbqB3MjBP/Zq6f8a5bx629NBtMbvtOrW4ZfVUJkOfb5KT2BHTxIsUSRxjCIoUDPQCnfjRR+NMArO12C7ubEpY6hJYSAhmmihWZ9o6hVYEZP0P0NaNZ+t29/c20Y0q/jsrhJA5eSATI685Vl3A4PHIIPHWgDmPh7q19qOp69b3N9PeWdpLEtu95AtvdDchLeZGFQqucbSUUnnrjNdvXN+HPD82natqeralfJe6nqAjR3ig8mJEjB2qqbmP8RJJY5rpPxoQB+NFH41HcSiGCSVskIpYgewzQBzPwvDf8ITYyOTvleeYknJO6Z2GffBFdVXOfDhDH4E0IHGTaI/HuM/1ro/xpLYHuFGfeiua8U+JptC1TRrUaVcTwahdxWn2vzUWONn3cYyXLALn7oHP3s0wOl/GjNc3rfiGa11u20XSLEX+qywm5ZJJvJihhDbd7vtY8ngAKScHpitu0adraNruOOK4KjzEikMiq3cBiqkj3wPpQBZo/GmqTmnfjTA4Xw6lrY/EXXluYI7G7ukjFpGqhEnhUfM4I4ZyxOc8gYruq5D4rwxnwTf3ZRftVmFnt5f4onDDDKeoNdfUrTQGFFV7u9trQwi6uYYTM4iiEkgXe56KuTyT6Cqura3pmjLG2r6nZWCyEhDdXCxBiOuNxGaYFPxVocmprbXmnTJbaxYsZLWdhlefvRvjqjDg/n9ZPDOu/wBrx3EN1bvZ6naMEurVznYTnBU/xKcEg1q286XESyxOkkTgMjo24MD3BrmvEHh7ULjXf7W0bWRpUrWv2edjAs28KxZThjgYJOT1xSemqA6o8imVjeCNUuda8LWGoXwjE86sT5alVYBiFYAnjIAP41uU0wGTSCGB5GyVRSxx1wBXNfDKMx+BNJ4RRJG0qqhBCq7syj8Aw47V0N9dwWNnPdXcix28KGSR2PCqBkmud+G0E0PhlXkia3t7ieW5tbZsboIHYsiHH1J9s4pdQ6HT7aUcClzXH+LiNc1zTfDkLSmMN9r1Dy5WQCAKyqjFSD8zEEDP8OabYEGl674h0TxX4wHh2DTbyCOa2uprWcP5smYVBWNgcAkI2Mg89q9S8P8Aj/wxrtmJ7TWbONwm6W3uJVilh45DqxyMdCenvXKaNoumaLC8WlWUFqr4L+WuC+Om49T17+tGpaLpeqMralp1ndspyDPCrkfnWbhcdzfuPil4Phv0tV1iOYGRY3uIUaS3iLcDfKBsAJIGc/XFYvjyCbxd47t/CNtrl3Y2R0me4vktHXLhnRFVgQeoZuDjg5p8tlay2T2clvE1o6lGh2jYVPUYpnwIsdP0zStc063t4Y9Qs9QeG4lzmWaP70LMTzjY2AOnB7kkzKNhpnpVnbx2lpBbQjEUMaxoPYDA/lU1FVtTvYdO066vrokQW0TzSEDJCqCT+gqQPO/FPjPxGPFGp6V4Us9Mng0+GNJ5Lt3VvPdSwCEZB2qUJBHeszwfoUHh/QrS0ihhS5ESfaZY1AMsgHzMT1POetV/AKSSaANTudv2zV5X1Kfb03SncB17LtH4VuX1rHe2klvM0yxyDBMMzwv1zw6MGH4GtYRtqJsnrg/Fei6no0ep674a1zVbW4kkFxNaR4khkG0K2YyDngA8hsAHApfgsgj+HGnRpnas92oySTgXMvc9a7lnVI2d2wqgkk9hVNcy1FseOfDHTtI17xL9n8Q6Vpslhq0fl20+mgoi3KhmwQrApuj3bkKqp2r8vc9Dp1l4o8Y+JNP8IaxqcMFh4eZGmNrnfM0CxqJPMPO/97kDG0FTnOATwvhzWrOb4y6JfeHLeyguXv2RpfNKQTRsCpO1sFHKluOckjAJ4Pv/AMKvDl9pGq+LL3VUInudRkSJyCPMi8x5RIM+pmI4/u+1c5bPRKKKKYgooooAKKKKACiiigDlfix/ySzxl/2Bb3/0Q9dVXK/Fj/klnjL/ALAt7/6IeuqoA5Xxl/yMfgT/ALDUn/puvK6quV8Zf8jH4E/7DUn/AKbryuqoAKKKKAOJ+I9mLVLbxDDhXs/3N0Mf6y3dgD2ySrYYfVvWqFdL8QI7STwTrR1ESfZYrV528tyrAoN6kEd9yjHX6GuR0wXC6baLev5l0IkEz4xufA3HHbnNaU30EyfHpThxRRWggpGAdSrgMpGCDyCKX8aKAON8PsfDGunw7OxGm3RabS3PRe7wE+2cr7E12VZPijRk1zSXtvMMNyjCa2nX70Mq8q4+h/QmoPCOtvq9jLHexiDVbN/IvYAfuyD+If7LDkH0PektNAN2uC1U6vqHxCkfQHsc6TZrFIt6r7N0zbjtKnIO1E5569K09R8UX8Os39pp+hTahBYeX9pliuFD/Ou7CRn7xAI4yD6e6/D+KWWw1DVbmOaKfVL2W42TLtdIwdkakdsKg/Oh66BsA1XxVbNtuvDltdKBzJZX68/8BkC/zoHjOGEMdS0bXbFV4Z5LJpEHvujLDFdTRRZgc9Z+NfDd2QsWtWau2AEmk8psnttfBz7VuwzxToHglSRD/EjAj9DUd7ZWl8my9toLlP7s0YcfkawpvA3huSYzJpUNtKRjfau1uf8AxwijUNDpfxrltfcy+OvC1sMFY1urpuemIwg/9GGj/hEprcMdN8Sa7bMTlRJcLcIPwkBOPxrn4LLxL/wnsqRa3Z3c9npygzXNlgESSE7CqOOf3YOePp6psaPSaPxrlTJ41hfJg8P3Uf8AsSzQt+oYfr/9dX1vxJCw83woZF7m21GN8fgwXNO4rHU0HmuWk8XSQAfafDfiGM99lssoH/fDnNKfHehRqTdy3lpjr9pspo8fUlcfrRdBY6bFOrAtfGfhq6XMOu6d9HuFQ/kxBrWtL+0vRmzu4LgYz+6lDfyPvTugLP41meKJPK8NavIMkpaTNwfRDWnWB4/l8nwRrzdf9BmXr6oR/Whgix4PhNv4S0SEkEx2UKkjoSIxWv8AjVfTk8rT7WMEYSJV49gKsfjQgCuI+I9vql7deH00zRby+Sx1KC/llilgVdqbwUHmSKS3IPTHPWu3ooA848S+GWuvGEWvXXhlddtLnT1tZLOVoDJbSKxYNiRghyG2kqxII4yDXV+DNOvtM8N2Vpq1x591GpzyGEa5O2MN1bauF3Hk4zW5RRYBAMUtGaPxoA5b4nYPgq+BwQZIAf8Av+ldTXLfE3/kS73n/lpB/wCj0rqaOoHn/wAULCzOqeD9QNrbm/GuWsAufLHm+XiQ7N3XbnnHTNUvES3Vx8Um/sa4s7bUbfRh5g1GPzIZ4mlPCgEMpHzEsCR90EHrXcar4c0PWLhbjVtH02+nVAiyXNqkrBck7QWBOMk8e9LqHh/RdSgt4NR0jTruG3XbDHPbJIsYxjCgjgYA6UrAc38GvLHw30dItxVBKhY9GYSuCy/7JOSPbFdVrltPe6Lf2tpKsNzPA8UcjdFZlIB/WrcMUcMSRQokcaAKqIMBQOgAHan5p9LAcl4P1qG1hs/Dup27abqlrCsKQyNlJ1QYDxP0YEDOOo9O9dbWR4q0m11nRbi3u4BMwRniI++jgfKykcg59KxtG8ZaRa+EtDutX1SNJp4EjdmLM3mqo8wN1IwepPr78rbRgN+KVxFDomnrcRyXEEmowLJbR8tOoYkoFyN2cDimx+N7ryZp7jwrrscG5lhZYQ7Pjj5kzuQk8dCPequmyT+MfFaanDdWSaZod3JHB5OZXuN0QyxbdtAIYYwCRiu+pb6jPPm0vxP4n1G3bXf+JLBZAXFs1jMHLSkgruByCUUEEEYO44rqfDuhro4vJJLqW9vbyXzZ7qUAM5AwowMAADgAcVsUfjTSsK5wHxJtUtdPvr6DUtaGtXKCLTba1vJVUT4wu2JSFZdxBYuCMZ6V3FgJ1soFvHV7kRqJWT7pfHJHtnNc7c+EN3iO/wBas9d1Wyu71I45FhFu6qqDAVfMicqMkkgHkkn0rpLWJoLaKKSeS4dFCtLJtDOcfeO0AZPsAPamBLmuL8dCPTru01HRZJrbxZMwhsmtcbp+mRKDw0YHJ3dP57fiTxHp+gW+67lDXLj9xaxnMszdgq9evfoK57RLjTtMuptb8V6tp0euXS7Sj3CYtYuohTnPGeT3NKVnoNHZaR8W9L/saBNZhu18Squ240q1tJHl8wHBKAjGw9QS2MHrmqGs634s8V2k9nHb2/hvSrhDHIzsLi8dDwcYOyPI92IrKk+IXhhZ1jj1Bp5X4XyLaWTfjsCqkHrT/wDhLLm4fZpvhrW7g4yHmiW2Q/jIwP6VCiu49TodNsoNOsLeys0EdvAgjjXPQAYFLfWsd7aSW8zTLHIMEwzPC/XPDowYfga50XnjG7VjBpWkaeO32q8eZvyRQPw3UjaP4nusG78Tx2wP3o7GxRfyZ2Y/p/8AXu5Jo+HPDem+HLd7fSEuIrdzny5buWZVOSSVEjMFyWJOMZJ5zxV291Ow09C19fWtso6maZU/maw/+ELtJmJ1HU9a1AHqk986r/3zHtH6VZsfBvhuxH+j6LYZ/vSRCRv++myaNQON8bnwN4pmtvOvZZryFvlbS4Wmd17odqsCO/P9Tnu/hH4hvZvEWpaMbfXJbBYo7lJtWk/fRs24McOd7ISo6Z2segBzWH49vNW0STR9Q0K0uLyKOWSCaxt1JEgdcqxAzjaV4P8AtH1rjfC2s3Phbx1p2peKV1ldUv8AEkjCVBEsfCupgQOSoGTkkH92DgdazmUj6J8dapfaR4fFxpTWy3st7Z2kb3MTSxp591FCWKqylsCQnG4cjrVX7D44/wChh8N/+CGf/wCTKj+Ik0dx4W0+aCRJYZNX0h0dGDKynULYggjqCK66oA4DxZc+N/D/AIV1nWf7b8N3H9nWU155P9iTp5nloX27vtZxnGM4OPSul8TeJ9K8NLZHV5p0a9m+z28dvay3DyybS20JErN0Unp2rP8Aix/ySzxl/wBgW9/9EPXNfGW+tNM174eXmo3UFpaQ65uknnkEaIPs8vJYkAfjQB2fh3xXo3iKS6i0q8L3NocXFtPC9vPD1xvikVXUHBwSMHFZf/CyfCxLNHfXMtssphN5FYXElrvBxj7QsZi68fe615/4vD+P/F15deBJhcxW3hy/sJ9UgP7iaaYAQwJIOHKsGYkEhc9c8VveCviJ4W0zwPoenm48nVrW3hsW0OOMm9SZVCmPyPvdf4iNvfNAHqVFFFAHK/Fj/klnjL/sC3v/AKIeuqrlfix/ySzxl/2Bb3/0Q9dVQByvjL/kY/An/Yak/wDTdeV1Vcr4y/5GPwJ/2GpP/TdeV1VABRRRQBmeJtIj17QrzTJpXhW4TaJE6owIKnHfBA46HpXFXWmeJNPdvN02DUbcZIksZwsmPeOTA/Jj9K9IopptbAeZ2N3He2yzQ7gpyCrjaysDgqR2IPGKn/GtDX/Cl4mo3OpeHJLVZLkh7izuAVSZwMb1dfuMQBn5SDj1yaw9MvTewyl4Xt5oZXgmicglHU4YZBIPPcVrGVyWi5+NH40fjR+NUAfjXIeLoJdF1GLxRp6M/kqItRgT/ltb/wB/Hdk6j2yK6+kYBgVbBB4IPeh6gcl4Buk1K78TajC4khn1IrHIDkOiRRqCD3Fddn3rj/AlvHo2o6/oMUflRW1yLq3GeDDKuQB9GVh+X49hSjsDCimsaFOKYDqPxoo/GgAzXLeF91x4r8WXZOY/tEFov/bOIEj85DXU1y/w8Bk0i/vS2RfajdTj/d8woP0QUdQOo/Gij8aPxoAM+9H40fjR+NAFa4sbO5H+k2tvNn/npGG/nWPP4K8Mzj59C01f+ucCp/6Diuho/GiwHmXjPw7pGg/2O+nT3WkrdajHDPLDfyxhYtrljy+0dAM9s1dn8O6LqdlJZHxlqlxbTr80Z1OOXcvX+IEkVp+LII73xf4UtLhI5bffczvHIAyttiwOPq4rRl8JeHJSTJoOlEk5J+yRgk/XFTbUdykvhy7eIPZ+LdaIPRi0EikfTy6P+Ec1j/obtU/78wf/ABFSv4F8LuSf7EslJ7om0j6YPFQt8P8Aw0WLJYSxH/pldzJz64DgZp2C43+wPEg+74zusds2FuT+eKcuieJ0zt8XGTP/AD102I4+m0iofA9ubPW/E9pFPcPZwXMSQpPO8pT9yrNyxJ5LV2H40JCucyNJ8TDn/hKISffTUx/6H/Wl/s3xR/0Mlj/4K/8A7dXSFuaUHNOwXOYNn4vQkJrGjyDsz2Dgn6gS4prweNEGYtQ0GQ+klpKo/SQ11P40fjSsFzzXx0viseGbg6rPoTWXmQ+YLaKVZP8AXJjBZyOuO3rXpX41z3xCtjeeCNbiUEuLV5VC9dyDcMe+VFZ2m+GzqOl2d1/wkniLZcQpLhbwDhgD1C5HXsaNmB2X40Vyg8FW+f3mt+I5F7q+qS4P5GpB4J0wkedc6vMv9yTU58fo9GoHT0VzJ8D6C337e6k9pL+4YfrJUb/D7wvIcy6WspHTzZ5Hx9MsaNQOpZgoLMQAOSSa8w0vXvCifE3ULu0u9Pihl08ebcuypG02/kBmIBJUrnHXBz0NYmn69pejab4yXTYLqztZ0ZLS0W1lIRljKeazEYUMSOCeNvNeneHdD0u10TTkhs7N9ltGolESkv8AKOc989aV+bYexh33jfwtotnOdEl0+5u5ZAVtbNlUzyEhcllBGfc9hWi2oeLZh+40LTbc+s+olv0WP+tdLHHHGMRoqD/ZGKfTsxHLxjxq/wDrJPDkH+6s8v8AVaadL8VysDL4mtIB3WDTQf1Zz/KtDxPp3263jmLatILcMfsmnXhtmnJwOWDp06j5wOuc1i/C26ubnw9dC9upppoL6eExXDl5rVQ3ywyOeXZQR83Oc8EjklgLb+HtWnGLnxbqhH/TCGCL+SE0sfg9B/rtf8Rzn1bUGTP/AHxtrpaeOlFkFzjx8N/CxnaefTmuZmOTJcXEkhP1y3NJfXPgrwtdC2mt9Ms7sReascdsDIwzgYwMkn06mnzeI9R1iaW28JWQlRHMcmpXYKW6kEg7B96QggjjjPetLw94ei0pZprmY3+pXEgmnvJkUMzhdo2gfdAGQAOmT60rLoP1M3SYNQ17xDBreo20un2NkrrY2soAlcuMNJIM/LxwF69SffrvxqtcahZ22ftN3bw4/wCekoX+ZrOh8VaBcXcVtb61p01xK21EiuUcsfQYNPYRtZrjPH01/ptrdalHrep2sEcJEVtYaek+ZAC26Rij4Tgc5QDu3Irs/wAa57XNL128nuBpuuW1paTx+WY5bHzmjOMFkYSLyc/xBqbAueFrq6vPDel3OoPbvdzW0bytbuGjLlQSVIOCM+nFav41meHNHt9B0Ow0qzLG3s4ViQucs2B1Puetaf40Ac74yuPEVvYSHw1Z21zK0TDc8wV42xwyqRtbHXBNUvh14b1fxp4e0fUPEq6dJDmVJLpWP2qRA7q8eAgCA42kqxyufWoNeRvF+oXGk6JBrR1Kx3JJPaXH2ZIScECQscMrDngMcD3rtvhH4AuvBNtKl1eRuGjWNYbd3MbHOWkbd/GSccAAAe5rKb10KWx1viHQLfWtDGlieewiSWCaGW0CB4WhlSWPaHVlwGjXgqRjis3/AIRfV/8Aoe/En/fjTv8A5FqH4rW0F54ShtbuGKe2n1bSo5YpVDJIh1C3BVgeCCCQQam/4Vx4H/6E3w3/AOCuD/4moAqat4HvdX0q903UPG3iSayvIXt54/KsF3xupVhkWoIyCeQQa7WvL/ib4B8HWfw28WXVn4T8PwXMGk3ckUsWnQo8brC5DKQuQQQCCKv/ABf8W694UttD/wCEYsLS/vL67eJoLhWJdEheVlTaww5CYGcjJ6UAeg0V5u/jjU9c1UWvgsadPHdeHRrFi92jnfKZdojfa4wCOD3VuecYqVPiGdRNhc6THEmnW9jJqeuPOhZ7NFDDyMBhiYukgOeAI245FAHodFeeaBqnjvxF4dtdesT4dsob1FubXTrq3md/JbBTzJ1kAVipBIERA6c16HQByvxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9dVQByvjL/kY/An/AGGpP/TdeV1Vcr4y/wCRj8Cf9hqT/wBN15XVUAFFFFABRRRQAVxninwpEguNW8P2yx6sHM0kSOUS767lYdNxzkNjOQMnFdnRQB5lp17BqFnHdWr74pBwe4IOCD6EHII9RVj8apxgQ+JvFFsq7Fj1AOoAwCHgicn/AL6Zvxq5+Nbp3VyQ/GmzSJDE8srhI0UszMcAAdSadXK+PbueW3t/D1gAL3WhJAJX+7FEF/eOeeSFPA7k027AU9HuZNe8bRa3pVrLHpUdo9pJdzDYLr5gy+Wp5IB3fMcdT+PbVDZW6WdnBawjEUMaxoPYDAqaklYBG6VyXinXtV0nX/D9tBa2LadqN4trJM8rmUEo7YCBQB93724/7veuu/GuL8baTruqarocul22mPb6beLebrm8kjaQhHUphYmAHzA7snp0psDtAcij8aZCXMamQKrkDcFbIB74PGfyp/40AVtSuRZ6fdXLHCwxPITnsATWP8PbX7H4H0SInLG1SRuf4nG8/qxpnxHn8jwNrRBw0luYB9ZCEH6tW/aQrbWsNvH9yJAi/QDFLqBL+NGcUfjQehpgN3U7Nee/FWxheXwteM0/nR67YRqoncR4M3Ux52E/7RGfevQV6UAL+NFH40UActeyed8TNLhz/wAe+mXE3/fUkS/0rqa5i2xL8Sr9gT+40uCM892lkP8AICunpIGFGaPxo/GmBzPg9d2reKpiTvbU9hHbCwRY/nXTfjXL+BWDyeJGHIOsTjd64VB+mMfhXUfjSWwMYa8z8ZXV7L42uLZV1rUNOt9NV2tdFvGt5beZnYK77WXfuA4GTjaSVxzXppHpXOap4VhvNZl1Sz1LUdLvpoBbzyWbx/vUBJXcHRhkZOGAB5603qAnw0v7rU/AWh3moXQu7uW2UyyjqW5BB/2h0PuDXTfjVDQdJtNC0e10zTYzHaW67UBbcTySST3JJJPuav8A40ICK6hW4tZoX+7IhQ/QjFc/8Np5J/AujGYYkig8hhnoYyU/9lrpfxrmfhwSfCFq56vNcOfq08h/rS6gdNR+NVNTt5buzlghvLiyd8YntwhdOc8b1ZeenIPX15rzrw7deIL/AOCdpPplzcXOtyIR5zuGlZfPIcgtxu2bsZ7gUwPUKM+9eZeFtVFv8QbfStMl12XTrrTnnmi1YXG6ORHUBlM434IYggfLnGO9elTSrDDJK5OxFLHHoOaLgcb4oxr/AIq03QRbGSC0db+9819sTx4YKu3q/wA2D/dGMHOa7UcAAcAVy3hzwRrniqaDxi2utoz3tvttLZLVJ2jtWIZCSTt3Nwx4OM49h1MPw4vmx9u8Z63J6+RFbw8+37s4rPnQ7BRXOfE3wQNA8C6xq1r4k8SyXdrDvj8y+Cru3AZIRVz1PHSuvT4WeFyuLqHUbts/euNTuW/DG8D9KPaBY5vxBYfbHtpV1u+0p4N2GtpIwrhsffWRWVsY4OMjJx1rM0Wbwz4UsZLVdbtA8sr3E0t1eRmWeVjlnbkZPToB24rvrT4YeCrVt0fhrTnbOczx+dn67yc1r23hPw7akG10DSYSOhjs41x+S0ufyCx5fJ468NISseqRXD9Ntqjzk/8AfANZnibVtX1aCyg0DSPFKwST/wCkz2+mtGxi2tkI0gABJxz/APqPovwxVdMm8SeHAFRdK1J3gRTwsE/75PyLuP8AgNdzS52x2PErSPxBonh9I9P8GyWem2UJ+e+1CCIIigks20sfUnjmrnhPwzq3jnSrPVvE91Jp2j3SCWLSrJyryoehml64I52rjgjJzxXrl3bQXlrNbXcMc9vMhjkikUMrqRggg8EEdq871rw/J4DiXXPB/wBsGnWzmS/0ZZWeGSA/feJGJ2Ov3gFwDjFJyYG/YfDzwfYqFt/DOk8DG6S1SRvzYE1a1rwfoeq6Fc6VJp9vb28y4DW0axtGw5V1IHDAgEfT0rX02+ttTsLe9sJkntLhBJFKhyGUjINWaQHm1r8N9UZQmqeNtVmjACgWlvDbt0xyxViT3zTNQ+G13YRLd+F9e1FtSQktFqty08Fyv91h/AfRlHHPBHT0yindgeP6Pr4ubx9M1W1l0rXIlzLY3BGSP70bdJE6/MKseJdWj0XRbm9dow6KREshIDyHhVP1OK6H4o6bYa3ptvpbWaXOt3DEae4cxvbN3m3jlVXgnHXgYOal0HwFaWQtJtavbnWr+3O5ZbhisQboGEIO3IHc5OckYziqVTQVjW8J+H4dAspV3me+uX827uWGGlfGPwUDgDsPxNblFFQM4/4rXMFn4SiuruaKC2g1bSpJZZXCpGg1C3JZieAAASSam/4WP4H/AOhy8N/+DSD/AOKrV8T61H4f0hr+W1ubv99BbpBbbPMkkmlSJAN7Ko+aReSwAGayv+Eo1f8A6ETxJ/3/ANO/+SqAOZ+Jvj7wdefDbxZa2fizw/Pcz6TdxxRRajC7yO0LgKoDZJJIAArqPF/h671nXvCd7ayQJFpOoNdziRiGZDBJHhcA5OXHXHGapat44vdI0q91LUPBPiSGys4XuJ5PNsG2RopZjgXRJwAeACa7WgDzPwX8PLzwx8T9Z1mC6t28O3Nq0VnaAt5ls7yiWRQMY2b97DnjdjFa3hzwY9oPHEGqm3ktPEN/LOFgJ3CGSFIyGyBhsq3TI5rtqKAPN9G0Xx/onhm08OWF14feG0RbWDWJXlMyQKNqk22za0gAHPmYOORXpFFFAHK/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9dVQByvjL/kY/An/Yak/9N15XVVyvjL/kY/An/Yak/wDTdeV1VABRRRQAUUUUAFFFFAHJ6v4MjvdYuNTtNW1CwnudvnJEInjkKqFBIdCRwOxFZv8Awh/iGML5fiCwmx94TaawLfQrMMfka76imm0B5xJofi6FvlttDukyeReSwkjscGNh+Gfx71xWrNq+r+LLOzi0xbSXQ79Hurs3SsgDRZaNABliySDsMHrXvlc74i8J2OsTfa43ksdUUYW8tzhjxwHXpIvA4YH2xT5n1A5zPvR+NUb99R0CQp4hgRbXOE1G3yYDyAPMB5jY5HXK/wC1V1HV0DowZWGQQcgitU09iRaODRR+NMAFGfeiigDlviAVltNHsmG4Xmq20bL6qr+Yf0Sup/GuW8RMZvGvhW1xuVGubtvQbY9gP5yf579TSW4B+NFH40UwMPxB4W0zxBLbvqi3chgZXiEV7NCqupyr7UcDcD0bqPWti2hW2tooI2kKRIEUySM7EAY5ZiSx9yST3qSj8aAD8aKPxooA5bw8m7xx4tmJ6G0gH/AYt3/tSup/GuV8EEzX/im5b+PVnjB9QkcafzBrqvxpIGH40UfjRTA5SfwxqFtqN1P4e1x9Nt7yQzXEDwLOPMJ5dNx+UnuORVbTvF50q3W08YR3NpeQkxvem3b7NPg4Dq65AyMHBxjNdpSEAgg4IPY0rdguYmneLdB1LUxp9hqlvc3ZBIWIlg2Bk4YfKTjnANblYniLw3Za3p0do7SWhikEsU1qQjxnvtPbIJB+tc7e+CNTtY0h8NeJL2ys1chbWV96Row2vtY5YnHKg9DnpnNF2g0O9o/GuJg8P+IdB8o6DrL6mhTynt9XkOxQPusjIMgjoR3z9Ktnw9rOpEnXPEdwsZOfs2mILZB7F8lyPxFFwOrrmfhsf+KMsef45v8A0c9Vm8N6joh83wnqD+WPvadfytLC/XO1ySyE57EgntVPwbqF5oFrpuha7pVzayzTSJDcLJHJE7MzyYJDZBxkdO1F9dRnZajbyXdnJDBeT2UjYxPAELpg54Dqy89OQevrzWL4Z8LL4d0FtJsdX1J7cKVgeYQF7fJJJTEYBOTn5g35cV0dFMRh6J4ct9M1C41GW6u9Q1O4QRPd3bIXEYOQihFVVXJzhVGTyc1Hr893qt8nhjQgG1O8jJnmYZSztz8rStzyeSFHc10FZnwmmN3498YTXNxi8g8m1FqIGXbCCzRyF84Ytub8qmbsho9L0TTo9I0Ww02BmaGzt47dGbqVRQoJx7CrtFFYjOG+OH/JKPEn/XuP/Q1rua4f42qz/CnxIEBJ+zZ49Ayk/pXbqwZQynKkZBFAxaKKKBHDX2dI+L2nT5C2+u6dJaMAOs8DeYhP1R5B/wABrua4j4uBrXw3a65Fu8zQ7+DUDtXJaMNslH08t3/Ku2RldFdCGVhkEdxQAtBoooA89vfDupeDruXU/A8Qn052Ml5oBbajZ6yW56I/qv3W9jiuq8L+I9N8Tab9s0qYsqsY5YZF2SwSDqkiHlWHofwyOa2K8/8AiFpx0G6j8baLbkXtkwOpRwnb9stMYcMMgMyA71J5+XHoKAPQKCQASTgDvWbd65plppS6lPewrZvCbhJN2fMQLuyoHLcc4GTXO3tlqHjG5tVv7O503w9GS8kMlw0c16CpAR40+7HzyrMSehUdaALHhVFvvEmva1EnmWlwYoLa4kHzERgq6p/0z3DI9WLHpiuspsUaRRJHEipGgCqqjAUDoAOwp1ABRRRQByvxL/5Fyz/7DWk/+nG3rqq5/wAdaXfav4fFvpS2zXsV7Z3kaXMrRRv5F1FMVLKrFciMjO08kcVV+3eOP+he8N/+D6f/AOQ6AD4sf8ks8Zf9gW9/9EPWF8ddUMHhGDQ4ftJufEF0mnEWsMk0qwH5rh1SNWZsRK/QHqKseLLbxv4g8K6zo39ieG7f+0bKaz87+2538vzEKbtv2QZxnOMjPrXXXWiafd65YaxcW5k1GxjkitpTI2I1kxvwuduTtHOM8UAeJ+GFudT+HHirwHo2oS6Xd6bfLDpz6kk1m8tnNL5kUbB1WQbh5kWQM8cZrf8ABa6TofjfSdOv/h9b+E9YvLaUWU9hPHLDcCNcyI5j2ksFIILr6856+iX3hXRL/VbrUb3T4p7q6tBYzmQsUkhD7wrJnaSGJIbGR61Bo3g3RNI1Qala29xJfrEYEuLu8munjjJyUQyu2xfZcCgDoaKKKAOV+LH/ACSzxl/2Bb3/ANEPXVVyvxY/5JZ4y/7At7/6IeuqoA5Xxl/yMfgT/sNSf+m68rqq5Xxl/wAjH4E/7DUn/puvK6qgAooooAKoaxrFjpEKyX86x7ztjjALPK391FHLH2ArDXXNR8QZXwxCsNluKNql2h2nHB8qLguQeMttGQfvVp6R4fs9OnN23mXepMpV725O+VgTnAP8K/7K4FAGHql94tubCXUtMsUs47YCaPTptrXN6ByUZhlYtw6Y3HOM45FXtC8UPcS21l4gsH0bVZohKkMrh45c9QknAZh3Xgj0I5rpqq6lp9lqlo1rqdpb3ls33obiNZEP1BGKALVFc3/whWixktZRXWntkn/Qbya3GT3KowU/iDQPD+pW4AsPE+qKq4wl1HDcLx6koHOe+Wz7igDpKKwvCuoXl4NUt9Se3kubC8NqXhQoHHlxuCVLNg4fpmt2gBHUOpVwGUjBBHBFcTqngk2zvceFZ47F2OWspQTbOcknaBzGTk8rx0+U129FGwHlcepeXeiw1OCTT9SxkQTdJPeN/uuPoc+oFX/xruNW0uy1eza01K2juIG52uOh9QeoPuOa4u58Ka1pkhXRrqHUrL+GHUJmSWLpwJQrbx1+8M9OT1rRT7isR/jRVWX+3bZC134a1DaoJZraWGYDHoA4Y57YXPtVSXXrW3B+3w6hYgYBa7spoV5/22Xb+tXzIVjLjJuPibKRgx2elKpPo0spP8ox/nr1NcV4S1SzvfFnim7jvrZ43mgt4sSjLCOPnHPI3O3+evT2VvrWs6nqUWkTafHb2SxqRcxOxlkYFiN6t8oA2/wn734UrpK47F78aPxpj6T4tg3GTTdKuUAyPs9+4dvba8YHr/FXKeI28Xw6vZg250LTXQo1xdRxXMbTZG1SUkyoIJGTjkd80c6Cx1340fjXLunjSJcRXHh65I/vxTRZ+pDN/KhNQ8XQr+/0LTLk8c2+olP0ZP6/nTuKx1H40Vy0fiLWo/8Aj98I6gg7m3uYJvy+cUN4zjiYC50LxDAD/EbAuo/FC1F0Fhfh2/naLd3Qxi61G7mBHcGZwOe/Suo/Gub+HVtJaeCtKinjkimMbSOkgIYM7MxyDznLV0n40LYGH40fjR+NH40wD8aPxpCcUoOaACj8aPxo/GgAo/Gj8aPxoAK5Px0t22oeFhp0UMt2dTCxpNL5aMxhk4Lc4/I11n41geJf+Q54M/7DsH/ouWlLYa3L39n+O/8AoB6N/wCDNv8A41UiaL48kUN9h8NxZ/ge/mLD6kRYr1KisuZ9xnl/9hePP+fbwx/4HXH/AMZqH4e6dqFn8UtdbXo9P/tL+y7fYbGV2RI2kkyrblBLEqDnsAK9WryjxG0lr+0D4afT7Qi4u9OlhuZpV3RtCpLfLt5VwRjc2ByB9U5Ngj1eiiikByHxd/5Jj4n/AOvCX+VdTZf8ecH/AFzX+Vct8Xf+SY+J/wDrwl/lXU2X/HnB/wBc1/lQBNRRRQBX1Gzg1HT7qyu08y2uYmhlTONyMCCPyJrkfhrf3FvFfeFtWlaXU9DdYhK3W4tmGYZfrt+U9eVPrXbVwnw6/wBN8QeNdUuT/p51VrErgjy4YUURAZ9QxfjjLUAd3RRRQAU2RFkjZJFDIwIZSMgg9qdSMQoJJAA5JNAHj0HhG5uNZtvBl4un6h4c0qdNShmcObi1jLMUtz2OSCAc/cU5HIr2KuS+Ho+22uoeIVBji12cXkUWQdsQjWONj/tMiKxHbOOoOetoAKKKKACiiigDn/HWqX2keHxcaU1st7Le2dnG9zE0saefdRQliqspbAkJxuHIHNVfsPjj/oYfDf8A4IZ//kyj4l/8i5Z/9hrSf/Tjb11VAHAeLLnxv4f8K6zrP9t+G7j+zrKa88n+xJ08zy0L7d32s4zjGcHHpXW+INc03w7pzX+tXcdpahljDvklmY4CqoyWY9gATWP8WP8AklnjL/sC3v8A6Ieud+LGdP8AFfgTxFfRSSaDpV5cG+ZIy4gMkJSKZgMnardT23ZoA3pPiL4ahgv5bu6vbMWNsbydLzTbm3dYQwUuEkjDMMsB8oPWtCDxdoc+maJqEN+r2etTJBYSLG586RlZguMZU4Rs7sYxg4PFed/F/wAa6D4g+GvjHTtAvo9TaHS3mlubM+bbx/MgCGVfl3ndkKCThTnHfE8TWdx4W+J/hbw/FCx0LUvES6zYMB8tvJ5My3EPsC8iyKP9tqAPXdF8ZaBrU2txabqUcr6JM9vqAZWj+zuu7dncBkfK3zDI4PNZKfFLwjJ4ds9dh1C5m0m7nNtDcQ6dcyBpQwXYQsZKkkgDIGT0zXm2geA7rxJca3eaZfR2UVz4g1TTtaU5DXVibtnKKQDh8hlBOPllfnoK55b/AE7TPg7Zw3V3aWYPjMtGkkix/JHfAsQCRwo5PoKAPc/ilKs3wm8XSoHCvol4wDoUYAwOeVOCD7EZrra5H4pSxz/CbxdNBIksUmiXjo6MCrKYHIII6g111AHK+Mv+Rj8Cf9hqT/03XldVXK+Mv+Rj8Cf9hqT/ANN15XVUAFFFcdrGtaq3ixNAt59P0r7REZbW5uFad7oLjzBGnyqrLnoSx5ztwOQCWCaPw14ouLa5ljh0rVSbm3d22rHc8CSPJOPnyHA9d9dYCCMjkV5n4pg1HStQWLV21bW/DN3Zypds1nDdCO4LJ5bGFUyFUBjwCM4z61Q+B2jeMNJslbVbqM6HOZGjs7iFopoPm+Ro152ow52HG3PA9UM9booopiCiiigDmtBKw+MvFFsAAZDa3pO7kl4vK6duIB/nk9LXNoBB8R5SFObzSky3b9zM3H/kxXSUAFFFFABRRRQAUUUUAZdz4d0S6SRLrR9OmSV2ldZLVGDu3Vjkck9zU2kaRp2jWzW+kWNrY27MXMVvEI13HqcAY7VeooAKgvbSC+tJrW7iWa3mUo8bDIYGp6KAPLb23uPDOpxaffu8unTnbZXzkctk/uZMYAYDG0/xAeoNXfxrutV0611bTp7HUIVmtZ12ujDqP6EdQexrzt7e60XVBpOoSmdXQyWd033pkGMq3+2uRk9wQfWtIS6MTRaozRR+NaCD8aPxo/Gj8aAD8aCaPxooAoaxLew6fNJpkFvPdKMqlxM0SH1yyqx/DHPt1rO8A6zceIfB+lateJFHcXcAldYgQoJz0BJP61pauLwWEo0yC2nuWGFS4nMKEHrlgjnp7Vi/DfSdT0DwnY6Rq6WYks4xEklrO0gkHqQyLt+nP1o6gdR+NH40fjR+NAB+NH40fjR+NAB+NYfjGyubvSBcaacapp8qX1meuZY+QpGeQwyv/Aq3Pxo/Ghq+gHY+GNat/EXh7T9Xsv8AUXcKyhSclD3U+4OQfcVqV5p8JHe31zxdpdud2l29zFPF6RSyqWljHtkK2B03mvS65yirq17HpmlXl/MCYrWF53APZVJP8q5L4aaXPLaN4q1oiTXNbiSZuDi1gI3RwID0Cg8+rEk5rd8bafd6t4P1rTtNaNby7s5YIjIcLllK8kdOtYFg3j2Gwgt4NI8NW6QxrEiy6hMxAUAA/LDj8KAO5oriZR8R3P7pvCMIH95bmXd+q4/WpvAGr61qN34gtNfksJZtNu0tlks4mjUkxI7cMzHgvjPtQBpePrT7f4G8Q2oXc02nzoo/2jG2P1xU3g6+Gp+EtFvgT/pNlDNz1+ZAeeT6+ta0iLJGyOoZGGGB6EV5P4I8a2vh7wZ4G0/UI2zeSy6a0hbHkGFzEGYc8FvLXtjeD7UgPWqjmmjgTfNIkadNzsAK8Na10TSr/VbL4pX2pyXNvKs0d4dUuWgnhmkcRYRGBjKkMCuMDbnODW1fW3wf0WxW9uotDmh2hg3N22CBjj5jzkdfWi47Hf3HjDwzbcXHiLRov9++iX+bVx/gjxJo998VPEltoup217BqFpb3wMDZCyJmJxn12iI10nhaw8IXmkWmo+HdM0hbK7XfE8Foke/seNoOeMEHnipvFPhS114afIl1c6Ze2Exltruy2rJHuG115BGGHUY7D0oEdHRXFyeBZpVIm8Y+LGzwSt5HHx6fJGMfXr70yP4cab/y9ax4nu89fO1m4OR6cMOKYHb1x/ijxpBpGvJof9g6zq1xNafamWxgSRfLLFCDudc89fqPWo5Phl4UmUi4sLqcEYIm1G5kyPQ7pDx7dKg8IfDiw8KeL77WNJuZYrK4t/Ii07GY4MlCzKxJPJTOPc0gL/wrKHwJpnlwSWwBlBt5FCmE+a+Y8A8BTwB6AV1lcvCDoXi94ScadrRMkYxxHdKvzDp/Go3cnqh7tXUUwCiiigAooooAyvE+ix+INIawlurm0/fQXCT22zzI5IZUlQjerKfmjXgqQRmsr/hF9X/6HvxJ/wB+NO/+Rah+K1tBeeEorW7hintp9W0qOWKVAySIdQtwVYHgggkEGpv+FceB/wDoTfDf/grg/wDiaAKmreB73V9KvdN1Dxt4kmsryF7eePyrBd8bqVYZFqCMgnkEGu1ry/4m+AfB1n8NvFl1Z+E/D8FzBpN3JFLFp0KPG6wuQykLkEEAgiuj8d+J7zRrvRNH0S2t7jXdaneG1FyxWGNY0LySvt5IVQOBgkkcigDraK4TVNQ8a6Bbald3/wDYWp2EGn3FwtxbW8lq0UsaFlDxtK+9DjGVYH+dU9W8c6lZ/Cbw34oigszf6kummaNkbyl+0NGH2jdkY3nGSe2c0Aej0UUUAcr8WP8AklnjL/sC3v8A6Ieuqrlfix/ySzxl/wBgW9/9EPXVUAcr4y/5GPwJ/wBhqT/03XldVXK+Mv8AkY/An/Yak/8ATdeV1VABXMeI9GvJvEOla5pcFhc3djBPB5V45jBEhQ7lcIxVhsxnHR2rp6pa1qdto2l3OoXr7YIELkAjLHsq5IyxPAHckUAc1e+O7bRDNH4qs59LnjjEqiMG5WZckEoUGTgjnIGMgniup027F/YW92sM8AmQOI502SLnsy9j7VyWq6nqHibQ5rPTvD2pwLeRBfPvxHbrGDjOVLF8jJ429jz0rtqACiiigAooooA5rWQsPjnw3ckNmWG7ssjp8wjl5/78H8/y6Wua8ZKsd54ZvHyPs2qoOB/z1ilhx+corpaACiiigAoorM1/XtN8P2sNxrF0LaGaZYEYqzZds4Hyg9cUAadFQ2V1DfWcF1aSCW3mQSRuOjKRkGpqACiiigAooooAK4z4oQiLS9O1UYDafexsx6fu5D5Ld+n7wNj/AGR3xXZ1U1iwh1XSrzT7ksIbqF4XK4yAwwSM8Z5oA4WiqV6t94dkjt9exJbEBY9TQYjc9MSD/lmx/wC+T69quZGMk8dc5rdNPYkXPvRTPC3hW08S6c+ra/8Aa54rqRntLb7RJFHHCCAh2qRktt35OfvYFa03gGzTJ0zVNYsOc7VufPXr6TB8D2BFT7RDsZn40fjVKNrzTtSfSdbKfbBloJ0BVLuMfxKOzDoy546jg1dq076iCjPvR+NH40AH40fjR+NH40AH40fjR+NGfegA/GiuN+IPi688OKIrDTvtMzwNOJpH/dxKrqrMwHJA3qTj19MmtOHXG13T5R4Qjl1S7eNhFLFGfJjfB2l3YhQMjpnPtzS5kFjo/grs/wCEf1lsMZzrV55zE53MJMA9em0KPwr0GvPfA+g+KfD/AIdt9OjTRreY7pri5lmlunknc5d2UCMck9N3HTJ61uLqXiSx41LRYL+MD/XaZcDd36xS7cdujt19snAo6aivO7Ofx3r2tXVzaXFpomjQSgWsV5prO90hUhvMBkVlKtjptzxyRnPQ+F/EX9oiOw1OGa01uOLdPDJbSRI5BwzRMww65I+6TjIzQBmfErxNe6AmmW9j/oovJWE2pzWjz29nGoyS4TuxIAyQOpzxXjZ+IeuweN9Vm0CKzvXvobezuLmxikMbzNnyp0hkwzPsDfKpKsoBzgZr6ZLLuxkZ9K8g8U+J/C13fafq0aRaXqTXRsZNUvLYwzRQ/OjvCzAK/I27gTsDE47UmNHTeE7CbX9Hgv7rxB4kZjJJFLBO0FuySRuY3UiFBjDIejH6kVUuPhRpLWV1b21/qSidZox9ol88QpNIjy+WG6MdnDHJBOTk12nh+LTodKhTRpIpLIZKPHJ5gck5JLZO4kkkknrWjQFzlI/h/wCG3cy6np0er3bAK11qYFzIwByBluAPZQBW6ukaaunmwXT7NbE9bcQqIzzn7uMdavUUxHD6n8L/AA1e3FlPDBdWEtk7SW32K5eJYWI6qudq4OG4AGRzkZBi8O+M7yRb3Sr3StSvdb066azc29vtjnAGUm3thEDLgkE9emcjPe0UAci+iaj4ivYLjxNFBa2UCt5Nja3EhfeSMO8q7cEAEbV4+ZuTUraRqGgstzod1fX1ug2yadeXJm3DI+aOSTLBgM8Ftpz2611NFAFDRdWtNZshc2MhZQxSRGG14nHVHXqrDuDV+sDV9Ek+2PquhPFaauQokLL+7ulUHCSgc9+GHI9xxV/w/qS6xoljqKxNCLqFZfLY5K5HTPf60AReJ9KOsaNPaxSCG6G2W2mxnypkO5H/AAYDI7jI70vhrVhrOkQ3TRGC4BaK4gJBMMqna6HHowP1GD3rUrl5Sug+LlmLbNP1phG+T8sd2owpHPG9Rj3ZF7mgDqKKKKACiiigDj/itcwWfhKK6u5ooLaDVtKklllcKkaDULclmJ4AABJJqb/hY/gf/ocvDf8A4NIP/iq1fE+tR+H9Ia/ltbm7/fQW6QW2zzJJJpUiQDeyqPmkXksABmsr/hKNX/6ETxJ/3/07/wCSqAOZ+Jvj7wdefDbxZa2fizw/Pcz6TdxxRRajC7yO0LgKoDZJJIAArofHvhe91m70TWNCuoLbXdFneW1NypaGVZE2SRvjkBl7joQOKh1bxxe6RpV7qWoeCfEkNlZwvcTyebYNsjRSzHAuiTgA8AE12tAHlcfw7utU8af23qmkeHdFjexu7W6XSpGmlvHuAoLyOYYuRg9QxyTzzUUPgfxTd+GPDvhPV5NFXRNJmti99bzSm4uYrdlMaeSYwsZOxQx8xu+BXrNFABRRRQByvxY/5JZ4y/7At7/6Ieuqrlfix/ySzxl/2Bb3/wBEPXVUAcr4y/5GPwJ/2GpP/TdeV1Vcr4y/5GPwJ/2GpP8A03XldVQAHOOOtcF4DW/8Sz3Wu+J7VYp4LuSCys/NDparGSpbaBxISDliScYxtBxXe157eCzsPiJfancXK6PZaZZC4nWJiq6h5pYB5AODsZGAABYs3XBAIB6FRXG/DzxPqXiebXpb/TX022tLtbe2gmQrNt8tXzID0JDqcYGM45612VABUN7cw2VnPdXUgit4I2lkduiqoySfoBU1eXfG/wAVWlvo8nhO3uUXV9YiMfIZlt4T993CgnkBlAAySfagD0uzuI7y0gubdt0MyLIjYxlSMg/kamryPwP4+1geDtLl1TSL661e61AWgsorNrfy4tpOU3cOFVCckjlsEjrXfeDfEQ8SabNdGzksZYriSB7aaRWkQoxX5tpIGcH+fIINAEPxDxH4Ye5LmMWl1a3bMOyx3Ebt+aqR+PeukrD8dWj33grXrWIlZZrCdEI6hjGcH88Vc0/V7K8isvLu4DNdQieOPzBuZSAcgdSMEdu9AGhRRRQAVh+JdDm1V7O6sL9rDUbMv5E/liVQHG1soeDwOD2+mQdyigCno+nw6TpVpp9sZGhtoliVpG3MwAxknuTS3+p2OnyQJfXlvbPcNsiWWQKZD6DPXqPzHrVuuf8AF3hi38SQW4lmaCeAtslCK/yONroVYEEEfiCAR0oA6CiuX1G/ufB/h6yijsdc8RvGBEZIUjkmOOhfG3t3A7cnJGafhPx9Z6z50erW50G8E7RQ2moSiOWZRgbgpxnk7eMjIIBNAHaUUUUAFFFFAEdxDFcwSQ3EaSwyKVdHUMrA9QQeori5vh1ZtIkEOpahFo2f3mnBwUZcfcV8b1XpkbjwMDAJruKKAGQRRwQxwwRpHDGoREQYVVAwAAOgxT6KKAMLxro7a1oFxDbELqEQ86zk/uTLyv4H7p9ia43S71NQ063u4wVWVA20nlT3U+4ORXp9eYXtsug+J72yciO01CU3dlk4BdstMg9wwZ8ej1cHZ2Ey1+NH40UfjWog/Gj8aPxrO1zXNN0Kz+1aveRWsOcAuclj6KByT7AGgDRqtf31tp9uZryZYoxxzySfQAck+w5rziw8C+MvHfm6rdGTSdN1G2V44Gv2Cq7AASBFB3LtUEo23lvY17L4P8A6X4dlW9maXVNaIw+o3h3ydOQmc7F68D1rP2nYdjO8L+Fk1a4k1fxJZyswLx2dpcgBUhZVyWT+8SDkN0x0Fd7bwRW0EcNvEkUMYCpGihVUDsAOgqSis3qMKKKKACszXNFg1dbZpJZra6tpPMt7m3IWSJiMHBIIwQSCCCCPwrTooA4a7+Gmj6letqOs3GoXus5Vo7/7Q0LxFR8mxY9qDaeRlTyTnOTW+fDemnw0+hvEZLF0dW8072LMSxfJ/i3EtnsemK2qKAOV8E+ET4bkvbi51KXUr67CCSZ4I4h8ueyAZyWY5OT0HauqoooAKKKKACiiigAooooAZO4jgkdjgKpYn0wK5f4VT203w58OLaXEE4h0+CKQwyrIFkEahlJBIyDkYrqZUWWN43GVYFSPUGvKvhz4ItPC/wAQtXi0q4kSxtLdT5R+VpWmORuwcOqBPlbA5dh/DQB6vWfr2mpq+kXNjI7RmVfklU4aNxyrj3DAH8K0KKAMbwnqkuq6Okl7GkWowM1veRJ0SZOGx/snhh6qwPetmuXvx/YXiyDUFBFhqxW1usDhJxxDIeP4h+7J9fLrqKACiiigDlfiX/yLln/2GtJ/9ONvXVVz/jrS77V/D4t9KW2a9ivbO8jS5laKN/IuopipZVYrkRkZ2nkjiqv27xx/0L3hv/wfT/8AyHQAfFj/AJJZ4y/7At7/AOiHrkvjtDDcaj4BiutJ/tiBtaw1hsibzx5Evy4lZUPr8xA4rY8WW3jfxB4V1nRv7E8N2/8AaNlNZ+d/bc7+X5iFN237IM4znGRn1rrtV0TT9Wu9NudQt/Nn06f7TatvZfLk2ld2AQDwxGDkc0AeBeKPDd1pWjW51DQPI0fUfGNjLZ+GxJDMI4tpVkwW8pfMYE7A2wZxnFdv8FktW8ReNJtLsxoenrcw240AhUezkRDvlaNconmbgRsJDBc5Pb0bWdF0/WhZDU7fzxZXUd7B87LsmjOUbgjOM9DkeoqL/hHtL/4SX+31tdmrmD7M1wkjL5kechXUHa+D0LAkdsUAa1FFFAHK/Fj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD11VAHK+Mv+Rj8Cf8AYak/9N15XVVyvjL/AJGPwJ/2GpP/AE3XldVQAVl61ZaSwTU9Ws7aVtPBnjnkhDvDtBJK8E569K1KKAPOfCOvahYGNtY0S7sbTVdSnP2u6lVWV5JH8hTHkkAoqLkkYYqACOR19t4m0S5is5YNWsXS9kMVsRMv75wSCqc/Mcg9Ks65pVrrek3Onaghe2uF2sAcEc5BHuCAfwriND8IeHv+E9bUtJ0qxs7fRUaFXgiVRJcuq7jkdkQAY/vSMetAzqvFOsS6XDZQ2cIlv9QuBa2wc4jVyrMWc9gFVjjqSABya881uSy8D/EXw/dXNtFeTXlpd/aLzftuGkJjLOy7TuHypGi7uNxA6V119dr4svrWy0xGl0q2uEuLjUVbCF42DLHCf4iWA3MOAMjJJxXX7V37to3YxnHOKBHL6FpWrXWqWeteILmLzUgkEVgkQ/0UyFTjfn5iFXbnHdsHBq9q3hrTtRuxeBZLPUgMLe2j+VKOnBI4YcDhgR7Vt0UAczPo3iEjZF4lRoiuGFzp0chJ7/dKjGO2K828QfDDVNJ1e01/w6Y2vbOGQRw6VbxWQDhfk+QnawLZ35JJyBjAwfb6KAPn+L4hX+s+G00DxRcXOiagRLDeanND5ULTbS0cO4ABOo3bsAhCMtkmux+C/j1/EWgWdvrMqHUcNGsu7/Wsn3kP+2Bg47qQeea7jUvDekanqUF/e2Uct1D0fkbh2DgcMAcEZzg9K5rxP4Es1snn8M2NvZXQcSSwWoEH2jBJBDDG2VSSVf14OVJpDO8orivAnjBNTeXR9Yl8nXbMhJFliMDTjAIcI3RsEEhcgHoSK7WmIKKKKAA88V57qvw10tPDENjp9pHevY3TXlrDfkSIdz7ni+YHCMCw6ZBOetehUUAc/wCCNPvtM0QQagzrmRmgt3lMzWsRxtiMh5fHPPPXAJABroK4vWotVufiHaR6Nq09qkWlyPcxPH5tvuMqiLKZHzN++5BzhB266eha3dS6nPo+u28FrqsUayo0MhaK6jORvjyAQQQdyHJXI5IINAHQ0UUUAFFFFABRRRQAVmeItFs9f0t7K+VtpIeORDh4ZB910PZh/wDWPBIrTooA8utGura9utL1Mqb60ClpEGFmjbOyQDPGdrZHYg1c/GjxXG1r8QEncFYr/TkhRtwwXhkkYrjrnbNn6A0VtF3RLAkDqRz71k/DHT9TvvFur3usXMczacTYDFlsjnjdFkBVi5wwJ5GDwRzycM8W6HF4g0j7JNdT2hSRZkngbDoynIINdP8ABfS00v4caQqFnNyjXhlc5eQSMWVmPrsKD8MVNR9Bo7cUUUVmMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/GGlXs0S6r4eES+ILONhb+acJOp6wycjKkgEejAHI5rpKKAOM+GOta/q1hqkHi+3tLXWbG8MDw2/TyzFG6t95s53tznt6g12dct4xgTT5rPxJBGFnsZFW6dQcyWrHa4OOoXIcZ6bTjqa3NK1bTtXg8/Sr+0vYe720yyKPxUmgBniCwj1PRL6ymXKzRMox1BxwR7g4I9xUHg/UH1bwnouozNulu7KGdzgDLMgY8D3NazsqIzOwVVGSScACub+GxH/CC6MiRvHHFAIYw2eUQlVYZ5wVAI9iKAOlooooA5/x1ql9pHh8XGlNbLey3tnZxvcxNLGnn3UUJYqrKWwJCcbhyBzVX7D44/wChh8N/+CGf/wCTKPiX/wAi5Z/9hrSf/Tjb11VAHAeLLnxv4f8ACus6z/bfhu4/s6ymvPJ/sSdPM8tC+3d9rOM4xnBx6V1l3runWeu6fo1zceXqOoJJJaxGNsSiMAvhsbcgEHGc1kfFj/klnjL/ALAt7/6Iesj41Ws0Phu08S2EZe/8NXaaoqqOXhXKzp9DEzn8BQB1k3iDTYtZuNJM7vqNvafbpIIoXkZYdxUH5VOSSDhR8xxwDUHhTxVpPiuzmutDluZreGQxM81nNbjeCQwHmIuSCCDjODwa5P4Tzx6jbeI/HV66wwa3dNJBJN8gjsYAY4ic/dBAdzn+/mq37O+o2V94IvEsry2uHj1W9Z1hlVyoe4kZScHgEcj1HNAHqNFFFAHK/Fj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD11VAHK+Mv+Rj8Cf8AYak/9N15XVVyvjL/AJGPwJ/2GpP/AE3XldVQAVja94o0Tw/Naw61qdtZy3LBIllbBYnp9BweTxWtMrtE6xv5blSFfGdp7HHeubsvA+gw3Fxd3tkmp39xjzrrUFE7vjOOo2qBnACgcUAcr4q8X6jfzQx6A0L6TJqA05pbW7VbidmjJBjYgqi7sKDySeQVHNbel+Gri/tIrbVYf7O0WPO3SIpvMM2Ty1xLyXyckqDg5+Yt0rd0/wAL6Hp2ptqFhpNlbXjII/MiiC4Az0A4H3jyOtbNADIo0hiSOJFjjQBVRRgKB0AFPoooAKKKKACiiigAooooA4v4q+D18ZeH49PjihS6a4i2XrIpe1QOGdlJIOSARgHnNY3wpaTTtTn0Jri4nays1guUaR3SKaKRk3gMTs81GRwo4wvHqfTaiit4YpZpYoo0kmIaR1UAuQMAk9+ABQBLRRRQAUUUUAcz8tr8RyS4B1HSvu4/595euf8At5//AF9szXdVHiCG2fw9Y3lxcW92htNSEeLdW3bXbOQXTaWBwCD6963PFXhyLxBBCDeXVlPFvVZ7YgN5brtkTkEYYd+oIBHIrZtoIrW2it7dFjhiQIiKMBVAwAPwoAkooooAKKKKACiiigAooooAwvGWjSa1oxitWSO/gkW4tZHJCrIvY47EEqfZjXCy6t9gmSDXbafSZ24X7TjynPHCyglCeRxnPtXq9R3MEN1BJBcxRzQyDa8cihlYehB4IpqTQHn3BHYg1p/DG48rSbnRXI36VL5UQ5/492+aL8AMp/wCp5fAHh9pC8Nvd2p3FsWt9PCoJ/2FcLjjpjFTeHvB9poes3GpW99qU8s8IgZLiYOgQNuXsCSMtgkn7x9acpXEkdLRRRUjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuR8awy6NC/ifSId13Yxk3NuuALuAcspPZl5ZW7YI6E111FAHmTeMIviB4CubXRtO1JbzVbaS2VWhby7cuGUO8oGzAHzYBzjAxyK9LiQRxoigAKAAAMAU4AAcdKKACiiigDK8T6LH4g0hrCW6ubT99BcJPbbPMjkhlSVCN6sp+aNeCpBGayv+EX1f/oe/En/AH407/5FrqqKAOK1bwPe6vpV7puoeNvEk1leQvbzx+VYLvjdSrDItQRkE8gg12tFFABRRRQAUUUUAcr8WP8AklnjL/sC3v8A6Ieuqrlfix/ySzxl/wBgW9/9EPXVUAcr4y/5GPwJ/wBhqT/03XldVXK+Mv8AkY/An/Yak/8ATdeV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFedeEvDdrr1hf3+p3/iB7l9W1KP8Ada7ewoEjvZ40VUSUKoCqoAAHStv/AIQPSP8An88Sf+FHqP8A8foA6qiuV/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6AOqorhbLSo9B+JOk2theau9tdaTfySxXmqXN2jPHNZhGAmkYAgSOMjH3jUnxA1jUoNc8J+H9HuzYS63dyxy3qxo7xRRQtKwQOCu5toALAgc8GgDtqK4n4eaxqVxq/irQNauzfXOiXqRx3bRojzQyxLKm8IAu4biCQADgcCu2oAKKKKACiivOPiTHJeeMvDli17qVvavYX87pZX81rvdJLRVLGJ1JwHfGf7xppXdgPR6K8k/4Ry3/AOgn4k/8KC//APj1H/COW/8A0E/En/hQX/8A8eq/ZMD1uivJP+Ect/8AoJ+JP/Cgv/8A49WL420r+zfBuvX1lq/iSK6tbC4nhf8At++ba6xsVODNg4IHBo9mwPdaKr6jHczafcR2FwltdvGywzvF5qxvjhimRuAPbIz61wdr4/u9K8U2XhnxdY239qXjhIJ9Im+0I+f4pIT+9hHI5IZB1L1mB6JRXn/jbV9f0rx/4LtrXUbZNG1O9e3ntVtP3rYgd+ZSx4yowFVT6k9K9AoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4sf8ks8Zf9gW9/9EPXVVyvxY/5JZ4y/wCwLe/+iHrqqAOV8Zf8jH4E/wCw1J/6bryuqrlfGX/Ix+BP+w1J/wCm68rqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4XRbTxjoMF5Z2ek+H7y2fUL27iml1iaF2Se5lmAZBasAQJADhj0rQ+3eOP+he8N/wDg+n/+Q66qigDlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q66qigDj9NsfEd540sdX1yx0ixtrPT7q0VbPUJLl5Hmkt2BIaCMKAID3P3hVvxj4YfXbjR7+xvRYavpFybm0uGh85PmQo6Om5SysrEHDKemDXS0UAc14L8MP4fbVrq9vhqGq6rdfa7u5WHyUJCqioibm2qqqAMsT1ya6WiigAooooAK4jx1oWuX/AIi0bVNBh024+yWt3bSxXt29v/rXt2VlKxSZx5JBBA6iu3opp21A80/snxx/0CPDf/g6n/8AkSj+yfHH/QI8N/8Ag6n/APkSvS6Kr2kgPNP7J8cf9Ajw3/4Op/8A5ErO8SeF/G+teHdU0v8As3w3D9utZbbzf7YnbZvQrux9lGcZzjIr1yijnkBR16ym1HRb+ytbprSe4geKO4XdmJiCAw2MrcdeGU+hFcj4R8Hax4YZI9PvfDEFo8ivdC30OZJrgZ53StdsS+MgMwbHoeld5RUAcR418Ja1r/iLQ9TsNb06yj0ic3NvDNpjzlpGjZG3sJ0yuGOAADnua7ZNwRQ5BbHJAwCfpS0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8WP8AklnjL/sC3v8A6Ieuqrlfix/ySzxl/wBgW9/9EPXVUAYvifQBry6cy6jfabc6fdfa4LizERdXMUkRBEqOpBWV/wCH0rP/AOEX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAP8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaKKAD/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWiigA/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoooAqat4HvdX0q903UPG3iSayvIXt54/KsF3xupVhkWoIyCeQQa7WiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Historically, tularemia has been reported from all states except Hawaii. To define the geographic distribution of",
"    <em>",
"     Francisella tularensis",
"    </em>",
"    subspecies, CDC requests that state public health laboratories forward isolates to the CDC laboratory in Fort Collins, Colorado.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39205=[""].join("\n");
var outline_f38_18_39205=null;
var title_f38_18_39206="Tumors of the nasal cavity";
var content_f38_18_39206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumors of the nasal cavity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Anamaria R Yeung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Robert J Amdur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     John W Werning, MD, DMD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39206/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/18/39206/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H362247780\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of the nasal cavity include a number of distinct histopathologic entities, the most common of which are squamous cell carcinoma and adenocarcinoma variants.",
"   </p>",
"   <p>",
"    The boundary between the nasal cavity and nasal vestibule is defined anatomically by the limen nasi. Nasal cavity tumors have a natural history similar to cancers of the paranasal sinuses with the same histopathology and are treated similarly. In contrast, cancers arising in the nasal vestibule behave more like squamous carcinomas of skin and are considered separately for the purposes of diagnosis and treatment.",
"   </p>",
"   <p>",
"    The initial evaluation and treatment of nasal cavity tumors will be reviewed here, with a primary focus on squamous cell carcinoma and adenocarcinoma variants. Related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13013?source=see_link\">",
"       \"Cancer of the nasal vestibule\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=see_link\">",
"       \"Paranasal sinus cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362247850\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal cavity tumors are about twice as common in men compared with women. The median age at presentation is approximately 60 to 65 years in contemporary series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies analyzing risk factors have generally combined nasal cavity cancer with tumors arising in the paranasal sinuses. Potential risk factors include tobacco smoke and occupational exposures such as wood dust, formaldehyde, leather dust, and textile dust. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=see_link&amp;anchor=H1027917#H1027917\">",
"     \"Paranasal sinus cancer\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362251618\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasal cavity begins at the limen nasi and ends posteriorly at the choanae, which communicate directly with the nasopharynx (",
"    <a class=\"graphic graphic_figure graphicRef67813 \" href=\"mobipreview.htm?33/24/34180\">",
"     figure 1",
"    </a>",
"    ). It is bounded inferiorly by the hard palate and superiorly by the base of skull, and is divided into right and left halves by the nasal septum. The lateral wall of each nasal cavity is composed of thin bony folds called the inferior, middle, and superior nasal turbinates (concha), which project into the nasal cavity. The nasal cavity communicates with the paranasal sinuses and other structures via multiple passages or meatuses.",
"   </p>",
"   <p>",
"    A wide variety of cancers arise in the nasal cavity (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cell carcinomas are the most common, accounting for more than one-half of cases in large series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/1,3-7\">",
"       1,3-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tumors arising in minor salivary gland are the second most common group of neoplasms in the nasal cavity. Within this group, adenocarcinoma is most common, followed by adenoid cystic, benign mixed, and mucoepidermoid carcinoma. Acinic cell carcinoma is rare in the nasal cavity.",
"     </li>",
"     <li>",
"      Neuroendocrine carcinomas consist of a spectrum of rare histologies that include olfactory neuroblastoma, sinonasal undifferentiated carcinoma, small cell carcinoma, and neuroendocrine carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/46/12008?source=see_link\">",
"       \"Olfactory neuroblastoma (esthesioneuroblastoma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=see_link\">",
"       \"Extrapulmonary small cell cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inverted papillomas are rare neoplasms that arise in the Schneiderian epithelium that lines the nasal cavity. Although inverted papillomas are benign, they are complicated by carcinomas in approximately 10 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/11\">",
"       11",
"      </a>",
"      ]. Associated malignancy is usually squamous cell carcinoma, and may be either synchronous or metachronous. Inverted papillomas are locally aggressive, even in the absence of squamous cell carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other, rarer neoplasms that occur in the nasal cavity include lymphomas, sarcomas, and melanoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/15-18\">",
"       15-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362251654\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tumors of the nasal cavity usually present with a history of chronic sinus congestion and recurrent nasal obstruction. Many patients complain of nasal discharge and intermittent epistaxis. These symptoms can mimic those of chronic sinusitis or nasal polyps and may delay the diagnosis of cancer. Chronic sinusitis is typically associated with bilateral symptoms; thus, unilateral symptoms should be an indication for further evaluation (nasal endoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging).",
"   </p>",
"   <p>",
"    The symptoms from advanced lesions depend upon the site of tumor spread: widening of the bridge of the nose from lesions invading the olfactory region, frontal headaches from extension through the cribriform plate or into the ethmoid sinus, and proptosis, diplopia, or a palpable orbital mass from invasion of the medial orbit.",
"   </p>",
"   <p>",
"    The nasal cavity drains to the retropharyngeal, submandibular, junctional, and subdigastric nodes. However, less than 10 percent of patients have lymph node metastasis at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/1,4,19\">",
"     1,4,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362251661\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362251675\">",
"    <span class=\"h2\">",
"     Diagnosis and staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history and physical examination should be performed with particular attention to signs and symptoms of orbital or cranial nerve involvement. Computed tomography (CT) is useful to assess for bone, nasopharyngeal, or lymph node invasion, while magnetic resonance imaging (MRI) is preferred to evaluate for intracranial, orbital, and perineural spread. MRI also helps determine whether the sinuses are opacified due to tumor, fluid, or secondary inflammatory mucosal changes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50420 \" href=\"mobipreview.htm?24/57/25491\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Biopsy is required to establish a tissue diagnosis. This is usually performed via nasal endoscopy.",
"   </p>",
"   <p>",
"    Nasal cavity tumors are staged using the American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/UICC",
"    </span>",
"    tumor node metastasis (TNM) system. The same system is used to stage tumors arising in the nasal cavity and the ethmoid sinus (",
"    <a class=\"graphic graphic_table graphicRef82601 \" href=\"mobipreview.htm?9/42/9902\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362247871\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for patients with nasal cavity cancers are based upon observational case series since there are no randomized trials that have compared various treatment alternatives. Furthermore, many retrospective studies combined nasal cavity tumors with paranasal sinus tumors, making it difficult to draw conclusions that are specific to nasal cavity cancers. The following discussion applies to squamous cell carcinomas, the most common tumor of the nasal cavity, and to adenocarcinoma and its variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362256986\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both surgery and radiation therapy (RT) have a role, depending upon the extent of disease and other patient specific factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with early stage nasal cavity tumors are managed with a multidisciplinary approach that includes both surgery and RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/4,21\">",
"       4,21",
"      </a>",
"      ]. There is a significant risk of local recurrence when patients are managed with surgery alone, and the critical anatomic location near the brain and eye make treatment with high doses of RT alone problematic. Surgery alone is a reasonable option for some carefully selected patients with T1N0 tumors.",
"     </li>",
"     <li>",
"      The standard treatment for advanced stage tumors is surgery followed by postoperative RT. Although preoperative RT has been used to minimize tumor bulk and limit the extent of resection, we favor postoperative RT to minimize the risk of wound complications following surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unresectable tumors are treated with definitive RT. Given the rarity of these tumors, randomized data neither support nor refute the use of chemotherapy. Based upon data from other head and neck cancers, chemotherapy (either as induction or concurrently with RT) is generally used for good performance status patients with unresectable, extensive lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362256868\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no definitive criteria that define resectability for tumors of the nasal cavity. Tumors that invade the cavernous sinus or optic chiasm or extend transdurally generally are not resectable without causing unacceptable morbidity and loss of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of traditional surgery is to provide an en bloc resection of all involved bone and soft tissue, while preserving function and cosmesis. The most common surgical techniques used for exposure of the nasal cavity are the lateral rhinotomy and the midface degloving procedures. If the superior extent of the tumor involves the fovea ethmoidalis or cribriform plate, then a craniofacial resection is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=see_link\">",
"     \"Paranasal sinus cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic resection of the extracranial component in combination with transcranial resection of the anterior skull base may be performed in many cases so that a lateral rhinotomy incision is not necessary. Complete resection with microscopically free margins of the mucosa, periorbita, and dura must be achieved to increase local-regional control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=see_link&amp;anchor=H6302735#H6302735\">",
"     \"Paranasal sinus cancer\", section on 'Endoscopic resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic resection is gaining acceptance as an alternative to transfacial or craniofacial surgeries. Endoscopic approaches may offer significant advantages in terms of lower frequency of surgical complications and decreased morbidity. As an example, the endoscopic resection of a single olfactory bulb during surgery for olfactory neuroblastoma is a significant benefit that is difficult to achieve during craniofacial resection. Careful patient selection is critical, because tumors with intraorbital or intracranial involvement are not good candidates. Although endoscopic resection frequently requires removal of the tumor in a piecemeal fashion, the final resection margins must be comparable to those that can be achieved via craniofacial resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362256875\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with nasal cavity cancers who are treated with radiation postoperatively, treatment is initiated four to six weeks after surgery to allow sufficient time for wound healing.",
"   </p>",
"   <p>",
"    Preoperative diagnostic CT, MRI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positron emission topography (PET) scans are used to delineate the target volume, which includes the tumor bed, any residual disease, and areas with a high likelihood of harboring microscopic disease.",
"   </p>",
"   <p>",
"    RT for nasal cavity cancer is almost always delivered using intensity-modulated RT (IMRT) rather than conventional external beam RT. IMRT provides improved target coverage with better sparing of critical structures such as the optic apparatus. Low rates of late complications, including blindness, have been reported with IMRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/6,26-29\">",
"     6,26-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When surgical resection margins are negative, a dose of 60 Gy delivered in 2 Gy fractions daily is considered sufficient. If surgical margins are positive or there is gross residual disease or if the tumor was removed piecemeal (ie, endoscopically), a dose of 66 to 70 Gy in 2 Gy daily fractions is recommended. Hyperfractionated irradiation may decrease the risk of optic neuropathy if any part of the optic apparatus is likely to receive doses in excess of the tolerance dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/30-34\">",
"     30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very advanced or unresectable tumors are treated with high doses of RT, usually 70 Gy in 2 Gy daily fractions or 74.4 Gy in 1.2 Gy fractions delivered twice daily with a six-hour split.",
"   </p>",
"   <p>",
"    Induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemotherapy is being adapted for use in nasal cavity and paranasal sinus cancers, despite minimal evidence of chemotherapy efficacy in nasal cavity cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28649?source=see_link\">",
"     \"Methods to overcome radiation resistance in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362247892\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective treatment of the N0 neck (RT or neck dissection) is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/1,3,5,26,42\">",
"     1,3,5,26,42",
"    </a>",
"    ]. Reported rates of nodal recurrence when the neck is not electively treated vary from 0 to 19 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/1,3,5,26,42,43\">",
"     1,3,5,26,42,43",
"    </a>",
"    ]. Our approach is to electively treat the N0 neck in patients with T3 and T4 disease or tumor extension to areas rich in lymphatics (ie, the nasopharynx), as well as in those with other histologies that have an increased risk of lymph node involvement (olfactory neuroblastoma, sinonasal undifferentiated carcinoma).",
"   </p>",
"   <p>",
"    Patients with clinical evidence of lymph node disease at presentation should be treated with neck dissection and postoperative radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362247899\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with a worse prognosis include higher T stage, lymph node involvement, squamous cell or sinonasal undifferentiated carcinoma histology, invasion of the orbit, cribriform plate, or dura, and treatment with RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/3-5,21\">",
"     3-5,21",
"    </a>",
"    ]. Although salvage is possible in some cases, local recurrence following treatment for nasal cavity tumors is associated with poor long-term outcome in most cases.",
"   </p>",
"   <p>",
"    The prognosis for patients with nasal cavity cancer is illustrated by a Danish series of 242 cases treated between 1995 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/2\">",
"     2",
"    </a>",
"    ]. In this series, 66 percent of cases originated in the nasal cavity, and 34 percent arose in paranasal sinuses. Surgery alone, RT alone, and combined surgery plus RT were used in 14, 39, and 47 percent of cases, respectively. For the patients with a primary lesion of the nasal cavity, the five-year rates of locoregional control and cancer-specific survival were 61 and 74 percent, respectively. Similar results were seen in several other large retrospective series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/4,21,24\">",
"     4,21,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes in patients with advanced or unresectable disease are poor, with reported rates five-year overall survival of about 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39206/abstract/23,35\">",
"     23,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362247906\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up has become an essential part of the care of patients after potentially curative treatment of head and neck cancer. In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences after curative intent treatment will occur within this timeframe. Follow-up imaging should include CT or MRI of the head, face, and neck. Our preference is contrast-enhanced CT because CT is more reliable at detecting neck adenopathy than MRI.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be a useful addition or may be sufficient in many cases.",
"   </p>",
"   <p>",
"    Posttreatment surveillance of head and neck cancer, including screening for treatment-related complications, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362247913\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors arising in the nasal cavity have a natural history similar to tumors of the paranasal sinuses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with early and advanced stage disease, we suggest surgical resection and adjuvant RT rather than either surgery or RT alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest postoperative RT rather than preoperative RT to minimize the risk of wound healing complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For T1N0 tumors, surgery alone is a reasonable treatment alternative. (See",
"      <a class=\"local\" href=\"#H362256986\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prophylactic nodal irradiation for patients with stage T3-T4 disease, tumor extension to areas rich in lymphatics (ie, nasopharynx), as well all patients with an olfactory neuroblastoma or sinonasal undifferentiated carcinoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H362247892\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For very advanced tumors, we suggest combined modality therapy with chemotherapy added to radiation, as induction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concurrent chemoradiation. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H362256986\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/1\">",
"      Allen MW, Schwartz DL, Rana V, et al. Long-term radiotherapy outcomes for nasal cavity and septal cancers. Int J Radiat Oncol Biol Phys 2008; 71:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/2\">",
"      Thorup C, Sebbesen L, Dan&oslash; H, et al. Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995-2004. Acta Oncol 2010; 49:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/3\">",
"      Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys 2007; 67:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/4\">",
"      Dulguerov P, Jacobsen MS, Allal AS, et al. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/5\">",
"      Dirix P, Nuyts S, Geussens Y, et al. Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/6\">",
"      Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys 2007; 69:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/7\">",
"      Harbo G, Grau C, Bundgaard T, et al. Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients. Acta Oncol 1997; 36:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/8\">",
"      Rosenthal DI, Barker JL Jr, El-Naggar AK, et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004; 101:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/9\">",
"      Tanzler ED, Morris CG, Orlando CA, et al. Management of sinonasal undifferentiated carcinoma. Head Neck 2008; 30:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/10\">",
"      Chen AM, Daly ME, El-Sayed I, et al. Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2008; 70:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/11\">",
"      Barnes L. Schneiderian papillomas and nonsalivary glandular neoplasms of the head and neck. Mod Pathol 2002; 15:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/12\">",
"      Mendenhall WM, Hinerman RW, Malyapa RS, et al. Inverted papilloma of the nasal cavity and paranasal sinuses. Am J Clin Oncol 2007; 30:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/13\">",
"      Buiret G, Montbarbon X, Fleury B, et al. Inverted papilloma with associated carcinoma of the nasal cavity and paranasal sinuses: treatment outcomes. Acta Otolaryngol 2012; 132:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/14\">",
"      Gomez JA, Mendenhall WM, Tannehill SP, et al. Radiation therapy in inverted papillomas of the nasal cavity and paranasal sinuses. Am J Otolaryngol 2000; 21:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/15\">",
"      Quraishi MS, Bessell EM, Clark D, et al. Non-Hodgkin's lymphoma of the sinonasal tract. Laryngoscope 2000; 110:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/16\">",
"      Abbondanzo SL, Wenig BM. Non-Hodgkin's lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 1995; 75:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/17\">",
"      Gal TJ, Silver N, Huang B. Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope 2011; 121:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/18\">",
"      Dauer EH, Lewis JE, Rohlinger AL, et al. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg 2008; 138:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/19\">",
"      Snyers A, Janssens GO, Twickler MB, et al. Malignant tumors of the nasal cavity and paranasal sinuses: long-term outcome and morbidity with emphasis on hypothalamic-pituitary deficiency. Int J Radiat Oncol Biol Phys 2009; 73:1343.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/21\">",
"      Guntinas-Lichius O, Kreppel MP, Stuetzer H, et al. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol 2007; 33:222.",
"     </a>",
"    </li>",
"    <li>",
"     Parsons JT, Stringer SP, Mancuso AA, Million RR. vestibule, nasal cavity, and paranasal sinuses. In: Management of Head and Neck Cancer: A Multidisciplinary Approach, Million RR, Cassisi NJ (Eds), J.B. Lippincott Company, 1994. p.551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/23\">",
"      Howard DJ, Lund VJ, Wei WI. Craniofacial resection for tumors of the nasal cavity and paranasal sinuses: a 25-year experience. Head Neck 2006; 28:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/24\">",
"      Mendenhall WM, Amdur RJ, Morris CG, et al. Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope 2009; 119:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/25\">",
"      Lund VJ, Howard DJ, Wei WI, Cheesman AD. Craniofacial resection for tumors of the nasal cavity and paranasal sinuses--a 17-year experience. Head Neck 1998; 20:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/26\">",
"      Dirix P, Nuyts S, Vanstraelen B, et al. Post-operative intensity-modulated radiotherapy for malignancies of the nasal cavity and paranasal sinuses. Radiother Oncol 2007; 85:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/27\">",
"      Gabriele AM, Airoldi M, Garzaro M, et al. Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. Tumori 2008; 94:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/28\">",
"      Daly ME, Chen AM, Bucci MK, et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 2007; 67:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/29\">",
"      Hoppe BS, Wolden SL, Zelefsky MJ, et al. Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity. Head Neck 2008; 30:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/30\">",
"      Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/31\">",
"      Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/32\">",
"      Takeda A, Shigematsu N, Suzuki S, et al. Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol Phys 1999; 44:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/33\">",
"      Monroe AT, Bhandare N, Morris CG, Mendenhall WM. Preventing radiation retinopathy with hyperfractionation. Int J Radiat Oncol Biol Phys 2005; 61:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/34\">",
"      Bhandare N, Monroe AT, Morris CG, et al. Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys 2005; 62:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/35\">",
"      Hoppe BS, Nelson CJ, Gomez DR, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2008; 72:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/36\">",
"      Dulguerov P, Allal AS. Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg 2006; 14:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/37\">",
"      Licitra L, Locati LD, Cavina R, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol 2003; 14:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/38\">",
"      Papadimitrakopoulou VA, Ginsberg LE, Garden AS, et al. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 2003; 98:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/39\">",
"      Lee MM, Vokes EE, Rosen A, et al. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am 1999; 5:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/40\">",
"      Samant S, Robbins KT, Vang M, et al. Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg 2004; 130:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/41\">",
"      Choi KN, Rotman M, Aziz H, et al. Concomitant infusion cisplatin and hyperfractionated radiotherapy for locally advanced nasopharyngeal and paranasal sinus tumors. Int J Radiat Oncol Biol Phys 1997; 39:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/42\">",
"      Katz TS, Mendenhall WM, Morris CG, et al. Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck 2002; 24:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39206/abstract/43\">",
"      Hawkins RB, Wynstra JH, Pilepich MV, Fields JN. Carcinoma of the nasal cavity--results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 1988; 15:1129.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16861 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39206=[""].join("\n");
var outline_f38_18_39206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H362247913\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362247780\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362247850\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362251618\">",
"      ANATOMY AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362251654\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362251661\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362251675\">",
"      Diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362247871\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362256986\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362256868\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362256875\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362247892\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362247899\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362247906\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362247913\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16861|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/57/25491\" title=\"diagnostic image 1\">",
"      Scans nasal ethmoid CA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16861|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/24/34180\" title=\"figure 1\">",
"      Nose lat wall nasopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16861|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/42/9902\" title=\"table 1\">",
"      TNM stage sinonasal sites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13013?source=related_link\">",
"      Cancer of the nasal vestibule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28649?source=related_link\">",
"      Methods to overcome radiation resistance in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/46/12008?source=related_link\">",
"      Olfactory neuroblastoma (esthesioneuroblastoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=related_link\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_18_39207="Protein kinase C and the vascular complications of diabetes mellitus";
var content_f38_18_39207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protein kinase C and the vascular complications of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39207/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39207/contributors\">",
"     Eli A Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39207/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39207/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39207/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39207/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/18/39207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who have had diabetes mellitus for five or more years, vascular dysfunction results in nephropathy, retinopathy and at least some forms of neuropathy. The most likely cause of vascular dysfunction is chronic hyperglycemia, although hyperglycemia alone may not be sufficient to cause microvascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous mechanisms have been proposed to explain the association between hyperglycemia and vascular complications (",
"    <a class=\"graphic graphic_algorithm graphicRef61356 \" href=\"mobipreview.htm?31/42/32430\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased activation of the polyol (or aldose reductase) pathway. Increased aldose reductase activity results in the depletion of NADPH, a decrease in cellular reduced glutathione levels, and increased oxidative stress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased activity of the hexosamine pathway, which may alter gene expression and protein function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased formation of advanced glycated end products (AGEs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/5\">",
"       5",
"      </a>",
"      ], which may activate protein kinase C (PKC isoforms) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/6\">",
"       6",
"      </a>",
"      ]. The mechanisms of oxidant-induced interaction between PKC isoforms and AGEs resulting in vascular disease are incompletely defined [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemodynamic alterations (increased capillary pressures and flows).",
"     </li>",
"     <li>",
"      Tissue hypoxia and oxidative stress.",
"     </li>",
"     <li>",
"      Increased activity of vascular protein kinase C (PKC) isoform(s) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic reviews the role of PKC in the pathogenesis of diabetic complications. The pathogenesis of diabetes mellitus and the roles of specific proteins in insulin regulation and resistance are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H8#H8\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Genetic defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reversible phosphorylation of proteins is a common means of governing protein activity within cells. Phosphates are transferred from ATP molecules onto target molecules by protein kinases and are removed by protein phosphatases (",
"    <a class=\"graphic graphic_figure graphicRef78694 \" href=\"mobipreview.htm?12/29/12765\">",
"     figure 1",
"    </a>",
"    ). In most, but not all, circumstances, the activated kinase &ldquo;turns on&rdquo; the next target by the addition of the phosphate and is &ldquo;turned off&rdquo; with the removal of the phosphate by a protein phosphatase. Within each cell, a large variety of kinases and phosphatases play a central role in intracellular signaling.",
"   </p>",
"   <p>",
"    Protein kinases belong to a large family of enzymes that contain a similar 250 amino acid catalytic (kinase) domain that is responsible for the phosphate transfer to the target protein. They differ according to the amino acids on either side of the kinase domain. These variable amino acids provide specificity and permit the recognition and phosphorylation of unique sets of proteins by each protein kinase. Other amino acid sequences within the kinase domain permit enzyme activity to be regulated (on or off) in response to specific signals.",
"   </p>",
"   <p>",
"    Kinases recognize target phosphorylation sites by the surrounding amino acid sequences, which are common to many proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396469\">",
"    <span class=\"h1\">",
"     ROLE OF PKC IN VASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein kinase C (PKC) activity is increased in both experimental animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] with diabetes. The hyperglycemia-induced increase in PKC activity is most likely mediated by enhanced de novo synthesis of diacylglycerol (DAG), which is a major endogenous activator of PKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/14\">",
"     14",
"    </a>",
"    ]. Diacylglycerol (DAG) levels are chronically elevated in the setting of hyperglycemia because of the increased availability of the DAG precursor, glycerol-3-phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3\">",
"     3",
"    </a>",
"    ]. Reactive oxygen species, free fatty acids, and growth factors may also contribute to PKC activation in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/15\">",
"     15",
"    </a>",
"    ]. Multiple PKC isoforms appear to be activated by hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activation of PKC initiates a complex network of intracellular signaling that may alter transcription factor binding to the promoter regions of responsive genes, which alters gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/16\">",
"     16",
"    </a>",
"    ]. Increases in vascular permeability, angiogenesis, cell growth and apoptosis, vessel dilation, cytokine activation, basement membrane thickening and extracellular matrix expansion have all been observed with increased PKC activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. Sustained alterations in PKC-regulated gene expression in vascular cells may contribute to some of the characteristic vascular abnormalities in diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diabetic nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experiments in diabetic mice and rats support a role for PKC in the pathogenesis of diabetic nephropathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PKC activity is increased in glomeruli isolated from diabetic rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/18\">",
"       18",
"      </a>",
"      ] and in mesangial cells cultured in high glucose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PKC inhibition prevents the glycated albumin-induced or glucose-induced increase in basement membrane type IV collagen production by glomerular endothelial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/19\">",
"       19",
"      </a>",
"      ] and mesangial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/20\">",
"       20",
"      </a>",
"      ] cells.",
"     </li>",
"     <li>",
"      PKC increases levels of mRNA that encode matrix components in glomeruli isolated from streptozotocin-induced diabetic rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PKCdelta promotes tubular cell injury and death in kidneys of streptozotocin-induced diabetic mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PKC activation has been associated with alterations in renal and glomerular blood flow, basement membrane thickening, extracellular matrix expansion, increased vascular permeability, enhanced angiogenesis, excessive apoptosis, and alterations in enzyme activation of Na(+)-K(+)-ATPase, cPLA(2), PI3Kinase, and MAP kinase in diabetic rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PKC inhibitors decrease hyperfiltration and proteinuria in animal models. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inhibitors of PKC'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple PKC isoform(s) contribute to the pathogenesis of diabetic nephropathy. Experiments with isoform-specific knock-out mice suggest that activation of PKCalpha underlies the development of albuminuria and that of PKCbeta contributes to glomerular hypertrophy and mesangial expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both isoforms appear to contribute to reactive oxygen species generation, which plays a substantive pathogenic role in the progression of diabetic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/15,24-26\">",
"     15,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of PKC in extrarenal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia-induced increases in PKC activity have been observed in nonrenal tissue including retina, endothelial, smooth muscle cells, monocytes and macrophages and cardiac tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3,27-30\">",
"     3,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies have suggested that increased PKC activity contributes to atherosclerosis, cardiomyopathy, diabetic retinopathy and diabetic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperglycemia-induced PKC activation appears to contribute to endothelial dysfunction by increasing expression of vascular endothelium growth factor (VEGF), thromboxane and endothelin, and decreasing levels of nitric oxide (NO) and prostacyclin resulting in increases in vasoconstriction and permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3,31,32\">",
"     3,31,32",
"    </a>",
"    ]. Extracellular matrix synthesis, fibrosis, dysregulation of cytokines and monocyte activation and impaired insulin-stimulated glucose transport in muscle may all result from PKC activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3,33\">",
"     3,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification of compounds that inhibit the PKC signaling pathway and block expression of PKC-regulated genes may lead to novel therapeutic approaches to prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treat diabetic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396990\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations that alter the expression or activity of protein kinases may underlie both abnormalities in glucose metabolism and the predisposition to vascular complications of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations that increase the activity of PKC isoforms may enhance susceptibility to diabetic nephropathy in humans. This was suggested by the following two studies that showed an association of PKCbeta1 single nucleotide polymorphisms (SNPs) and diabetic nephropathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nine PKCbeta1 SNPs were identified among patients who had type 1 diabetes and diabetic nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/40\">",
"       40",
"      </a>",
"      ]. The frequency of each SNP was compared among case patients (defined as patients with type 1 diabetes and persistent proteinuria or end stage renal disease as a result of diabetic nephropathy) and control subjects (defined as patients with type diabetes for &gt;15 years and who have an albumin-to-creatinine ratio &lt;17",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      for men, and &lt;25",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      for women on spot urine specimens). The frequency of two SNPs in the promoter region was greater among case patients compared with control patients. The association was stronger among those who had a duration of diabetes less than 24 years.",
"     </li>",
"     <li>",
"      Eighteen common SNPs were genotyped in 1172 Chinese patients without renal disease who were recruited from 1995-1998 and compared with 1049 patients with early-onset type 2 diabetes without renal disease who were recruited after 1998 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/41\">",
"       41",
"      </a>",
"      ]. After a mean of 7.9 years, 90 patients (7.7 percent) progressed to end stage renal disease (ESRD). End stage renal disease was associated with four common SNPs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INHIBITORS OF PKC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapies aimed at lowering PKC may be beneficial in slowing the progression of diabetic nephropathy, as shown in animal studies; however, studies in humans to date are rather inconclusive in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The most widely studied isoform-specific PKC inhibitor is ruboxistaurin mesylate, which is highly specific for PKCbeta isoforms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/44\">",
"     44",
"    </a>",
"    ]. Ruboxistaurin has been examined in animal models of diabetes mellitus and a few pilot studies in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Animal studies of ruboxistaurin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of ruboxistaurin on diabetic neuropathy, vascular permeability and renal function have been studied in multiple animal models:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two weeks of treatment with ruboxistaurin completely reversed the diabetes-induced reduction in sciatic motor and saphenous sensory nerve conduction velocity (NCV) in streptozotocin-induced diabetic rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/46\">",
"       46",
"      </a>",
"      ]. When combined with the antioxidants vitamin E or alpha-lipoic acid, motor and sensory NCV and sciatic nerve perfusion improved to the non-diabetic range, demonstrating synergism between PKCbeta and blockers of oxidative stress.",
"     </li>",
"     <li>",
"      The topical application of ruboxistaurin to newly grown vessels in granulation tissue blocked glucose-induced increases in both blood flow and permeability (",
"      <a class=\"graphic graphic_figure graphicRef73671 \" href=\"mobipreview.htm?12/18/12590\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/47\">",
"       47",
"      </a>",
"      ]. Oral administration of ruboxistaurin for eight weeks prevented diabetes-induced increases in albumin permeation in the retina, nerve, and aorta, but not in muscle or brain of diabetic rats, an effect possibly mediated by inhibition of transcription factor binding to specific PKC-regulated genes that are involved in vascular function.",
"     </li>",
"     <li>",
"      The oral administration of ruboxistaurin was associated with reversal of glomerular hyperfiltration (from 4.6",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      to the normal range of 3.0 &plusmn; 0.2",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      and reduction of urinary albumin excretion (11.7 to 4.9",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [normal 1.6",
"      <span class=\"nowrap\">",
"       mg/day])",
"      </span>",
"      in diabetic rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/48\">",
"       48",
"      </a>",
"      ]. This occurred without a change in glycated hemoglobin or DAG content in the retina or glomeruli.",
"     </li>",
"     <li>",
"      Ruboxistaurin normalized glomerular hyperfiltration, decreased urinary albumin excretion, and reduced glomerular transforming growth factor-beta1 and extracellular matrix protein production in the streptozotocin (STZ) rat,",
"      <span class=\"nowrap\">",
"       Lepr(db)/Lepr(db)",
"      </span>",
"      mouse, and STZ-Ren 2 rat models of diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/49\">",
"       49",
"      </a>",
"      ]. Improvements were also noted in mesangial expansion, glomerulosclerosis, tubulointerstitial fibrosis, and renal function.",
"     </li>",
"     <li>",
"      Ruboxistaurin significantly attenuated increases in PKC-induced osteopontin expression in tubular epithelial cells of the renal cortex, macrophage recruitment and tubulointerstitial injury associated with activity of TGF-beta in the Ren-2 diabetic rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Human studies of ruboxistaurin",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orally administered ruboxistaurin did not prevent the progression of retinopathy in initial clinical trials of moderately severe to very severe nonproliferative diabetic retinopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link&amp;anchor=H11#H11\">",
"       \"Prevention and treatment of diabetic retinopathy\", section on 'Treatment of NPDR'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ruboxistaurin stabilized the progression of nephropathy in 123 patients with type 2 diabetes and early diabetic nephropathy (albumin to creatinine ratios of 200 to 2000",
"      <span class=\"nowrap\">",
"       mg/gm",
"      </span>",
"      and serum creatinine &le;1.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [150",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in women, and &le;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [177",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in men) who were on stable doses of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/52\">",
"       52",
"      </a>",
"      ]. Patients were randomly assigned to receive ruboxistaurin, 32",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      or placebo. After one year, treatment with ruboxistaurin was associated with a reduction in albuminuria and stabilization of estimated glomerular filtration rate (GFR), with no change in albuminuria and worsening of estimated GFR in the placebo group. There was no difference between groups in mean blood pressure at baseline and at the end of the study.",
"     </li>",
"     <li>",
"      The effect of ruboxistaurin on long-term (greater than one year) renal outcomes was evaluated in a secondary analysis of three diabetic retinopathy trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/53\">",
"       53",
"      </a>",
"      ]. During median follow-up at 33 to 39 months, no differences in kidney outcomes were observed between ruboxistaurin and placebo. The result of a prospective study of the effect of ruboxistaurin versus placebo in 9 diabetic and 11 control patients was also disappointing; no difference was found between cohorts in peripheral nerve conduction velocity or symptoms of sensory neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/54\">",
"       54",
"      </a>",
"      ]. Adding to disappointment in the use of ruboxistaurin in diabetes is a randomized, 14-day double-blind, crossover, placebo-controlled trial of ruboxistaurin mesylate in 13 subjects with type 2 diabetes without evidence of cardiovascular disease and 15 healthy control subjects. No significant change in endothelium-dependent or endothelium-independent vasodilation or blood-based markers of inflammation, fibrinolysis, endothelial damage, and oxidative stress was noted in either diabetic or healthy subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much larger trials are required before determining the potential clinical role of this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/56\">",
"     56",
"    </a>",
"    ]. Ruboxistaurin is in phase 2 clinical trials in diabetic retinopathy and cardiac ventricular hypertrophy cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2540320\">",
"    <span class=\"h2\">",
"     Other PKC inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of diabetic rats with d-alpha-tocopherol, which decreases DAG and inhibits PKC activation, prevents glomerular hyperfiltration and minimizes the development of proteinuria (2.4 versus 9.1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in control diabetic rats [versus 1.2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in nondiabetic rats]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated cytosolic glucose promotes the accumulation of glyceraldehyde 3-phosphate, which activates PKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/4\">",
"     4",
"    </a>",
"    ]. Large doses of thiamine and the thiamine monophosphate derivative, benfotiamine decreased the formation of glyceraldehyde 3-phosphate and mitigated PKC activation in an experimental model of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/57\">",
"     57",
"    </a>",
"    ]. This was associated with a decrease in the development of moderately increased albuminuria (the new term for what was previously called &ldquo;microalbuminuria&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39207/abstract/58\">",
"     58",
"    </a>",
"    ]) and prevention of hyperfiltration, without a change in elevated plasma glucose concentration and glycated hemoglobin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28926637\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased activity of protein kinase C (PKC) appears to contribute to the micro- and macro-vascular complications of diabetes mellitus. Mechanisms by which this occurs likely include PKC-induced changes in vascular permeability, angiogenesis, cell growth and apoptosis, vessel dilation, cytokine activation, basement membrane thickening and extracellular matrix expansion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H396469\">",
"       'Role of PKC in vascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple PKC isoforms appear to be involved in the development of diabetic nephropathy. Studies of isoform-specific knock-out mice suggest that PKCalpha contributes to albuminuria and PKCbeta to glomerular hypertrophy and mesangial expansion. Both isoforms may play a role in the generation of reactive oxygen species. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diabetic nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased PKC activity may also underlie the development of atherosclerosis, cardiomyopathy, diabetic retinopathy and diabetic neuropathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Role of PKC in extrarenal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations that alter expression or activity of PKC may enhance susceptibility to diabetic nephropathy in humans. Single nucleotide polymorphisms of the PKCbeta1 gene have been associated with proteinuria and with end stage renal disease. (See",
"      <a class=\"local\" href=\"#H396990\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical benefit of therapies aimed at lowering PKC activity in preventing or delaying the complications of diabetes mellitus is not clear at this time. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inhibitors of PKC'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/2\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/3\">",
"      Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/4\">",
"      Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/5\">",
"      Garay-Sevilla ME, Regalado JC, Malacara JM, et al. Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. J Endocrinol Invest 2005; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/6\">",
"      He, Z, King, GL. Protein kinase C beta isoform inhibitors: a new treatment for diabetic cardiovascular disease. Circulation 2004; 6:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/7\">",
"      Cai W, Torreggiani M, Zhu L, et al. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol 2010; 298:C624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/8\">",
"      Craven PA, Studer RK, Negrete H, DeRubertis FR. Protein kinase C in diabetic nephropathy. J Diabetes Complications 1995; 9:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/9\">",
"      Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/10\">",
"      Craven, PA, DeRubertis, FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: Possible mediation by glucose. J Clin Invest 1989; 87:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/11\">",
"      Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/12\">",
"      Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam Horm 2000; 60:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/13\">",
"      Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005; 16 Suppl 1:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/14\">",
"      Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992; 89:11059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/15\">",
"      Menne J, Meier M, Park JK, Haller H. Inhibition of protein kinase C in diabetic nephropathy--where do we stand? Nephrol Dial Transplant 2009; 24:2021.",
"     </a>",
"    </li>",
"    <li>",
"     Karin, M. The AP-1 complex and its role in transcriptional control by protein kinase C. In: Molecular Aspects of Cellular Regulation, Cohen, P, Foulkes, JG (Eds), Elsevier, New York, 1991, p. 235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/17\">",
"      Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl 2007; :S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/18\">",
"      Haneda M, Kikkawa R, Sugimoto T, et al. Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diabetes Complications 1995; 9:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/19\">",
"      Chen S, Cohen MP, Lautenslager GT, et al. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 2001; 59:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/20\">",
"      Studer RK, Craven PA, DeRubertis FR. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993; 42:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/21\">",
"      Ziyadeh FN, Fumo P, Rodenberger CH, et al. Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. J Diabetes Complications 1995; 9:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/22\">",
"      Li X, Pabla N, Wei Q, et al. PKC-delta promotes renal tubular cell apoptosis associated with proteinuria. J Am Soc Nephrol 2010; 21:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/23\">",
"      Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/24\">",
"      Swaminathan S, Shah SV. Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/25\">",
"      Kenwar, YS, Wada, J, Sun, L, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 2008; 233:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/26\">",
"      Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004; 34:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/27\">",
"      Kunisaki M, Bursell SE, Clermont AC, et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 1995; 269:E239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/28\">",
"      Hattori Y, Kawasaki H, Fukao M, Kanno M. Phorbol esters elicit Ca(2+)-dependent delayed contractions in diabetic rat aorta. Eur J Pharmacol 1995; 279:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/29\">",
"      Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 2001; 38:S178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/30\">",
"      Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). Int J Mol Med 2002; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/31\">",
"      Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265:E783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/32\">",
"      Wolf BA, Williamson JR, Easom RA, et al. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 1991; 87:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/33\">",
"      Temofonte N, Sajan MP, Nimal S, et al. Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Diabetologia 2009; 52:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/34\">",
"      Kuo DY, Yang SF, Chu SC, et al. Amphetamine-evoked changes of oxidative stress and neuropeptide Y gene expression in hypothalamus: regulation by the protein kinase C-delta signaling. Chem Biol Interact 2009; 180:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/35\">",
"      O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 diabetes: the end of the beginning? Science 2005; 307:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/36\">",
"      Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004; 25:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/37\">",
"      Wilkin TJ. Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis. Pediatr Diabetes 2008; 9:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/38\">",
"      Perry JR, Frayling TM. New gene variants alter type 2 diabetes risk predominantly through reduced beta-cell function. Curr Opin Clin Nutr Metab Care 2008; 11:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/39\">",
"      Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009; 6:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/40\">",
"      Araki S, Ng DP, Krolewski B, et al. Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-beta1 (PRKCB1) gene locus. J Am Soc Nephrol 2003; 14:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/41\">",
"      Ma RC, Tam CH, Wang Y, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA 2010; 304:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/42\">",
"      Koya D, Lee IK, Ishii H, et al. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 1997; 8:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/43\">",
"      Williams ME, Tuttle KR. The next generation of diabetic nephropathy therapies: an update. Adv Chronic Kidney Dis 2005; 12:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/44\">",
"      Gassel M, Breitenlechner CB, K&ouml;nig N, et al. The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A. J Biol Chem 2004; 279:23679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/45\">",
"      G&aacute;lvez MI. Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review. Curr Diabetes Rev 2009; 5:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/46\">",
"      Cameron NE, Cotter MA. Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 2002; 18:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/47\">",
"      Birch KA, Heath WF, Hermeling RN, et al. LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element. Diabetes 1996; 45:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/48\">",
"      Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/49\">",
"      Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003; 42:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/50\">",
"      Kelly DJ, Chanty A, Gow RM, et al. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005; 16:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/51\">",
"      PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/52\">",
"      Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/53\">",
"      Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007; 2:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/54\">",
"      Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. J Diabetes Complications 2008; 22:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/55\">",
"      Beckman JA, Goldfine AB, Goldin A, et al. Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes. J Clin Endocrinol Metab 2010; 95:3783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/56\">",
"      Mehta NN, Sheetz M, Price K, et al. Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther 2009; 23:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/57\">",
"      Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39207/abstract/58\">",
"      KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3:19. file://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3079 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39207=[""].join("\n");
var outline_f38_18_39207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28926637\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396469\">",
"      ROLE OF PKC IN VASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of PKC in extrarenal complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H396990\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INHIBITORS OF PKC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Animal studies of ruboxistaurin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Human studies of ruboxistaurin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2540320\">",
"      Other PKC inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28926637\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3079|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?31/42/32430\" title=\"algorithm 1\">",
"      Hyperglycemic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3079|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/29/12765\" title=\"figure 1\">",
"      Protein kinase and phosphatase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/18/12590\" title=\"figure 2\">",
"      LY290181 and vascular function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_18_39208="Nabumetone: Drug information";
var content_f38_18_39208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nabumetone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/56/23429?source=see_link\">",
"    see \"Nabumetone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nabumetone&reg;;",
"     </li>",
"     <li>",
"      Gen-Nabumetone;",
"     </li>",
"     <li>",
"      Mylan-Nabumetone;",
"     </li>",
"     <li>",
"      Novo-Nabumetone;",
"     </li>",
"     <li>",
"      Relafen&reg;;",
"     </li>",
"     <li>",
"      Rhoxal-nabumetone;",
"     </li>",
"     <li>",
"      Sandoz-Nabumetone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Osteoarthritis, rheumatoid arthritis:",
"     </b>",
"     Oral: 1000 mg/day; an additional 500-1000 mg may be needed in some patients to obtain more symptomatic relief; may be administered once or twice daily; maximum dose: 2000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients &lt;50 kg are less likely to require doses &gt;1000 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F198814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; do not exceed 2000 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1865801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, NSAIDs are not recommended for use in patients with advanced renal disease, but the manufacturer of nabumetone does provide some guidelines for adjustment in renal dysfunction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute): Initial dose: 750 mg/day; maximum dose: 1500 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Initial dose: 500 mg/day; maximum dose: 1000 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg, 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of osteoarthritis and rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F198843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14080566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (14%), dyspepsia (13%), abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 9%), headache (3% to 9%), fatigue (1% to 3%), insomnia (1% to 3%), nervousness (1% to 3%), somnolence (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (3% to 9%), rash (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (3% to 9%), flatulence (3% to 9%), guaiac positive (3% to 9%), nausea (3% to 9%), gastritis (1% to 3%), stomatitis (1% to 3%), vomiting (1% to 3%), xerostomia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to  important or life-threatening): Abnormal vision, acne, agitation, albuminuria, alopecia, anaphylactoid reaction, anaphylaxis, anemia, angina, angioneurotic edema, anorexia, anxiety, arrhythmia, asthma, azotemia, bilirubinemia duodenitis, bullous eruptions, CHF, chills, confusion, cough, depression, duodenal ulcer, dysphagia, dyspnea, dysuria, eosinophilic pneumonia, eructation, erythema multiforme, fever, gallstones, gastric ulcer, gastroenteritis, gingivitis, GI bleeding, glossitis, granulocytopenia, hematuria, hepatic failure, hyperglycemia, hypersensitivity pneumonitis, hypertension, hyperuricemia, hypokalemia, impotence,  interstitial nephritis, interstitial pneumonitis, jaundice, leukopenia, liver function abnormalities, malaise, melena, MI, nephrotic syndrome, nightmares, palpitation, pancreatitis, paresthesia, photosensitivity, pseudoporphyria cutanea tarda, rectal bleeding, renal failure, renal stones, Stevens-Johnson syndrome, syncope, taste disorder, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, tremor, urticaria, vasculitis, vertigo, weakness, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nabumetone, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity reactions:  May cause photosensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F198805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Nabumetone peak serum concentrations may be increased if taken with food or dairy products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9642512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies nabumetone as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.  A registry is available for pregnant women exposed to autoimmune medications including nabumetone. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in  breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9642515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if nabumetone or 6MNA are excreted into breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F198796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Murine Tears Plus Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05-0.5-0.6% (15 mL): $3.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nabumetone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $129.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $153.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F198786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with renal insufficiency: Baseline renal function followed by repeat test within weeks (to determine if renal function has deteriorated)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Balmox (PT);",
"     </li>",
"     <li>",
"      Bumetone (KP, TH);",
"     </li>",
"     <li>",
"      Goflex (AE, BH, CY, EG, ID, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Labuton (TW);",
"     </li>",
"     <li>",
"      Lavex (KP);",
"     </li>",
"     <li>",
"      Mebutan (NL);",
"     </li>",
"     <li>",
"      Nabone (TH);",
"     </li>",
"     <li>",
"      Nabuco (IL);",
"     </li>",
"     <li>",
"      Nabucox (FR);",
"     </li>",
"     <li>",
"      Nabuflam (IN);",
"     </li>",
"     <li>",
"      Naburen (CO, DO, GT, PA, SV);",
"     </li>",
"     <li>",
"      Nabuser (IT);",
"     </li>",
"     <li>",
"      Nametone (TH);",
"     </li>",
"     <li>",
"      Noac (UY);",
"     </li>",
"     <li>",
"      Relafen (CL, KP);",
"     </li>",
"     <li>",
"      Relifen (JP, ZA);",
"     </li>",
"     <li>",
"      Relifex (AE, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CY, CZ, DE, DK, EE, EG, ET, FI, GB, GH, GM, GN, GR, GY, HN, IE, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NO, NZ, OM, PH, PK, PL, QA, SA, SC, SD, SE, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Relisan (ZA);",
"     </li>",
"     <li>",
"      Relitone (ZA);",
"     </li>",
"     <li>",
"      Rodanol (RU);",
"     </li>",
"     <li>",
"      Unimetone (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Several days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Diffusion occurs readily into synovial fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 6MNA: 29-82 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 6MNA: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug, rapidly metabolized in the liver to an active metabolite [6-methoxy-2-naphthylacetic acid (6MNA)] and inactive metabolites; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 6MNA: &sim;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 6MNA: Oral: 2.5-4 hours; Synovial fluid: 4-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: 6MNA: Urine (80%) and feces (9%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernhard GC, &ldquo;Worldwide Safety Experience With Nabumetone,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1992, 19(Suppl 36):48-57.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brier ME, Sloan RS, and Aronoff GR, &ldquo;Population Pharmacokinetics of the Active Metabolite of Nabumetone in Renal Dysfunction,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(6):622-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/7781261/pubmed\" id=\"7781261\" target=\"_blank\">",
"        7781261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(9):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/6363936/pubmed\" id=\"6363936\" target=\"_blank\">",
"        6363936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Court H and Volans GN, &ldquo;Poisoning After Overdose With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Adverse Drug React Acute Poisoning Rev",
"      </i>",
"      , 1984, 3(1):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/6541425/pubmed\" id=\"6541425\" target=\"_blank\">",
"        6541425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):675-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2642452/pubmed\" id=\"2642452\" target=\"_blank\">",
"        2642452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hedner T, Samulesson O, Wahrborg P, et al, \"Nabumetone: Therapeutic Use and Safety Profile in the Management of Osteoarthritis and Rheumatoid Arthritis,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(20):2315-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/15456329/pubmed\" id=\"15456329\" target=\"_blank\">",
"        15456329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hyneck ML, &ldquo;An Overview of the Clinical Pharmacokinetics of Nabumetone,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1992, 36:20-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/1474531/pubmed\" id=\"1474531\" target=\"_blank\">",
"        1474531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackson RE, Mitchell FN, and Brindley DA, &ldquo;Safety Evaluation of Nabumetone in United States Clinical Trials,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1987, 83(4B):115-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/3318422/pubmed\" id=\"3318422\" target=\"_blank\">",
"        3318422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenner PN, &ldquo;A 12-Month Postmarketing Surveillance Study of Nabumetone: A Preliminary Report,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 40(Suppl 5):80-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2081502/pubmed\" id=\"2081502\" target=\"_blank\">",
"        2081502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knodel LC, &ldquo;Preventing NSAID-Induced Ulcers: The Role of Misoprostol,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1989, 4:37-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pounder R, &ldquo;Silent Peptic Ulceration: Deadly Silence or Golden Silence?&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2642448/pubmed\" id=\"2642448\" target=\"_blank\">",
"        2642448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolinske SC, Hall AH, Vandenberg SA, et al, &ldquo;Toxic Effects of Nonsteroid Anti-inflammatory Drugs in Overdose. An Overview of Recent Evidence on Clinical Effects and Dose-Response Relationships,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1990, 5(4):252-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2198051/pubmed\" id=\"2198051\" target=\"_blank\">",
"        2198051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vale JA and Meredith TJ, &ldquo;Acute Poisoning Due to Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1986, 1(1):12-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/3537613/pubmed\" id=\"3537613\" target=\"_blank\">",
"        3537613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39208/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9671 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39208=[""].join("\n");
var outline_f38_18_39208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709160\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198809\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198847\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198813\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198814\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1865801\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198788\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198774\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874934\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198791\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198843\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080566\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198845\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198794\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198778\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299733\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198783\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198805\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198784\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9642512\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198817\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9642515\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198796\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198786\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869396\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198777\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198793\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9671|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/56/23429?source=related_link\">",
"      Nabumetone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_18_39209="Ethinyl estradiol and desogestrel: Drug information";
var content_f38_18_39209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and desogestrel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/10/17574?source=see_link\">",
"    see \"Ethinyl estradiol and desogestrel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apri&reg;;",
"     </li>",
"     <li>",
"      Azurette&trade;;",
"     </li>",
"     <li>",
"      Caziant&reg;;",
"     </li>",
"     <li>",
"      Cyclessa&reg;;",
"     </li>",
"     <li>",
"      Desogen&reg;;",
"     </li>",
"     <li>",
"      Emoquette&trade;;",
"     </li>",
"     <li>",
"      Kariva&reg;;",
"     </li>",
"     <li>",
"      Mircette&reg;;",
"     </li>",
"     <li>",
"      Ortho-Cept&reg;;",
"     </li>",
"     <li>",
"      Reclipsen&reg;;",
"     </li>",
"     <li>",
"      Velivet&trade;;",
"     </li>",
"     <li>",
"      Viorele",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclessa&reg;;",
"     </li>",
"     <li>",
"      Linessa&reg;;",
"     </li>",
"     <li>",
"      Marvelon&reg;;",
"     </li>",
"     <li>",
"      Ortho-Cept&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day.",
"     <b>",
"      With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For 28-tablet package: Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Dose starts on first day of menstrual cycle taking 1 tablet daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For 28-tablet package: Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, pregnancy test is required before new dosing cycle is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      monophasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as remembered or 2 tablets next 2 days.",
"     <b>",
"      An additional method of contraception should be used for 7 days after missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 or three consecutive doses missed at any time: Schedule 1 (Sunday starter): Continue to take 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack is started that same day. Schedule 2 (Day 1 starter): Current pack should be discarded, and a new pack started that same day.",
"     <b>",
"      An additional method of contraception should be used for 7 days after missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      biphasic/triphasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Two consecutive doses missed in week 1 or week 2 of the pack: Take 2 tablets as soon as remembered and 2 tablets the next day. Resume taking 1 tablet daily until the pack is empty.",
"     <b>",
"      An additional method of contraception should be used for 7 days after a missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 of the pack;",
"     <b>",
"      an additional method of contraception must be used for 7 days after a missed dose",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Take 1 tablet every day until Sunday. Discard the remaining pack and start a new pack of pills on the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Discard the remaining pack and start a new pack the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Three or more consecutive doses missed;",
"     <b>",
"      an additional method of contraception must be used for 7 days after a missed dose",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Take 1 tablet every day until Sunday; on Sunday, discard the pack and start a new pack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Discard the remaining pack and begin new pack of tablets starting on the same day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Oral: See adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F168207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [low dose formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azurette&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-21: Ethinyl estradiol 0.02 mg and desogestrel 0.15 mg [21 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-23: 2 inactive green tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 24-28: Ethinyl estradiol 0.01 mg [5 blue tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kariva&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-21: Ethinyl estradiol 0.02 mg and desogestrel 0.15 mg [21 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-23: 2 inactive light green tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 24-28: Ethinyl estradiol 0.01 mg [5 light blue tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mircette&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-21: Ethinyl estradiol 0.02 mg and desogestrel 0.15 mg [21 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-23: 2 inactive green tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 24-28: Ethinyl estradiol 0.01 mg [5 yellow tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viorele:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-21: Ethinyl estradiol 0.02 mg and desogestrel 0.15 mg [21 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-23: 2 inactive green tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 24-28: Ethinyl estradiol 0.01 mg [5 yellow tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [monophasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apri&reg; 28: Ethinyl estradiol 0.03 mg and desogestrel 0.15 mg [21 rose tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desogen&reg;, Reclipsen&reg;: Ethinyl estradiol 0.03 mg and desogestrel 0.15 mg [21 white tablets and 7 green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emoquette&trade;: Ethinyl estradiol 0.03 mg and desogestrel 0.15 mg [21 white tablets and 7 light green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ortho-Cept&reg; 28: Ethinyl estradiol 0.03 mg and desogestrel 0.15 mg  [21 light orange tablets and 7 green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [triphasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caziant&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.025 mg and desogestrel 0.1 mg [7 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.025 mg and desogestrel 0.125 mg [7 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.025 mg and desogestrel 0.15 mg [7 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day  22-28: 7 green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclessa&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.025 mg and desogestrel 0.1 mg [7 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.025 mg and desogestrel 0.125 mg [7 orange tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.025 mg and desogestrel 0.15 mg [7 red tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Velivet&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.025 mg and desogestrel 0.1 mg [7 beige tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.025 mg and desogestrel 0.125 mg [7 orange tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.025 mg and desogestrel 0.15 mg [7 pink tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 white inactive tablets (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F168218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Apri&reg; may be confused with Apriso&trade;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ortho-Cept&reg; may be confused with Ortho-Cyclen&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following reactions have been associated with oral contraceptive use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Increased risk or evidence of association with use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI, venous thrombosis (with or without embolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gallbladder disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic adenomas, liver tumors (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions considered drug related:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, varicose vein aggravation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, migraine, mood changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Chloasma, melasma, rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast changes (enlargement, pain, secretion, tenderness), fluid retention, infertility (temporary), lactation decreased (with use immediately postpartum), menstrual flow changes, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal cramps, abdominal pain, appetite changes, nausea, weight changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cervical ectropion, cervical secretion, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Folate decreased, porphyria exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature changes (steepening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions (including angioedema, circulatory collapse, respiratory collapse, urticaria), SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions in which association is not confirmed or denied:",
"     </i>",
"     Acne, Budd-Chiari syndrome, cataracts, colitis, cystitis-like syndrome, dizziness, dysmenorrhea, erythema multiforme, erythema nodosum, headache, hemolytic uremic syndrome, hemorrhagic eruption, hirsutism, libido changes, nervousness, optic neuritis (with or without partial or complete loss of vision), pancreatitis, premenstrual syndrome, renal function impaired, scalp hair loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethinyl estradiol, etonogestrel, desogestrel, or any component of the formulation; breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding, cholestatic jaundice of pregnancy, jaundice with prior combination hormonal contraceptive use",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), headaches with focal neurological symptoms, hypertension (uncontrolled), valvular heart disease with complications, major surgery with prolonged immobilization",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism; discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use another form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use another form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Should not be used in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used. New patients should be started on products containing  &le;0.035 mg of estrogen per tablet.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F168216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy has not been associated with teratogenic effects.  Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC,  2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; a nonhormonal form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Apri Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $30.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Azurette Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.02/0.01 mg (28): $59.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Caziant Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1/0.125/0.15 -0.025 mg (28): $33.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cesia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1/0.125/0.15 -0.025 mg (28): $33.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cyclessa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1/0.125/0.15 -0.025 mg (28): $59.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Desogen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $52.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Emoquette Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $39.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Kariva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.02/0.01 mg (28): $59.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mircette Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-0.02/0.01 mg (28): $107.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ortho-Cept (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $64.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Reclipsen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $39.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Solia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-30 mg-mcg (28): $30.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Velivet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1/0.125/0.15 -0.025 mg (28): $33.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ciclidon (CN, PE);",
"     </li>",
"     <li>",
"      Daisy (TH);",
"     </li>",
"     <li>",
"      Desmin (DE);",
"     </li>",
"     <li>",
"      Desolett (TR);",
"     </li>",
"     <li>",
"      Desolett 28 (SE);",
"     </li>",
"     <li>",
"      Gedare (GB);",
"     </li>",
"     <li>",
"      Gracial 28 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lamuna (DE);",
"     </li>",
"     <li>",
"      Lovina (DE);",
"     </li>",
"     <li>",
"      Marvelon (AE, AR, AT, BE, BF, BG, BH, BJ, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, HK, HN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, OM, PE, PK, PL, PT, PY, QA, RU, SA, SC, SD, SL, SN, SY, TN, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Marvelon 21 (NZ, TH, TW);",
"     </li>",
"     <li>",
"      Marvelon 28 (AU, DK, ID, NZ, PH, TH);",
"     </li>",
"     <li>",
"      Marviol (IE);",
"     </li>",
"     <li>",
"      Mercilon (FR, KP, PH, SG);",
"     </li>",
"     <li>",
"      Microdiol (BR, IL);",
"     </li>",
"     <li>",
"      Minny (TH);",
"     </li>",
"     <li>",
"      Minny 28 (TH);",
"     </li>",
"     <li>",
"      Miravelle Suave (CO);",
"     </li>",
"     <li>",
"      Novelon (IN);",
"     </li>",
"     <li>",
"      Novynette (BB, BM, BS, BZ, GY, HK, JM, SR, TH, TT);",
"     </li>",
"     <li>",
"      Oilezz (TH);",
"     </li>",
"     <li>",
"      Primera 30 (BR);",
"     </li>",
"     <li>",
"      Regulon (BG, MY);",
"     </li>",
"     <li>",
"      Varnoline (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination hormonal contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Desogestrel and ethinyl estradiol: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Etonogestrel (active metabolite): 98%, primarily to sex hormone-binding globulin; Ethinyl estradiol: primarily bound to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desogestrel: Hepatic via CYP2C9 to active metabolite etonogestrel (3-keto-desogestrel); etonogestrel metabolized via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol: Hepatic; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Etonogestrel: ~38 hours; Ethinyl estradiol: ~26 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Etonogestrel and ethinyl estradiol: Urine and feces (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;An Open-Label, Multicenter, Noncomparative Safety and Efficacy Study of Mircette, a Low-Dose Estrogen-Progestin Oral Contraceptive. The Mircette Study Group,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1998, 179(1):S2-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/9704812/pubmed\" id=\"9704812\" target=\"_blank\">",
"        9704812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,&rdquo; August 13, 2001. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenfield GM and Griffin JM, &ldquo;Clinical Pharmacokinetics of Contraceptive Steroids. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 20(1):15-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/2029800/pubmed\" id=\"2029800\" target=\"_blank\">",
"        2029800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/18/39209/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8741 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39209=[""].join("\n");
var outline_f38_18_39209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708760\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168201\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168202\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168221\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168205\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168215\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168206\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168207\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168178\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168162\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168180\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168179\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168218\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168227\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168219\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168183\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168166\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168216\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168171\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168196\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168173\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168186\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168210\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168187\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168188\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168185\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168176\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168189\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168165\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168182\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/10/17574?source=related_link\">",
"      Ethinyl estradiol and desogestrel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_18_39210="Prevention and treatment of chemotherapy-induced nausea and vomiting";
var content_f38_18_39210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of chemotherapy-induced nausea and vomiting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39210/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39210/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39210/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39210/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/18/39210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/18/39210/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/18/39210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few side effects of cancer treatment are more feared by the patient than nausea and vomiting. Although nausea and emesis (vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retching) can result from surgery, opiates, or radiotherapy, chemotherapy-induced nausea and vomiting (CINV) is potentially the most severe and most distressing. Although significant progress has been made, CINV remains an important adverse effect of treatment.",
"   </p>",
"   <p>",
"    Three distinct types of CINV have been defined, with important implications for both prevention and management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute emesis, which most commonly begins within one to two hours of chemotherapy and usually peaks in the first four to six hours",
"     </li>",
"     <li>",
"      Delayed emesis, occurring more than 24 hours after chemotherapy",
"     </li>",
"     <li>",
"      Anticipatory emesis, occurring prior to treatment as a conditioned response in patients who have developed significant nausea and vomiting during previous cycles of chemotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The objective of antiemetic therapy is the complete prevention of CINV, and this should be achievable in the majority of patients receiving chemotherapy, even with highly emetic agents (",
"    <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"     table 2",
"    </a>",
"    ). The three categories of drugs with the highest therapeutic index for the management CINV include type three 5-hydroxytryptamine (5-HT3) receptor antagonists, the neurokinin-1 (NK1) receptor antagonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    , and glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of these drugs alone and in combination for antiemetic prophylaxis in patients receiving cancer chemotherapy will be reviewed here. The pathophysiology of CINV is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=see_link\">",
"     \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY DRUG EMETOGENICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of CINV has been greatly facilitated by the development of classification schemes that reflect the likelihood of emesis developing following treatment with particular agents. A 1997 classification scheme gained broad acceptance and was utilized as the basis for treatment recommendations by guideline panels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A modification of this schema was proposed at the 2004 Perugia Antiemetic Consensus Guideline meeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/3\">",
"     3",
"    </a>",
"    ]. Chemotherapy agents were divided into four categories (",
"    <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Highly emetic &mdash; &gt;90 percent risk of emesis",
"     </li>",
"     <li>",
"      Moderately emetic &mdash; &gt;30 to 90 percent risk of emesis",
"     </li>",
"     <li>",
"      Low emetogenicity&mdash; 10 to 30 percent risk of emesis",
"     </li>",
"     <li>",
"      Minimally emetic &mdash; &lt;10 percent risk of emesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This drug classification schema is utilized in both the updated antiemetic guidelines of the Multinational Association of Supportive Care in Cancer (MASCC) and the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. For combination regimens, the emetic level is determined by identifying the most emetic agent in the combination and then assessing the relative contribution of the other agents. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    are both moderately emetogenic agents, but when given together, the regimen is highly emetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In updated antiemetic guidelines from ASCO, combined anthracycline and cyclophosphamide regimens have been reclassified as highly emetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NCI Common Terminology Criteria for Adverse Events (CTCAE) grading schema for classifying the severity of CINV is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef69015 \" href=\"mobipreview.htm?31/24/32139\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE EMESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive clinical trials have evaluated the 5-HT3 receptor antagonists, the NK1 receptor antagonists, and glucocorticoids in patients with acute and delayed CINV. These trials have focused primarily on patients receiving either highly or moderately emetic chemotherapy regimens. Although not all antiemetic regimens have been evaluated with all chemotherapy combinations, it is reasonable to extrapolate data to other chemotherapy regimens of comparable emetogenicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     5-HT3 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key advance in the prevention of CINV was the development of selective type three 5-hydroxytryptamine (5-HT3) receptor antagonists, a drug class that has a high therapeutic index for prevention of CINV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have shown that single-agent 5-HT3 receptor antagonists are more effective than less specific agents such as high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and as effective as the combination of high-dose metoclopramide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . When 5-HT3 antagonists are used in combination with dexamethasone, they are more effective than high-dose metoclopramide plus dexamethasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In addition to increased efficacy, these agents are easier to administer and are associated with significantly fewer serious side effects than the less specific serotonin inhibitor metoclopramide.",
"   </p>",
"   <p>",
"    Four first-generation 5-HT3 receptor antagonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    , and tropisetron) and one second-generation agent (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    ) are available (",
"    <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"     table 3",
"    </a>",
"    ). An orally disintegrating formulation of ondansetron also is available that disperses rapidly when placed on the tongue and does not need to be swallowed with water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/11\">",
"     11",
"    </a>",
"    ]. This formulation may be particularly useful for patients with dysphagia or anorexia. A granisetron transdermal system is also available. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Granisetron transdermal patch'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     First generation agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of randomized trials have clarified the properties of the first-generation 5-HT3 receptor antagonists. Key findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first-generation 5-HT3 receptor antagonists all appear equally effective at preventing CINV at the recommended doses. At least two meta-analyses have shown no clear advantage for either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       granisetron",
"      </a>",
"      in the prophylaxis of acute or delayed emesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a plateau in therapeutic efficacy at a definable dose level for each drug, and further dose escalation does not improve outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single dose of a 5-HT3 receptor antagonist prior to chemotherapy is therapeutically equivalent to a multiple dose schedule [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/15-19\">",
"       15-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy of 5-HT3 receptor antagonists is significantly improved when they are combined with glucocorticoids. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Oral formulations of these agents are as effective as intravenous formulations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/14,20,21\">",
"       14,20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2662553\">",
"    <span class=\"h4\">",
"     EKG interval changes and cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;EKG interval changes are a class effect of the first-generation 5-HT3 antagonists, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    , although they have not been reported with transdermal granisetron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Granisetron transdermal patch'",
"    </a>",
"    below.) EKG interval changes appear to be most prominent one to two hours after a dose of these agents, are mostly small and clinically insignificant, and return to baseline within 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. However, potentially fatal cardiac arrhythmias, including torsade to pointes, have been reported in association with QTc prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/23,25-27\">",
"     23,25-27",
"    </a>",
"    ]. The following sections describe the",
"    <span class=\"nowrap\">",
"     warnings/precautions",
"    </span>",
"    regarding cardiotoxicity of these agents from the US FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13889233\">",
"    <span class=\"h5\">",
"     Dolasetron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the risk of QTc prolongation from increased drug exposure the injection form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    is contraindicated for prophylaxis of CINV in both children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of developing an abnormal heart rhythm with oral dolasetron is less than that seen with the injection form. However, there is still a potential risk.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration recommends the following precautions in patients receiving",
"    <strong>",
"     oral",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potassium and magnesium levels should be assessed, and if abnormal, corrected before initiation of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      . These electrolytes should be monitored after administration as clinically indicated.",
"     </li>",
"     <li>",
"      Use electrocardiographic monitoring in patients with heart failure, a slow heart rate, underlying cardiac disease, the elderly, and in patients with renal impairment.",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      should be avoided in patients with congenital long-QT syndrome (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Drugs known to prolong the PR (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) or QRS interval (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ) should be avoided in patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13889240\">",
"    <span class=\"h5\">",
"     Ondansetron",
"    </span>",
"    &nbsp;&mdash;&nbsp;FDA has issued a warning about QTc prolongation and potentially fatal cardiac arrhythmias in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/29\">",
"     29",
"    </a>",
"    ]. QT prolongation occurs in a dose-dependent manner and specifically at a single IV dose of 32 mg. Revised labeling includes a recommendation to limit single IV doses to no more than 16 mg, avoid use of ondansetron in patients with congenital long-QT syndrome, and to use ECG monitoring in certain patients, including those with hypokalemia or hypomagnesemia, heart failure, bradyarrhythmias, and in patients taking other medications that increase the risk of QTc prolongation (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Palonosetron",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second-generation agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    has a 30- to 100-fold higher affinity for the 5-HT3 receptor and a significantly longer half-life (40 hours) compared to first generation 5-HT3 receptor antagonists (",
"    <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"     table 3",
"    </a>",
"    ). In contrast to first-generation 5-HT3 antagonists, QTc prolongation has not been described with palonosetron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a single agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    is more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    at preventing emesis due to moderately emetic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This was illustrated by a multicenter trial in 592 patients, the majority of whom received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for breast cancer. Subjects were randomly assigned to a single IV dose of palonosetron at one of two dose levels (0.25 or 0.75 mg IV) or dolasetron (100 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/31\">",
"     31",
"    </a>",
"    ]. More patients treated with palonosetron (0.25 mg) had complete control of both acute (63 versus 53 percent) and delayed emesis (54 versus 39) compared to dolasetron. A dose of 0.75 mg was not significantly superior compared to 0.25 mg.",
"   </p>",
"   <p>",
"    When used in combination with glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    provides superior control of delayed emesis compared to first-generation 5-HT3 receptor antagonists combined with glucocorticoids:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III double-blind, double-dummy trial, 1143 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or an",
"      <span class=\"nowrap\">",
"       anthracycline/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"      </span>",
"      combination were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       palonosetron",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       granisetron",
"      </a>",
"      on day 1 prior to chemotherapy followed by dexamethasone alone on days 2 and 3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/34\">",
"       34",
"      </a>",
"      ]. During the acute phase, the rate of complete control of CINV was similar (75 versus 73 percent with palonosetron and granisetron, respectively), but during the delayed phase (24 to 120 hours), complete responses occurred in significantly more patients receiving palonosetron (57 versus 45 percent). An unresolved question arising from this study design is whether the efficacy differences noted would have persisted with the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      , which all evidence-based guidelines recommend in this setting.",
"     </li>",
"     <li>",
"      In a second phase III trial, in which 667 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       palonosetron",
"      </a>",
"      (0.25 mg), palonosetron (0.75 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      (32 mg), no significant differences in antiemetic control were noted between palonosetron and ondansetron [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/35\">",
"       35",
"      </a>",
"      ]. Approximately two-thirds of patients received concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . In this subset of patients, complete response rates were numerically higher in both palonosetron arms compared to ondansetron during the first 24 hours. During the delayed (24 to 120 hours) phase, complete response was significantly higher on the 0.25 mg palonosetron arm compared to the ondansetron arm (42 versus 29 percent, p = 0.021). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Updated antiemetic guidelines from the American Society of Clinical Oncology (ASCO) recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    as the preferred 5-HT3 antagonist for patients who receive moderately emetic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An oral formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    is approved. A non-inferiority trial documented similarity between the oral and IV formulations and validated the correct dose (0.5 mg oral) (",
"    <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/36\">",
"     36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurokinin-1 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of the NK1 receptor (NK1R) antagonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    (a parenteral water-soluble prodrug of aprepitant that is effective as a one-day treatment (see",
"    <a class=\"local\" href=\"#H428644927\">",
"     'One versus three-day administration'",
"    </a>",
"    below)) have significantly improved the ability to prevent both acute and delayed CINV in patients receiving highly and moderately emetic chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"     table 2",
"    </a>",
"    ). Casopitant is another NK1R antagonist that can be given as a single day-one oral dose or in a mixed intravenous plus oral three day schedule in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ; it is not yet commercially available in any country.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of combining an NK1R antagonist (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    , or casopitant) with an 5-HT3 receptor antagonist plus a glucocorticoid for the prevention of acute CINV was addressed in a meta-analysis of 17 trials, totaling 8740 patients who were receiving highly or moderately emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/37\">",
"     37",
"    </a>",
"    ]. The addition of a NK1R antagonist to standard antiemetic therapy significantly improved the rate of complete response (CR, absence of emesis and no need for rescue antiemetics) in both the overall phase (during the first 120 hours of chemotherapy, 72 versus 54 percent, OR 0.51, 95% CI 0.46-0.57) and in the acute (first 24 hours, OR 0.56, 95% CI 0.48-0.65) as well as delayed phase (OR 0.48, 95% CI 0.42-0.56). For other secondary outcomes (rate of emesis, no nausea, no substantial nausea in all phases), the addition of an NK1R antagonist was also superior to the control arm. (See",
"    <a class=\"local\" href=\"#H127217821\">",
"     'NK1 receptor antagonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In subgroup analyses, benefit was seen for both highly emetogenic (CR, 73 versus 54 percent, OR 0.46, 95% CI 0.40-0.53) and moderately emetogenic chemotherapy (CR 71 versus 54 percent, OR 0.59, 95% CI 0.61-0.67). There appeared to be no differences in treatment efficacy for",
"    <span class=\"nowrap\">",
"     aprepitant/fosaprepitant",
"    </span>",
"    and casopitant. The use of an NK1R antagonist did not increase the risk of diarrhea, although rates of hiccups and",
"    <span class=\"nowrap\">",
"     fatigue/asthenia",
"    </span>",
"    were significantly higher. There was a suggestion that use of an NK1R antagonist increased the risk of a severe infection (6 versus 2 percent in a pooled analysis of three trials); however, this was not associated with an increased rate of neutropenia or febrile neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3798759\">",
"    <span class=\"h4\">",
"     Need for a 5-HT3 agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     Aprepitant",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    improve control of CINV when combined with a 5-HT3 receptor antagonist and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Aprepitant plus dexamethasone alone is not as effective as the three-drug combination regimen. A 5-HT3 receptor antagonist remains necessary, at least in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy.",
"   </p>",
"   <p>",
"    This was illustrated by a randomized trial in which patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    chemotherapy were randomly assigned to the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , granisetron, or aprepitant (on one of two schedules) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/38\">",
"     38",
"    </a>",
"    ]. All patients also received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (20 mg orally) before cisplatin. While the three-drug combination blocked emesis in 80 percent of patients, dexamethasone plus either granisetron or aprepitant was effective in only 57 percent and 43 to 46 percent of cases, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428644927\">",
"    <span class=\"h3\">",
"     One versus three-day administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    are approved for use in three-day schedules. However, a single-day dosing schedule for fosaprepitant was approved by the FDA based upon the results of a phase III trial involving 2247 patients receiving single-day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (&gt;70",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/39\">",
"     39",
"    </a>",
"    ]. The control group received aprepitant administered in the standard three-day schedule along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ; this was compared to a single 150 mg dose of fosaprepitant combined with ondansetron on day 1 plus dexamethasone on days 2, 3, and 4. Complete antiemetic response rates were nearly identical between the aprepitant and fosaprepitant arms (72.3 versus 71.9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Issues related to inhibition of CYP3A4",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK1 receptor antagonists such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    are moderate inhibitors of the cytochrome P450 enzyme CYP3A4, which is particularly important in drug metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CYP3A4 is responsible for the metabolism of glucocorticoids, and thus the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was reduced in clinical trials from 20 mg to 12 mg on day 1 and from 8 mg twice daily to 8 mg daily on days 2 and 3 when given concurrently with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. This dose reduction applies only when glucocorticoids are used as antiemetics in conjunction with NK1 receptor antagonists,",
"    <strong>",
"     not",
"    </strong>",
"    when given as an antitumor component of a chemotherapy regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Theoretically,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    could decrease the clearance of drugs metabolized by CYP3A4 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , vinca alkaloids), resulting in prolonged exposure and increased toxicity. However, there is no clinical evidence that this actually occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short courses of glucocorticoids are widely used both as single agents for regimens with low risk of causing CINV and in combination with 5-HT3 receptor inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NK1 receptor antagonists for more emetic chemotherapy regimens. When used in this fashion, glucocorticoids have a high therapeutic index. Although the various glucocorticoids are probably equally effective when used at an appropriate dose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been the most extensively evaluated and is the most widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Single agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been compared to either placebo or no treatment in a number of randomized trials. A meta-analysis of 32 randomized trials evaluated 5613 patients who received moderately or highly emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/45\">",
"     45",
"    </a>",
"    ]. Dexamethasone was superior to placebo or no treatment for complete protection from both acute emesis (risk ratio [RR] 1.30) and delayed emesis (RR 1.30). However, dexamethasone as a single agent is insufficient to control CINV in most of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Combination with a 5-HT3 antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids alone represent insufficient first-line therapy for patients receiving either moderate or highly emetic chemotherapy agents. However, the antiemetic efficacy of the 5-HT3 receptor antagonists is significantly enhanced by the addition of a glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/7,46-50\">",
"     7,46-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit for combined therapy was shown in a meta-analysis of 3791 patients enrolled in 22 randomized trials in which a 5-HT3 receptor antagonist plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was compared with a 5-HT3 antagonist plus placebo or no treatment in patients receiving moderate or highly emetic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/45\">",
"     45",
"    </a>",
"    ]. The pooled risk ratio for emesis protection was 1.25, indicating that the addition of dexamethasone increased the chance of no acute vomiting by 25 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of glucocorticoid dose was explored in a double-blind trial that randomly assigned 531 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &ge;50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    to one of four intravenous doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    administered by a 15-minute infusion prior to cisplatin administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/51\">",
"     51",
"    </a>",
"    ]. All patients received 8 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    as well. At doses of 20, 12, 8, and 4 mg, complete protection from vomiting was achieved in 83, 79, 69, and 69 percent of patients, respectively, and nausea was prevented in 71, 67, 61, and 61 percent.",
"   </p>",
"   <p>",
"    The optimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for highly to moderately emetic chemotherapy not containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was evaluated by the Italian Group for Antiemetic Research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/52\">",
"     52",
"    </a>",
"    ]. In this trial, all patients received IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and were randomized to one of three schedules of dexamethasone following chemotherapy (either 8 or 24 mg IV prior to chemotherapy, or 8 mg IV before treatment followed by 4 mg every six hours). Rates of complete protection from acute or delayed emesis were similar among the groups, and the authors concluded that a single 8 mg IV dose prior to chemotherapy represented the appropriate dexamethasone regimen.",
"   </p>",
"   <p>",
"    As noted above, the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is reduced when it is in combination with an NK1 receptor antagonist. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Issues related to inhibition of CYP3A4'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents that have been used in the treatment or prevention of CINV include phenothiazines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    )",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , butyrophenones, and cannabinoids. These agents have a lower therapeutic index than the 5-HT3 receptor antagonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    , and glucocorticoids for highly or moderately emetogenic chemotherapy regimens. Their use should be restricted to patients who are intolerant of or refractory to these first line agents. The benefits of synthetic oral cannabinoids in this setting remain controversial given the lack of evidence on their safety and efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. Phenothiazines could be used as an alternative to single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for those receiving chemotherapy with a low risk of emesis, if a glucocorticoid is contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H40\">",
"     'Poor emesis control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other drugs that may be useful as adjuncts to conventional antiemetic agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    . These are not recommended as single agent antiemetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of the antipsychotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    for prevention of delayed nausea in patients receiving high-risk regimens is discussed below. (See",
"    <a class=\"local\" href=\"#H127218074\">",
"     'Olanzapine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DELAYED EMESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed emesis is defined by its occurrence more than 24 hours after chemotherapy. Although it is most common following high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/58-60\">",
"     58-60",
"    </a>",
"    ], delayed emesis may occur with other agents as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127218108\">",
"    <span class=\"h2\">",
"     Regimens with a high risk of delayed emesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of delayed emesis after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (doses &gt;70",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    ranges between 60 and 90 percent in the absence of effective prophylaxis. The risk of delayed emesis without any prophylaxis is estimated to be between 20 and 30 percent in patients receiving chemotherapy with an anthracycline plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the risk of delayed emesis has been best studied with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , other moderately emetogenic agents are also associated with delayed emesis. These include doxorubicin &ge;40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a single agent or &ge;25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in combination with other chemotherapeutic agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    &ge;75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a single agent or &ge;50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    when given in combination with other agents, combinations of cyclophosphamide &ge;600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in combination with other drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    &ge;300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (as used in the FOLFOX [oxaliplatin plus short-term infusional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ] regimen for advanced colorectal cancer), and cisplatin at doses between 20 and 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/19,62-65\">",
"     19,62-65",
"    </a>",
"    ]. One study found that among 68 patients treated with one of these regimens who had no post-chemotherapy vomiting in the 24 hours after administration of prechemotherapy",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , 28 (41 percent) vomited in the next four days when no further antiemetics were given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/19\">",
"     19",
"    </a>",
"    ]. This frequency was reduced to 15 of 75 (20 percent) when ondansetron was continued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127217965\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the regimens associated with delayed emesis are classified as high-emetic risk, and guidelines from ASCO recommend the use of an NK1 receptor antagonist (either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    on days 1 to 3 or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    on day 1 only), plus a glucocorticoid on days 1 to 4, and a 5-HT3 receptor antagonist on day 1 (",
"    <a class=\"graphic graphic_table graphicRef72865 \" href=\"mobipreview.htm?28/6/28781\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ]. This regimen is effective against both acute and delayed emesis. The data supporting the individual components of this regimen are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127217842\">",
"    <span class=\"h4\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of maintenance therapy with oral glucocorticoids following treatment of acute CINV was shown in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy regimens in at least two randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. However, glucocorticoids alone are often not sufficient to prevent delayed emesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127217821\">",
"    <span class=\"h4\">",
"     NK1 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding an NK1R antagonist to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and a 5-HT3 antagonist for prevention of delayed emesis in patients receiving highly or moderately emetogenic chemotherapy was shown in a meta-analysis of 17 trials and described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/37\">",
"     37",
"    </a>",
"    ]. Importantly, the addition of NK1R antagonists increased control rates in the overall phase (ie, 120 hours after chemotherapy) independently of whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    was used in the control arm beyond day 1 or not. However, patients who did not use ondansetron after day 1 seemed to have a greater benefit from the addition of the NK1R antagonist. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Neurokinin-1 receptor antagonists'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127217828\">",
"    <span class=\"h4\">",
"     5-HT3 antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting results have been described with the use of first generation 5-HT3 receptor antagonists as single agents for protection against delayed emesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/58,66-70\">",
"     58,66-70",
"    </a>",
"    ]. Although some benefit has been seen when these agents are used as monotherapy, the benefit was not as great as that seen with corticosteroids. Furthermore, continuing a 5-HT3 receptor antagonist beyond 24 hours along with glucocorticoids did not confer additional benefit compared to corticosteroids alone. Thus the use of the 5-HT3 receptor antagonists as a sole maneuver to prevent delayed emesis in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended.",
"   </p>",
"   <p>",
"    There is evidence to suggest that the second generation 5-HT3 receptor antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    is superior to other 5-HT3 receptor antagonists for the treatment of delayed emesis due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III trial of patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       palonosetron",
"      </a>",
"      (at one of two doses, either 0.25 mg or 0.75 mg) yielded higher rates of emetic control compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      in preventing delayed emesis (complete response rates of 45 and 48 versus 39 percent, respectively), although the results were not statistically significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/35\">",
"       35",
"      </a>",
"      ]. However, in a subset analysis, palonosetron 0.25 mg was superior to ondansetron for control of delayed and overall emesis in patients receiving concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The superiority of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       palonosetron",
"      </a>",
"      for prevention of delayed emesis was also shown in another phase III trial in which 1114 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or an",
"      <span class=\"nowrap\">",
"       anthracycline/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"      </span>",
"      (AC) combination were randomly assigned to a single dose of palonosetron or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       granisetron",
"      </a>",
"      30 minutes prior to chemotherapy with all patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      for three days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/34\">",
"       34",
"      </a>",
"      ]. Significantly better control of delayed emesis was achieved in both the cisplatin and AC subgroups on the palonosetron arm (complete response 57 versus 45 percent with granisetron).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results suggest the superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    over other 5-HT3 antagonists for the prevention of delayed emesis, it is unclear whether this difference would persist with the addition of an NK1 receptor antagonist. To date, there are no randomized trials in which the combination of palonosetron and an NK1 receptor antagonist has been compared to a first generation 5-HT3 receptor antagonist plus an NK1 receptor antagonist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127218074\">",
"    <span class=\"h4\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional antiemetics are more successful at preventing emesis than in preventing nausea, particularly delayed nausea. The superiority of the antipsychotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    for the prevention of delayed nausea was suggested in a phase III trial conducted in 247 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients were randomly assigned to olanzapine (10 mg orally on the day of chemotherapy, and then 10 mg once daily on days 2 through 4), or aprepitant (125 mg orally prior to chemotherapy, followed by 80 mg orally on days 2 and 3), both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    (0.25 IV on the day of chemotherapy) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Dexamethasone (20 mg) was only given on the day of chemotherapy, while the aprepitant group received dexamethasone 12 mg on the day of chemotherapy followed by dexamethasone 4 mg twice daily on days 2 and 3.",
"   </p>",
"   <p>",
"    Following cycle 1, rates of prevention of acute nausea (87 percent in both the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    groups), and of complete control of acute (97 versus 87 percent) and delayed vomiting (77 versus 73 percent) were similar. However, patients treated with olanzapine had a significantly higher rate of nausea control in the delayed period (69 versus 38 percent). The results were maintained during cycles 2 to 4.",
"   </p>",
"   <p>",
"    While these data are intriguing, these findings need to be replicated in a larger study.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    may also be useful for management of breakthrough emesis. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Poor control of emesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Moderate risk agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of delayed emesis following treatment with moderate risk agents other than the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus an anthracycline is not well characterized. Other cyclophosphamide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based regimens, as well as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , can cause delayed emesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\", section on 'Delayed emesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The contribution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    to the control of delayed emesis with moderate risk agents was shown in a meta-analysis and is described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Glucocorticoids are also consistently useful agents. The value of maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was demonstrated in a randomized placebo controlled trial of patients undergoing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/59\">",
"     59",
"    </a>",
"    ]. In this trial, 98 patients were given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    and dexamethasone before chemotherapy and randomized to receive either oral dexamethasone 4 mg twice daily as maintenance or no maintenance. Maintenance dexamethasone was associated with a higher rate of compete (57 versus 33 percent) and major control (33 versus 15 percent) of delayed emesis.",
"   </p>",
"   <p>",
"    The 5-HT3 receptor antagonists also have activity as single agents for delayed emesis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there is no evidence that they are superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    alone or that combination therapy with dexamethasone is superior to dexamethasone alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial of 708 patients receiving moderately emetogenic chemotherapy and concurrent antiemetics illustrates the relative roles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and 5-HT3 receptor antagonists in the management of delayed emesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients without acute nausea or vomiting (the low-risk group) were randomized to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (4 mg orally twice daily on days 2 through 5) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      (8 mg orally twice daily on days 2 through 5), dexamethasone alone on the same schedule, or a placebo. Among these 618 patients, there was a complete absence of delayed nausea and vomiting in 92, 87, and 77 percent of patients in the combined therapy, dexamethasone, and placebo groups, respectively. Protection with dexamethasone alone or with dexamethasone plus ondansetron was better than that with placebo; however, the combination was not statistically superior to dexamethasone alone.",
"     </li>",
"     <li>",
"      The key factor in preventing delayed emesis was the control of acute symptoms following chemotherapy. Patients who had either vomiting or moderate to severe nausea in the 24 hours following chemotherapy constituted a high-risk group. These 87 patients were randomly assigned to oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      alone or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      , at the same doses and schedules as in the low-risk group. Despite treatment, complete protection from delayed emesis or moderate to severe was achieved in only 41 and 23 percent of patients treated with the combination and dexamethasone, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative roles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    in controlling delayed nausea was studied in a randomized trial of 944 evaluable patients receiving primarily (95 percent) moderately emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/72\">",
"     72",
"    </a>",
"    ]. Palonosetron did not provide superior control of delayed nausea compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , when both were provided on day 1 with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    was administered on days 2 and 3. In addition, aprepitant was not more effective than prochlorperazine when both were combined with dexamethasone on days 2 and 3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ANTICIPATORY EMESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticipatory emesis is a conditioned response that occurs in patients who experienced severe nausea and vomiting during prior cycles of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/73\">",
"     73",
"    </a>",
"    ]. It appears to be induced by sensory cues and cognitive anticipation of subsequent chemotherapy. Anticipatory nausea has also been described among patients who have a high expectation of developing nausea despite never having received chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most effective means to prevent anticipatory nausea or emesis is to ensure good control of acute and delayed emesis, starting from the initial chemotherapy cycle (",
"    <a class=\"graphic graphic_table graphicRef72865 \" href=\"mobipreview.htm?28/6/28781\">",
"     table 6",
"    </a>",
"    ). Once anticipatory emesis has been established, nonpharmacologic methods (eg, hypnosis, behavioral therapy with systemic desensitization) may be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link\">",
"     \"Complementary and alternative therapies for cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although few formal trials have been carried out, benzodiazepines before and during chemotherapy may be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In one double-blind trial of 57 women undergoing adjuvant chemotherapy for primary breast cancer for example, the addition of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    (0.5 mg to 2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to a psychologic support program including progressive relaxation training was associated with a significantly reduced rate of anticipatory nausea compared to placebo (0 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Consecutive day therapy with highly emetogenic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;When moderately or highly emetogenic chemotherapy agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) are administered on several consecutive days, prophylaxis is more difficult. This may be due to anticipatory emesis on the subsequent days of therapy or to the compounding of acute and delayed effects of treatment. Updated ASCO antiemetic guidelines suggest that antiemetics appropriate for the emetogenic risk class of the chemotherapy be administered for each day of the chemotherapy and for two days after, if appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trials conducted before the availability of NK1R antagonists suggested that repetitive daily dosing with a 5-HT3 receptor antagonist combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was the best approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, more recently, the benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    to a 5-HT3 antagonist and dexamethasone was shown in a small trial of 69 patients receiving a five-day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing chemotherapy regimen for germ cell cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/82\">",
"     82",
"    </a>",
"    ]. All patients received a 5-HT3 antagonist (other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    ) once daily on days 1 through 5, plus dexamethasone 20 mg once daily on days 1 and 2, and were randomly assigned to aprepitant (125 mg on day 3, 80 mg on days 4 and 5) or no aprepitant. The group receiving aprepitant also received dexamethasone 4 mg twice daily on days 6, 7, and 8, while the placebo group received dexamethasone 8 mg twice daily on days 6 and 7 and 4 mg twice daily on day 8. A complete response (no emetic episodes and no use of rescue medication) was noted in significantly more patients receiving aprepitant (42 versus 13 percent), and the visual analog scale (VAS) score for nausea was numerically lower for aprepitant, although the difference compared to placebo was not statistically significant.",
"   </p>",
"   <p>",
"    Although the authors provided a rationale for starting the NK1R on day 3 rather than on day 1, the optimal schedule for NK1R antagonists for patients receiving consecutive day therapy with highly emetogenic chemotherapy is unknown given the lack of comparative trials addressing this question. For regimens containing five days of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (eg, for testicular germ cell cancer), we suggest a daily dose of an oral 5-HT3 receptor antagonist (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    transdermal patch, see below) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    starting on day 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Granisetron transdermal patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transdermal preparation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    is available (Sancuso&reg;) that contains 34.3 mg of granisetron and is designed to deliver 3.1 mg of the drug every 24 hours for up to seven days. The efficacy of the granisetron patch relative to daily oral administration of granisetron was shown in a multinational randomized, double-blind, double-dummy controlled trial in which 641 patients receiving the first cycle of a multiday regimen of either moderately or highly emetogenic chemotherapy were randomly assigned to the patch (applied 24 to 48 hours before the first day of chemotherapy) plus a placebo capsule or to oral granisetron (2 mg daily, one hour prior to chemotherapy on each day of chemotherapy administration) plus a placebo patch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/83\">",
"     83",
"    </a>",
"    ]. Concurrent glucocorticoids, which were administered at the investigator's discretion, were given to about 70 percent of the patients in each arm.",
"   </p>",
"   <p>",
"    The percentage of patients who had complete control of nausea and vomiting until 24 hours after the last chemotherapy dose was not worse with the transdermal patch (60 versus 65 percent with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    ). Fewer than 1 percent of the patches became detached during treatment. In both groups, the most commonly reported toxicities were constipation and headache.",
"   </p>",
"   <p>",
"    Based upon this trial, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    transdermal system was approved in the US for the prevention of CINV in patients receiving moderately or highly emetogenic chemotherapy for up to five days. It is recommended that the patch be applied to the upper outer arm a minimum of 24 hours before chemotherapy and removed 24 hours or more after the last chemotherapy dose is administered. It can be worn for up to seven days, depending on the duration of the chemotherapy regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044202\">",
"    <span class=\"h2\">",
"     Induction therapy for acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    regimens (in which cytarabine is administered daily for five or seven days, often with an anthracycline) are the cornerstone of treatment for acute myeloid leukemia (AML). Few studies have addressed the issue of CINV and optimal prophylaxis in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/31,84,85\">",
"     31,84,85",
"    </a>",
"    ]. Although data are lacking, a daily dose of a 5-HT3 receptor antagonist (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    16 mg) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    appears to be a reasonable option in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     High-dose chemotherapy regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of high dose chemotherapy in association with a bone marrow or peripheral blood stem cell transplant presents a special challenge to achieving good antiemetic control. The chemotherapy agents employed are often of moderate to high emetogenic risk.",
"   </p>",
"   <p>",
"    In addition, there are a number of potential factors that can contribute to an increased incidence and severity of CINV in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher doses of chemotherapy",
"     </li>",
"     <li>",
"      Consecutive day administration",
"     </li>",
"     <li>",
"      Prior treatment with chemotherapy",
"     </li>",
"     <li>",
"      Inclusion of radiation therapy (especially total body irradiation), which has high emetogenic risk",
"     </li>",
"     <li>",
"      Associated other medical conditions or medications that may cause emesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are few randomized trials specifically studying the issue of emesis in the high dose setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. Most studies have focused on the combination of a 5-HT3 receptor antagonist and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. However, a role for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    in this setting was suggested in a phase III trial in which 181 patients undergoing a preparative regimen for hematopoietic stem cell transplantation were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    plus dexamethasone and either aprepitant or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/93\">",
"     93",
"    </a>",
"    ]. Significantly better emetic control was noted in patients who received aprepitant (no emesis for the entire study period in 73 versus 23 percent of the placebo group), although there were no differences between the groups in use of rescue antiemetics.",
"   </p>",
"   <p>",
"    The 2011 updated antiemetic guidelines from ASCO suggested a 5-HT3 receptor antagonist plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    with consideration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Poor control of emesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the use of appropriate antiemetic prophylaxis, many patients experience clinically significant CINV. Before considering any change in the antiemetic regimen, it is important to exclude other disease- and medication-related causes for emesis. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The use of opiate analgesics",
"     </li>",
"     <li>",
"      Certain antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central nervous system metastases",
"     </li>",
"     <li>",
"      Gastrointestinal obstruction",
"     </li>",
"     <li>",
"      Hypercalcemia",
"     </li>",
"     <li>",
"      Abdominopelvic radiotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assuming these factors are excluded, it is important to ensure that the patient is receiving the antiemetic appropriate for the drug(s) being given (",
"    <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"     table 3",
"    </a>",
"    ) and the correct dose (",
"    <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"     table 3",
"    </a>",
"    ). If the patient was receiving chemotherapy with low emetic risk and is experiencing poor emesis control, it is possible to adjust the regimen to that typically used for a higher risk group. The addition of a benzodiazepine may help to counter increased patient anxiety and possible anticipatory emesis.",
"   </p>",
"   <p>",
"    The majority of patients who have breakthrough emesis have derived some benefit from the original antiemetic regimen employed. One or two episodes of emesis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is less than ideal but still reflects substantial antiemetic efficacy. Thus, the original antiemetic regimens should usually be retained.",
"   </p>",
"   <p>",
"    Additional agents can be added, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/94\">",
"     94",
"    </a>",
"    ], a dopaminergic antagonist (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , thiethylperazine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ), or substituting high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    for the 5-HT3 antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ]. Superiority for olanzapine (10 mg orally daily for three days) over metoclopramide (10 mg orally three times daily for three days) for treatment of breakthrough nausea and vomiting was shown in a double-blind randomized trial involving 80 patients receiving highly emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/94\">",
"     94",
"    </a>",
"    ]. In a preliminary report, presented at the 2012 meeting of the American Society of Clinical Oncology (ASCO), during the 72-hour observation period, significantly more patients receiving olanzapine had no recurrent emesis (71 versus 32 percent) and no nausea (67 versus 24 percent).",
"   </p>",
"   <p>",
"    Another alternative is to switch to a different serotonin antagonist, since there may be incomplete cross-resistance between agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. This approach was tested in a double-blind trial, in which patients who failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in the first 24 hours following highly emetogenic chemotherapy were randomly assigned to continue the same treatment or switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    plus dexamethasone. There was a significantly higher rate of complete protection from emesis in the patients who switched to granisetron (47 versus 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other cases, chemotherapy can be altered. Alterations could include single day instead of multiple day therapy, lengthening infusion time, or substituting a less emetogenic agent if such maneuvers do not compromise antitumor activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634354453\">",
"    <span class=\"h3\">",
"     Cannabinoids and medical marijuana",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential antiemetic utility of cannabinoids was first observed in scattered reports of improved emetic control in patients using marijuana during chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/98\">",
"     98",
"    </a>",
"    ]. Two synthetic cannabinoids are available (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     dronabinol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/63/6133?source=see_link\">",
"     nabilone",
"    </a>",
"    ), but antiemetic efficacy is modest at best, rigorous comparisons of either drug with the most effective antiemetic therapies are lacking, and adverse effects tend to be more intense and more frequent than with other rescue agents such as neuroleptics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link&amp;anchor=H11#H11\">",
"     \"Characteristics of antiemetic drugs\", section on 'Cannabinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest antiemetic activity of this class of agents combined with their relatively unfavorable side effect profile (vertigo, xerostomia, hypotension, dysphoria), especially in older patients, has limited their clinical utility. Nevertheless, guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    , ASCO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ], and the MASCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/4\">",
"     4",
"    </a>",
"    ] state that cannabinoids can be considered for refractory nausea and vomiting and as a rescue antiemetic.",
"   </p>",
"   <p>",
"    The use of medical marijuana for refractory CINV is very controversial. Medical use of marijuana is legal in several countries, including the Netherlands and Canada. Despite legalization by several states, marijuana use is still illegal in the United States at the federal level (which considers marijuana a schedule I controlled substance), and individuals prescribing or using marijuana for medical use are at risk for prosecution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While an early prospective uncontrolled pilot study from 1988 found that inhaled cannabis was effective in 78 percent of 56 patients who had inadequate control of nausea and vomiting with the conventional antiemetics that were available at that time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/101\">",
"     101",
"    </a>",
"    ], there have been no other clinical reports of efficacy of inhaled marijuana and there are no controlled clinical trials comparing marijuana versus other rescue strategies in patients who are refractory to modern antiemetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/102\">",
"     102",
"    </a>",
"    ]. Furthermore, the use of marijuana is associated with adverse effects on the cardiovascular, respiratory, and central nervous systems, and concerns about increased risk of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4554?source=see_link&amp;anchor=H25#H25\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\", section on 'Long term medical effects of cannabis use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of medical and legal concerns, the use of medical marijuana is not recommended for management of CINV, and is not included in the most recent guidelines for CINV from the NCCN, ASCO, or MASCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2134987\">",
"    <span class=\"h2\">",
"     Ginger",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional antiemetics are more successful at preventing emesis than in preventing nausea. The benefit of ginger (Zingiber officinale) as an aid to reduce nausea during chemotherapy was addressed in a randomized trial in which 744 patients who experienced nausea following any chemotherapy cycle were randomly assigned to placebo, or supplemental ginger (at doses of 0.5, 1.0 or 1.5 g twice daily) for six days, starting three days prior to the first day of the next two chemotherapy cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/103\">",
"     103",
"    </a>",
"    ]. All patients received a 5-HT3 receptor antagonist on day 1 of all cycles. Two-thirds of the enrolled patients were receiving chemotherapy for breast cancer.",
"   </p>",
"   <p>",
"    All doses of ginger were associated with a significant reduction in acute nausea throughout day 1 of the chemotherapy cycles, although the largest reduction was seen with the 0.5 and 1.0 g doses. The authors concluded that ginger supplementation significantly aids in reduction of day 1 nausea during chemotherapy.",
"   </p>",
"   <p>",
"    A benefit for ginger root in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was also shown in a placebo-controlled randomized trial of 57 children and young adults receiving",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"    </span>",
"    chemotherapy for bone sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/104\">",
"     104",
"    </a>",
"    ]. Compared to conventional antiemetics, the addition of ginger (334 or 800 mg depending on the size of the patient) one hour before, and three and eight hours after the start of chemotherapy significantly reduced the incidence of both acute and delayed emesis.",
"   </p>",
"   <p>",
"    However, in contrast to these results, a benefit for ginger in addition to conventional antiemetics (5-HT3 antagonists",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    ) could not be shown in a randomized, placebo-controlled phase II trial of 162 cancer patients who had suffered CINV during at least one prior cycle of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/105\">",
"     105",
"    </a>",
"    ]. In fact, patients who took ginger plus aprepitant had more severe acute nausea than did those who took only aprepitant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2135002\">",
"    <span class=\"h2\">",
"     Acupuncture and related therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques have been used to stimulate the pericardium 6 (P6 or neiguan) site, which is commonly thought to be useful in the management of chemotherapy-induced nausea and vomiting. These include manual stimulation with the insertion of fine needles (acupuncture), electrostimulation, and noninvasive pressure on the skin over the P6 pressure point (ie, acupressure). Unfortunately, interpretation of the results of randomized trials is hampered by a high risk of bias in most studies, and lack of standardization of treatment methods and comparison groups. A year 2013 systematic review of acupuncture in cancer care included 11 randomized trials in which nausea and vomiting were assessed; eight were considered to have a high risk of bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/106\">",
"     106",
"    </a>",
"    ]. Only one trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/107\">",
"     107",
"    </a>",
"    ] had a low risk of bias and was positive for short term benefit of electroacupuncture after chemotherapy for breast cancer. The authors concluded that based upon the single positive study with low risk of bias that acupuncture could be considered an appropriate adjunctive treatment for chemotherapy-induced nausea and vomiting but that additional studies were needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H28#H28\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Nausea and vomiting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other nonpharmacologic strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings from randomized controlled trials of reasonable quality provide limited support for several nonpharmacologic methods to reduce CINV, including cognitive distraction (eg, playing video games during treatment), systematic desensitization (a cognitive approach using visualization and learned relaxation techniques), exercise, hypnosis, acupuncture, and transcutaneous electrical nerve stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link\">",
"     \"Complementary and alternative therapies for cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28457?source=see_link\">",
"     \"Acupuncture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       \"Patient information: Nausea and vomiting with cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of treatment, despite recent advances in prevention. CINV is classified as acute, delayed, and anticipatory, and these distinctions have important implications for patient management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\", section on 'Types of emesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most important factor determining the likelihood of acute or delayed emesis developing is the intrinsic emetogenicity of a particular chemotherapy agent (",
"      <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\", section on 'Chemotherapy agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The three categories of drugs with the highest therapeutic index for the management of CINV are the type three 5-hydroxytryptamine (5-HT3) receptor antagonists, the neurokinin-1 (NK1) receptor antagonists (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"       fosaprepitant",
"      </a>",
"      ), and the glucocorticoids (especially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       '5-HT3 receptor antagonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Neurokinin-1 receptor antagonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      These agents are used alone (glucocorticoids) and in combinations depending on the specific chemotherapy regimen being administered, as recommended in the ASCO and",
"      <span class=\"nowrap\">",
"       MASCC/ESMO",
"      </span>",
"      guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute emesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All of the first-generation 5-HT3 receptor antagonists appear equally effective when used at the recommended dose. An orally disintegrating formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      , one that disperses rapidly when placed on the tongue and does not need to be swallowed with water, may be particularly useful for patients with dysphagia or anorexia.",
"      <br/>",
"      <br/>",
"      EKG interval changes appear to be a class effect of the first generation 5-HT3 antagonists. Their use should be avoided in patients with congenital long-QT syndrome. Potassium and magnesium levels should be assessed, and if abnormal, corrected before initiation of treatment. ECG monitoring is recommended in patients with underlying cardiac disease including heart failure and bradyarrhythmias, and in patients taking other medications that increase the risk of QTc prolongation (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2662553\">",
"       'EKG interval changes and cardiac arrhythmias'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The second-generation agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       palonosetron",
"      </a>",
"      may be more effective than first generation 5-HT3 antagonists, particularly for prevention of delayed emesis, and QTc prolongation has not been described with palonosetron. In settings when an NK1R antagonist is not indicated, available evidence would support palonosetron as the preferred 5-HT3 receptor antagonist. (See",
"      <a class=\"local\" href=\"#H4\">",
"       '5-HT3 receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2135834\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiemetic recommendations from ASCO according to the emetogenicity of the chemotherapy regimen are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef72865 \" href=\"mobipreview.htm?28/6/28781\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"     5",
"    </a>",
"    ]. In general, our recommendations parallel these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Cisplatin and other high risk agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy or another agent with high emetogenic risk (",
"      <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"       table 2",
"      </a>",
"      ), we recommend antiemetic therapy with a combination of a 5-HT3 receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , and a neurokinin-1 receptor (NK1R) antagonist (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"       fosaprepitant",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      is used on day 1, we recommend maintenance therapy with a combination of aprepitant on days 2 and 3 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      on days 2 through 4&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H127217965\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A single dose schedule of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"       fosaprepitant",
"      </a>",
"      (dose 150 mg IV 30 minutes prior to chemotherapy in conjunction with a 5-HT3 receptor antagonist on day 1 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      on days 1 through 4) is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H428644927\">",
"       'One versus three-day administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Anthracycline plus cyclophosphamide",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving chemotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus an anthracycline, we recommend antiemetic therapy with a combination of a 5-HT3 receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , and an NK1R antagonist (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      is used on day 1, we recommend maintenance therapy with a combination of aprepitant on days 2 and 3 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      on days 2 through 4 (",
"      <a class=\"graphic graphic_table graphicRef68894 \" href=\"mobipreview.htm?27/49/28446\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H127217965\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A single dose schedule of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"       fosaprepitant",
"      </a>",
"      (dose 150 mg IV 30 minutes prior to chemotherapy in conjunction with a 5-HT3 receptor antagonist on day 1 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      on days 1 through 4) is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H428644927\">",
"       'One versus three-day administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Moderate risk agents and regimens",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving moderately emetogenic chemotherapy (",
"      <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"       table 2",
"      </a>",
"      ), we recommend the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       palonosetron",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      on day 1 (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If palonosetron is not available, clinicians may substitute a first-generation 5-HT3 receptor antagonist, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       granisetron",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Combination with a 5-HT3 antagonist'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      To prevent delayed emesis in this population, we suggest single agent treatment with dexamethasone on days 2 and 3 (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If a first generation 5-HT3 receptor antagonist is used rather than palonosetron on day 1, then treatment with a first generation 5-HT3 receptor antagonist alone on days 2 and 3 is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Moderate risk agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Low risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving low emetic risk agents (",
"      <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"       table 2",
"      </a>",
"      ), we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (8 mg) as a single agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative approach for patients in whom glucocorticoid use is contraindicated or undesirable (such as with the use of long-term weekly chemotherapy) is a single dose of a drug such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/18/39210/abstract/110\">",
"       110",
"      </a>",
"      ]. This patient population generally does not require prophylaxis against delayed emesis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Minimal risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients receiving chemotherapy agents with minimal risk of causing emesis (",
"      <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"       table 2",
"      </a>",
"      ), we suggest that antiemetic therapy",
"      <strong>",
"       not",
"      </strong>",
"      be routinely administered to prevent either acute or delayed CINV (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prophylactic antiemetics (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      8 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ) may be administered to patients who have had emesis with prior low-risk regimens, or on as \"as needed\" basis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\", section on 'Chemotherapy agent'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Anticipatory emesis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary approach to the prevention of anticipatory emesis is the prevention of CINV beginning with the initial cycles of chemotherapy. For patients who do develop anticipatory emesis, we suggest behavioral therapy or benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Anticipatory emesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     High-dose chemotherapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving high-dose chemotherapy, we recommend a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , a 5-HT3 receptor antagonist, and an NK1R antagonist&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'High-dose chemotherapy regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Multiday regimens",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving multiday (three or more) regimens that are moderately or highly emetogenic, we suggest the use of a daily dose of an oral 5-HT3 receptor antagonist or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       granisetron",
"      </a>",
"      transdermal patch plus daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , with the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      (days 1, 2, and 3) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6471?source=see_link\">",
"       fosaprepitant",
"      </a>",
"      (day 1) for highly emetogenic regimens (eg, five days of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      in regimens for testicular or ovarian germ cell cancer) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Consecutive day therapy with highly emetogenic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Poor emesis control",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who do not achieve adequate control of CINV with their initial antiemetic regimen, the patient's management should be reviewed to ensure that there are no other factors responsible for continued emesis and that adequate antiemetic therapy actually was administered for the given chemotherapy regimen. If CINV remains an issue, the addition of a second line agent (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ) or changing from one 5-HT3 receptor antagonist to another may be useful. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Poor control of emesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Other agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/1\">",
"      Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/2\">",
"      Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/3\">",
"      Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/4\">",
"      Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 Suppl 5:v232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/5\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) available online at file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/7\">",
"      Heron JF, Goedhals L, Jordaan JP, et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann Oncol 1994; 5:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/8\">",
"      Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer 1990; 26 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/9\">",
"      Warr D, Wilan A, Venner P, et al. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. Eur J Cancer 1992; 29A:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/10\">",
"      Chevallier B, Cappelaere P, Splinter T, et al. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer 1997; 5:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/11\">",
"      Davidson N, Rapoport B, Erikstein B, et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. Clin Ther 1999; 21:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/12\">",
"      Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev 2010; :CD006272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/13\">",
"      del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000; 89:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/14\">",
"      Gandara DR, Roila F, Warr D, et al. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer 1998; 6:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/15\">",
"      Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992; 66:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/16\">",
"      Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/17\">",
"      Ettinger DS, Eisenberg PD, Fitts D, et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996; 78:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/18\">",
"      Harman GS, Omura GA, Ryan K, et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996; 38:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/19\">",
"      Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/20\">",
"      Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998; 16:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/21\">",
"      Gralla RJ, Navari RM, Hesketh PJ, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/22\">",
"      Mason JW, Selness DS, Moon TE, et al. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 2012; 18:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/23\">",
"      Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003; 37:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/24\">",
"      Pinarli FG, Elli M, Dagdemir A, et al. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer 2006; 47:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/25\">",
"      Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010; 5:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/26\">",
"      Turner S, Mathews L, Pandharipande P, Thompson R. Dolasetron-induced torsades de pointes. J Clin Anesth 2007; 19:622.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm272041.htm (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     FDA safety communication available online at file://www.fda.gov/Drugs/DrugSafety/ucm237081.htm (Accessed on December 21, 2010).",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm310190.htm (Accessed on July 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/30\">",
"      Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012; 20:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/31\">",
"      Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/32\">",
"      Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/33\">",
"      Likun Z, Xiang J, Yi B, et al. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 2011; 16:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/34\">",
"      Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/35\">",
"      Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17:1441.",
"     </a>",
"    </li>",
"    <li>",
"     Grunberg S, Voisin D, Zufferli M, et al. Oral palonosetron is as effective as intravenous palonosetron: A phase III dose ranging trial in patients receiving moderatelty emetogenic chemotherapy. Presented at the 14th European conference of Clinical Oncology, Barcelona, Spain, September 23-27, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/37\">",
"      dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012; 104:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/38\">",
"      Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/39\">",
"      Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol 2011; 29:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/40\">",
"      McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/41\">",
"      Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21:4112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/42\">",
"      Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97:3090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/43\">",
"      Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/44\">",
"      Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005; 55:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/45\">",
"      Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000; 18:3409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/46\">",
"      Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. The Italian Group for Antiemetic Research. N Engl J Med 1995; 332:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/47\">",
"      Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/48\">",
"      Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 1991; 303:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/49\">",
"      Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/50\">",
"      Joss RA, Bacchi M, Buser K, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/51\">",
"      Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol 1998; 16:2937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/52\">",
"      Italian Group For Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:. J Clin Oncol 2004; 22:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/53\">",
"      Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986; 17:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/54\">",
"      Sallan SE, Zinberg NE, Frei E 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/55\">",
"      Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/56\">",
"      Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2012; 10:487.",
"     </a>",
"    </li>",
"    <li>",
"     Grunberg SM, et al. Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea. J Clin Oncol 30, 2012 (suppl; abstr 9061). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=92888 (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/58\">",
"      Olver I, Paska W, Depierre A, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996; 7:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/59\">",
"      Koo WH, Ang PT. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996; 7:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/60\">",
"      Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/61\">",
"      Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med 2000; 342:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/62\">",
"      Pater JL, Lofters WS, Zee B, et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1997; 8:181.",
"     </a>",
"    </li>",
"    <li>",
"     Hesketh PJ, Sanz-Altamira P, Bushey J, et al. Prospective evaluation of the incidence of nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (abstract #9645). J Clin Oncol 2008; 26:9645.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/64\">",
"      Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 2012; 20:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/65\">",
"      Fleishman SB, Mahajan D, Rosenwald V, et al. Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer. J Oncol Pract 2012; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/66\">",
"      Navari RM, Madajewicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/67\">",
"      Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/68\">",
"      Goedhals L, Heron JF, Kleisbauer JP, et al. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 1998; 9:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/69\">",
"      Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 2001; 37:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/70\">",
"      Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/71\">",
"      Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/72\">",
"      Roscoe JA, Heckler CE, Morrow GR, et al. Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 2012; 30:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/73\">",
"      Morrow GR, Roscoe JA, Kirshner JJ, et al. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998; 6:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/74\">",
"      Roscoe JA, Bushunow P, Morrow GR, et al. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 2004; 101:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/75\">",
"      Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/76\">",
"      Burish TG, Jenkins RA. Effectiveness of biofeedback and relaxation training in reducing the side effects of cancer chemotherapy. Health Psychol 1992; 11:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/77\">",
"      Fallowfield LJ. Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer 1992; 28A Suppl 1:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/78\">",
"      Greenberg DB, Surman OS, Clarke J, Baer L. Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat Rep 1987; 71:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/79\">",
"      Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993; 11:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/80\">",
"      Hainsworth JD. The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol 1992; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/81\">",
"      R&auml;th U, Upadhyaya BK, Arechavala E, et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993; 50:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/82\">",
"      Albany C, Brames MJ, Fausel C, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 2012; 30:3998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/83\">",
"      Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011; 19:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/84\">",
"      Mattiuzzi GN, Cortes JE, Blamble DA, et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 2010; 116:5659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/85\">",
"      L&oacute;pez-Jim&eacute;nez J, Mart&iacute;n-Ballesteros E, Sureda A, et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006; 91:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/86\">",
"      Bosi A, Guidi S, Messori A, et al. Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study. J Chemother 1993; 5:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/87\">",
"      Okamoto S, Takahashi S, Tanosaki R, et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996; 17:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/88\">",
"      Gilbert CJ, Ohly KV, Rosner G, Peters WP. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 1995; 76:2330.",
"     </a>",
"    </li>",
"    <li>",
"     Stiff P, Fox-Geiman M, Kiley K, et al. Aprepitant vs. placebo plus oral ondansetron and dexamethasone for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to hematopoietic stem cell transplantation; A prospective, randomized double-blind phase III trial. Blood (ASH Annual Meeting Abstracts) 2009; 114:2267.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/90\">",
"      Abbott B, Ippoliti C, Bruton J, et al. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 1999; 23:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/91\">",
"      Barbounis V, Koumakis G, Hatzichristou H, et al. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Support Care Cancer 1999; 7:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/92\">",
"      Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/93\">",
"      Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2013; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     Navari RM, Nagy CK, Gray SE, et al. The use of olanzapine verrsus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. J Clin Oncol 2012; (suppl; abstr 9064). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=93399 (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/95\">",
"      de Wit R, de Boer AC, vd Linden GH, et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001; 85:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/96\">",
"      Harousseau JL, Zittoun R, Bonneterre J, et al. [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. Bull Cancer 2000; 87:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/97\">",
"      Sigsgaard T, Herrstedt J, Christensen P, et al. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer 2000; 8:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/98\">",
"      de Jong FA, Engels FK, Mathijssen RH, et al. Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol 2005; 23:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/99\">",
"      Machado Rocha FC, St&eacute;fano SC, De C&aacute;ssia Haiek R, et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008; 17:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/100\">",
"      Furlow B. States and US Government spar over medical marijuana. Lancet Oncol 2012; 13:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/101\">",
"      Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. N Y State J Med 1988; 88:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/102\">",
"      Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol 2012; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/103\">",
"      Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 2012; 20:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/104\">",
"      Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 2011; 56:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/105\">",
"      Zick SM, Ruffin MT, Lee J, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 2009; 17:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/106\">",
"      Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013; 31:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/107\">",
"      Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA 2000; 284:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/108\">",
"      Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26:5618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/18/39210/abstract/109\">",
"      Ezzo JM, Richardson MA, Vickers A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006; :CD002285.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1151 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39210=[""].join("\n");
var outline_f38_18_39210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMOTHERAPY DRUG EMETOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE EMESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      5-HT3 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - First generation agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2662553\">",
"      EKG interval changes and cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H13889233\">",
"      - Dolasetron",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H13889240\">",
"      - Ondansetron",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Palonosetron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurokinin-1 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3798759\">",
"      Need for a 5-HT3 agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H428644927\">",
"      - One versus three-day administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Issues related to inhibition of CYP3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Single agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Combination with a 5-HT3 antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DELAYED EMESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H127218108\">",
"      Regimens with a high risk of delayed emesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H127217965\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H127217842\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H127217821\">",
"      NK1 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H127217828\">",
"      5-HT3 antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H127218074\">",
"      Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Moderate risk agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ANTICIPATORY EMESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Consecutive day therapy with highly emetogenic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Granisetron transdermal patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1044202\">",
"      Induction therapy for acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      High-dose chemotherapy regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Poor control of emesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H634354453\">",
"      - Cannabinoids and medical marijuana",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      COMPLEMENTARY THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2134987\">",
"      Ginger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2135002\">",
"      Acupuncture and related therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other nonpharmacologic strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2135834\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Cisplatin and other high risk agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Anthracycline plus cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Moderate risk agents and regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Low risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Minimal risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Anticipatory emesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - High-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Multiday regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Poor emesis control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/1151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/23/7549\" title=\"table 1\">",
"      Emetogenicity chemo drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/53/27484\" title=\"table 2\">",
"      Emetogenicity oral chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/49/28446\" title=\"table 3\">",
"      Doses antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/24/32139\" title=\"table 4\">",
"      NCI CTCAE for NV v4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/48/2830\" title=\"table 5\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/6/28781\" title=\"table 6\">",
"      Rx recs antiemetic IV chemo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=related_link\">",
"      Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_18_39211="Intratumoral heterogeneity Ki67 grades";
var content_f38_18_39211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intratumoral heterogeneity of well-differentiated neuroendocrine tumors metastatic to the liver based on the mean and highest Ki67 grades on whole-slide subsections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tumor grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Homogeneous",
"        <br/>",
"        (n = 24, 53 percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Heterogeneous",
"        <br/>",
"        (n = 21, 47 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Mean Ki67",
"        </strong>",
"       </td>",
"       <td>",
"        G1 (82 percent)",
"       </td>",
"       <td>",
"        22 (59 percent)",
"       </td>",
"       <td>",
"        15 (41 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G2 (18 percent)",
"       </td>",
"       <td>",
"        2 (25 percent)",
"       </td>",
"       <td>",
"        6 (75 percent)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Highest Ki67",
"        </strong>",
"       </td>",
"       <td>",
"        G1 (49 percent)",
"       </td>",
"       <td>",
"        22 (100 percent)",
"       </td>",
"       <td>",
"        0 (0 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G2 (51 percent)",
"       </td>",
"       <td>",
"        2 (9 percent)",
"       </td>",
"       <td>",
"        21 (91 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The percentage of G1 or G2 cases is based on the total number of cases. The percentage of homogeneous or heterogeneous cases in G1 (low grade) or G2 (intermediate grade) group is based on the number of cases in that particular grade.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011; 35:853. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39211=[""].join("\n");
var outline_f38_18_39211=null;
var title_f38_18_39212="Pediatric dosing TB drugs";
var content_f38_18_39212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug dosing for the treatment of tuberculosis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage forms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily dosage, mg/kg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Twice a week dosage, mg/kg per dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethambutol",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Tablets",
"         </strong>",
"         :",
"        </p>",
"        <p>",
"         100 mg",
"        </p>",
"        400 mg",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        2.5 g",
"       </td>",
"       <td>",
"        Optic neuritis (usually reversible), decreased red-green color discrimination, gastrointestinal tract disturbances, hypersensitivity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Isoniazid*",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Scored tablets:",
"         </strong>",
"        </p>",
"        <p>",
"         100 mg",
"        </p>",
"        <p>",
"         300 mg",
"        </p>",
"        <p>",
"         <strong>",
"          Syrup:",
"         </strong>",
"        </p>",
"        10 mg/mL",
"       </td>",
"       <td>",
"        10-15",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        20-30",
"       </td>",
"       <td>",
"        <p>",
"         Daily, 300 mg",
"        </p>",
"        Twice a week, 900 mg",
"       </td>",
"       <td>",
"        Mild hepatic enzyme elevation, hepatitis,",
"        <sup>",
"         &bull;",
"        </sup>",
"        peripheral neuritis, hypersensitivity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pyrazinamide*",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Scored tablets:",
"         </strong>",
"        </p>",
"        500 mg",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        2 g",
"       </td>",
"       <td>",
"        Hepatotoxic effects, hyperuricemia, arthralgia, gastrointestinal tract upset",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"1\">",
"        Rifampin*",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Capsules:",
"         </strong>",
"        </p>",
"        <p>",
"         150 mg",
"        </p>",
"        <p>",
"         300 mg",
"        </p>",
"        <strong>",
"         Syrup formulated capsules",
"        </strong>",
"       </td>",
"       <td rowspan=\"1\">",
"        10-20",
"       </td>",
"       <td rowspan=\"1\">",
"        10-20",
"       </td>",
"       <td rowspan=\"1\">",
"        600 mg",
"       </td>",
"       <td rowspan=\"1\">",
"        Orange discoloration of secretions or urine, staining of contact lenses, vomiting, hepatitis, influenza-like reaction, thrombocytopenia, pruritus; oral contraceptives may be ineffective",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Rifamate is a capsule containing 150 mg of isoniazid and 300 mg of rifampin. Two capsules provide the usual adult (&gt;50 kg) daily doses of each drug. Rifater, in the United States, is a capsule containing 50 mg of isoniazid, 120 mg of rifampin, and 300 mg of pyrazinamide. Isoniazid and rifampin also are available for parenteral administration.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     When isoniazid in a dosage exceeding 10 mg/kg per day is used in combination with rifampin, the incidence of hepatotoxic effects may be increased.",
"    </div>",
"    <div class=\"reference\">",
"     From: American Academy of Pediatrics. Tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. Used with the permission of the American Academy of Pediatrics. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39212=[""].join("\n");
var outline_f38_18_39212=null;
var title_f38_18_39213="Secretin amino acid sequence";
var content_f38_18_39213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amino acid sequence of secretin in various animal species",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 167px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39213=[""].join("\n");
var outline_f38_18_39213=null;
var title_f38_18_39214="Treatment of acute cholecystitis";
var content_f38_18_39214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Treatment of acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 448px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39214=[""].join("\n");
var outline_f38_18_39214=null;
var title_f38_18_39215="Laparoscopic mobilization of the superior hemorrhoidal artery";
var content_f38_18_39215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic mobilization of the superior hemorrhoidal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the laparoscopic transection of the superior hemorrhoidal vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_18_39215=[""].join("\n");
var outline_f38_18_39215=null;
